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2Abstract
Serological methods to differentiate recent from non-recent HIV infections were introduced
to routine surveillance in Poland, Estonia and Ukraine, to estimate HIV incidence and to
characterisethosenewly-diagnosedandinfected. Establishingthecharacteristicsofpopulations
at greatest risk of HIV enables appropriate and target prevention and intervention strategies to
be developed, reducing risk of onward transmission.
Using existing testing services within each country, residual samples from newly-diagnosed
persons were tested for evidence of recent infection using an avidity assay. Data were collated in
2013-2014 using modiﬁed existing methods in Kiev City, Poland and Estonia.
Diagnosis rates for Kiev City, Poland and Estonia were 21.5, 1.2 and 29.7 per 100,000 population,
respectively. Incidence estimates for Kiev City were 21.5 per 100,000 population, with 6.5%
classiﬁed as recent. The disproportionate distribution of HIV were among men who have sex
with men (MSM) and persons who inject drugs (PWID) was evident. Uncorrected estimates for
Poland and Estonia were 30% and 44%, respectively.
This work enables targeted public health action and health promotion work to be made,
laying the foundation for local and national guidelines.
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18Chapter 1
Characterising the Population
The following chapter describes Human Immunodeﬁciency Virus (HIV) in Europe and the
epidemics within the three countries of focus Ukraine, Estonia and Poland. I describe the
distribution of those newly diagnosed using published literature, and how the epidemic has
changed over time.
191.1 Introduction
The HIV is a retrovirus which attacks an individual’s immune system leaving them
vulnerable to opportunistic infections and cancers which are collectively known as Acquired
Immunodeﬁciency Syndrome (AIDS). The ﬁrst diagnosis of AIDS was reported in San Francisco
in 1981, and since then the number of people living with HIV world-wide is estimated to have
reached an 33.3 million [31.4-35.3 million] in 2009 [1]. While there is no cure for HIV, the virus
can be managed using combinations of Antiretroviral (ARV) drugs. These drugs introduced
in the mid-1990s have increased the life expectancy of HIV infected individuals, resulting in
a decrease in the number of AIDS diagnoses and mortality. Individuals who are diagnosed
early with their infection and adhere to treatment can expect a life expectancy close to that of
a negative individual. Although treatment is effective, there are still a number of challenges to
face, the development of drug resistance to certain treatment regimes, the lifetime cost of an
individual with HIV and early diagnosis ensuring individuals can experience the full beneﬁt
of treatment. Transmission of HIV can occur through sexual contact (vaginal or anal), vertical
transmission (from mother to child), injecting drugs or through contact with contaminated
blood. The distributions of these transmission routes differ considerably from country to
country.
The ability to estimate HIV incidence is of major public health importance, establishing
current transmission patterns and monitoring prevention efforts. Data collected on testing
and new diagnoses by many countries through national surveillance systems do not have the
ability to determine whether increases to the HIV epidemic are due to onward transmission or
increased testing of previously undiagnosed infections. Eastern Europe is an area of particular
interest, where rates of diagnosed HIV have increased dramatically in recent years, and relatively
little is known about each epidemic.
201.2 HIV Epidemic in Europe
Thirty years since the ﬁrst AIDS diagnosis, HIV is still a communicable disease of major public
health importance in Europe [2]. With no indication of a decline in new HIV diagnoses and
continued growing numbers of persons living with HIV, it is imperative to build an enhanced
picture of the current epidemic, whilst monitoring and evaluating new and current public health
initiatives. Until recent years, European ﬁgures for HIV and AIDS have been primarily based on
numbers of newly diagnosed persons with HIV or AIDS alongside those accessing HIV-related
care services. This prevalent pool, although important to quantify is not necessarily reﬂective
of the current situation given the long latent period which characterises HIV, meaning a person
may be infected for many years before a diagnosis is made. Determining the number of persons
who have been recently infected with HIV in a deﬁned period enable current transmission
patterns to be ascertained, highlighting populations at greatest risk, and guiding prevention and
intervention strategies.
Methodologies for identifying whether an infection is recent have previously been achieved
through observational studies following a cohort of sero-negative persons overtime screening
for new infections or using surveillance data, through serial sero-surveys, back-calculations
or other mathematical models. However, these methods can be expensive to conduct, raise
questions regarding generalisability and rely heavily on epidemiological data which may or
may not be collected through country speciﬁc surveillance [3]. In recent years, serological tests
which identify biological markers indicative of a recent infection have been introduced. These
serological tests supported by clinical evidence of either a recent or established infection enable
recent infections to be monitored, calculating the proportion of diagnoses newly infected or
incidence estimates for the population. This methodology is known as the Recent Infection
Testing Algorithm (RITA) [4,5].
Until the mid-1990s the HIV epidemic experienced in Europe was led predominately by
Western Europe and, in particular, the 15 Western European countries of the European Union
(EU) [6]. On average, 23,000 AIDS diagnoses were reported per year between 1992 and 1995 in
Western Europe, 29 times higher than the 800 reported in Central Europe and 383 times higher
than the 60 in Eastern Europe [6]. However, from the mid-1990s, this distribution changed
dramatically, and within a short period of time Eastern Europe became the leading European
21region with rapid increases in both the number of new HIV and AIDS diagnoses. Changes to the
political, social and economic structure of Eastern Europe after the collapse of the Soviet Union
in 1991 were inﬂuential in driving forward the HIV epidemic, with increases in illicit drug use,
prostitution and rates of Sexually Transmitted Infections (STIs) [7–9]. During the ensuing seven
years the diagnosis rate of HIV in Eastern Europe increased from 0.61 per 100,000 population
in 1995 to 34.7 per 100,000 in 2001. HIV diagnosis rate in 2001 was six times higher than the 5.5
per 100,000 population in Western Europe [6]. Unlike the east and west regions of Europe the
HIV diagnosis rate in Central Europe during this time period remained relatively low and stable,
although with signiﬁcant variation between countries [7].
By the end of 2010, Eastern Europe was still experiencing the highest overall rates of HIV
in Europe with 31.7 cases per 100,000 population, considerably higher than that of Western
Europe (6.6 cases per 100,000) and Central Europe (1.3 cases per 100,000) [10], and higher than
the 18.9 per 100,000 in 2009 [11]. Importantly, in 2009, the Ukraine, Estonia alongside Russia
were identiﬁed as having HIV diagnostic rates greater than 20 cases per 100,000 population.
Unlike Western Europe, where the risk of HIV was primarily among Men who have sex
with men (MSM) and sex between men and women, the increasing rates of HIV in Eastern
Europe were dominated by injecting drug use. As the rates of injecting drug use increased across
Eastern Europe so did HIV prevalence. The ﬁrst outbreaks of HIV among PWID were identiﬁed
in the Ukraine, in the southern regions of Odessa and Nikolayev, preceded by outbreaks in
the Russian regions of Kaliningrad, Irlutsk, Rostov-on-Don and Moscow and Sretlogorsk in
Belarus [7,12,13]. Increases in HIV diagnoses continued, and new HIV diagnoses were detected
in all regions across Ukraine, Russia, Latvia and Estonia, each predominately due to injecting
drug use [9]. Central Europe experienced a very heterogeneous spread of HIV, dependent on the
country affected [11]. Although, the transmission routes in Central Europe were predominately
reported as either sex between men or between men and women like Western Europe, Poland
bore similarities to the Ukraine and Belarus with injecting drug use being the leading route of
infection [7,9].
Injecting drug use is still a predominate factor in Eastern Europe and areas of central Europe,
and it is estimated that of a population of 3,400,000 PWID in Eastern Europe, in 2007, over a
22quarter (27%; 940,000) were estimated to be HIV positive [14]. Among those diagnosed with
HIV in Eastern Europe during 2010, 43% were PWID, much higher than the 4% reported for
Western and Central Europe [10]. Alongside PWID, numbers of HIV infections attributable to
sex between men and women have also risen, suggesting a shift in transmission from PWID
to their sexual partners. In Eastern Europe 48% of diagnoses were attributable to sex between
men and women [10]. Data for Central Europe, indicate that 24% of diagnoses were due to sex
between men and women, 29% were among MSM, 4% among PWID and the remainder (43%)
with an unknown risk group [10]. It is not possible to understand the possible contribution to
the epidemic of those risk groups with such a high proportion unknown.
To understand what is pushing forward the recent increase in HIV infections in Eastern
Europe, the European Comission (EC) funded network of excellence, EuroCoord, made
identifying and characterising new HIV diagnoses and recent HIV infection in three countries in
Eastern and Central Europe: Poland, Estonia and Ukraine a priority.
This integrated network is formed from the biggest HIV cohorts and collaborations in
Europe, CASCADE, COHERE, EuroSIDA and PENTA. These cohorts include seroconverters,
adult, paediatric and mother/child cohorts, patients attending for care and children and
pregnant women enrolled in trials and observational studies. The diversity of these cohorts
enables EuroCoord to address key areas of HIV research; characterising populations in Europe,
improving management of those living with HIV, and exploring speciﬁc subgroups. By
investigating Eastern and Central European countries included within EuroCoord, enables
populations at greatest risk to be identiﬁed, and the correct intervention and prevention
methods to be adopted.
231.3 Countries and Resources: Ukraine
In2012theUkrainehadoneofthehighestratesofdiagnosedHIVinEuropewith37.1per100,000
population [15] (ﬁgure 1.1) and an adult (15-49yrs) prevalence of 1.1% (95% CI 1.0-1.3) [1]. The
ﬁrst HIV diagnosis was recorded in 1987 and, between 1987 and 2012, 187,316 persons were
diagnosed with HIV [15]. Cumulative ﬁgures for AIDS diagnoses 1987 to 2009 were 31,241
AIDS diagnoses and 17,791 AIDS-related deaths [16]. The majority of the diagnoses in Ukraine
occurred from 1995 onwards [16] with the number of HIV diagnoses in 2009 more than double
that in 2001 [1]. Rates of diagnosed HIV rose from 12.5 per 100,000 population in 2001 [10] to
37.1 in 2012 [15] (ﬁgure 1.1). It is estimated that only 28% of persons living with HIV in the
Ukraine are aware of their status, equating to an estimated 360,000 persons [16].
Testing for HIV is accessible nationwide, with service initiated screening also available in
antenatal settings, prisons, blood donor facilities and for policy and regulation reasons. In 2012
just over 2 million HIV tests were reported to have been performed, a 49% increase on the 1.5
million reported in 2004 [10,15] (ﬁgure 1.1). However, even with increased testing there are still
barriers, including lack of knowledge about risk, geographical barriers as individuals elect to
travel to the city due to limited services outside it and their wish to maintain anonymity. stigma,
and the barriers faced when identifying as an injecting drug user, a sex worker or being in a
same-sex relationship [17,18].
24Figure 1.1: Rate of new HIV diagnoses and number of HIV tests performed, Ukraine: 2001-2010.
Source: European Centre for Disease Prevention and Control [15].
25There is little information about the overall testing frequencies in Ukraine, however UNAIDS
reported that in 2009 59% of sex workers, 31% of MSM and 70% of PWID had had an HIV test in
the last 12 months and knew the result [1]. A study monitoring the behaviour of 3,711 PWID in
Ukraine identiﬁed that only half had ever had an HIV test, of whom half again had tested within
the past 12 months [19]. In relation to all PWID participating within the survey this resulted in
29% of PWID seeking an HIV test within the past 12 months. Interestingly, testing for HIV was
found to be linked to seeking medical attention, with 76% of PWID who had tested for HIV had
also sought medical attention; among those who had never tested for HIV this was 44%. PWID
who were identiﬁed as positive for HIV, 16% reported their previous test as negative and 39% had
never had a previous test or were unaware of the result [19].
Although numbers of MSM are low compared to other European countries there is still a
need to monitor this subgroup and understand testing behaviours. A study investigating MSM
in Ukraine identiﬁed that the proportion having an HIV test in the past 12 months had increased
from 28% in 2007 to 42% in 2009. Among MSM who reported their last HIV test as negative, 5%
tested positive using rapid testing [20].
Testing for HIV should be sought at regular intervals among Female Sex Workers (FSW),
however among those surveyed only 57% had tested within the past 12 months and knew their
result. Furtherinvestigationsuggestedtheirreasonsfornottestingwereduetolackofknowledge
regarding where to test and the necessity of regular testing alongside fear of the result [21].
The leading route of infection until recent years has been injecting drug use, which was
instrumental in the rapid increase in the number of new HIV diagnoses. The ﬁrst outbreaks of
HIVamongPWID withinUkraine were inthe southernregionsofOdessa andMykolaiv [7,12,13],
and in more recent years there has been an increase in HIV rates from sexual transmission.
Predominately this increase is reported to be due to sex between men and women, however
due to stigma which surrounds same-sex transmission it is unknown how much MSM is also a
contributing factor [16,22]. It is postulated that the 94 MSM reported in 2009 is a considerable
underestimation, with the prevalence of surveyed MSM 8.6% [20]. Most at risk populations
for Ukraine are PWID, FSW and MSM, with a sentinel epidemiological study estimating the
proportion infected with HIV in each population to be 21.5%, 9.0%, and 6.4% respectively.
26In addition, in 2008, the number of diagnoses reported to be due to sex between men and
women crossed that of persons infected through injecting drug use [16], suggesting a shift in
transmission from most-at-risk populations to the general public [23] (ﬁgure 1.2). However, the
sero-prevalence of HIV among PWID in 16 Ukrainian cities in 2008 remained high at 32% [24].
In addition to this shift is the increasing number of new diagnoses among women, with recent
ﬁgures suggesting that women account for almost half of those diagnosed. It has been suggested
that this shift in the epidemic is predominantly due to women who inject drugs being at higher
risk as they are more likely to be second on the needle, to be commercial sex workers exchanging
sex for drugs, subject to gender-based violence and stigma, or through unsafe sex with an
injecting partner [25–27].
Mother to Child Transmission (MTCT) in the Ukraine is the leading route of infection among
children, resulting in the introduction of the national MTCT programme for preventing HIV in
newborns in 2001 [28,29]. The outcome has been a decrease in rates of MTCT from an estimated
27.5% in 2000 [28] to 7.0% in 2006 [29]. However, even with these successes, the uptake of
antenatal services among hard to reach populations such as female PWID is low [30].
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28The predominant subtype for the Ukraine has been identiﬁed as A, followed by a smaller
proportionofsubtypeB[31,32]. Of163specimensfromHIVinfectedpatientssequencedin2006,
66% were classiﬁed as subtype A and 30% as subtype B, other subtypes identiﬁed were C (2%),
D (1%) and a unique A/B recombinant (1%) [33]. The formation of these subtypes followed the
initial outbreak of PWID, with transmission by subtype A occurring within the Odessa outbreak
and subtype B in Nikolaev region. Following the outbreaks, subtype A subsequently spread to
other former Soviet union states, whereas subtype B did not [34]. However, as a result of both
subtypes being active within the Ukrainian population and in neighbouring countries, a small
proportion (1%) of infected individuals with a recombinant A/B subtype CRF03_AB has been
identiﬁed [33,35].
291.3.1 Odessa
Overall ﬁgures at the end of 2009 suggest that 11,204 individuals are infected with HIV in the
OdessaregionwithanHIVprevalenceof470,7per100,000population[36]. Theseﬁguressuggest
that of the 101,000 individuals infected in the Ukraine in 2009 one in ten originated from Odessa.
Odessa had the third highest number of HIV infections after Donetsk and Dnipropetrovsk
regions. Population estimates of at risk groups most vulnerable to HIV for 2009 were 40,000
PWID, 8,000 MSM and 5,500 FSW [36].
Following outbreaks of HIV among PWID in 1995, Odessa has contributed to the high numbers
of HIV diagnoses in Ukraine. The rapid increase in HIV prevalence of PWID following 1995 is
illustrated in ﬁgure 1.3 using a mathematical stimulation model [37] with the prevalence in 2009
estimated to be 53% [38]. The mathematical stimulation model uses data available on PWID
population, PWID mortality rate, mean duration spent as an PWID, demographic distribution of
PWID, risk behaviour indicative of injecting drugs, sexual behaviour and HIV transmission rate
by behaviour risk.
Strathdee et al also projected the number of new HIV infections among PWID in Odessa,
assuming no change in risk. This ﬁgure is estimated to be 6200 (95% CI: 4500-6500) new
infectionsbetween2010 and2015(ﬁgure1.4). AttributablerisksfornewHIVinfectionsindicated
by Strathdee et al include inadequate Antiretroviral therapy (ART) access by those already
diagnosed and non-sterile equipment use [37], the proportion of PWID using unsterilized
equipment in Odessa is estimated to be between 10 and 20% [19].
30Figure 1.3: HIV prevalence among PWID, 1990-2015. Blue crosses show prevalence estimates
from data; the pink area shows envelope of posterior model ﬁts; and the thick red line shows the
epidemic projection for the best-ﬁtting model.
Source: Strathdee et al Lancet 2010. [37].
Figure 1.4: Projected number of HIV infections every year for 2010-15 in the PWID population,
assuming no further changes in patterns of risk.
Source: Strathdee et al Lancet 2010. [37].
311.3.2 Kiev
Overall ﬁgures at the end of 2009 suggest that 6,847 individuals are infected with HIV in Kiev city
withanHIVprevalenceof249,8per100,000population[36]. Ofthe26regionswithintheUkraine
ﬁve, including Kiev City, accounted for 69% of all HIV infections. Kiev city had the fourth highest
number of HIV infections after Odessa, Donetsk and Dnipropetrovsk. Population estimates of at
risk groups most vulnerable to HIV for 2009 were 38,000 PWID, 14,000 MSM and 6,800 FSW [36].
321.4 Countries and Resources: Poland
Poland has a relatively stable epidemic [9,39] and since the ﬁrst diagnosis in 1985, the reported
cumulative number of persons newly diagnosed in Poland by the end of 2010 was 16,562,
including 2,907 AIDS diagnoses and 1,206 AIDS-related deaths [15]. The rate of diagnosed HIV
for Poland was higher than the overall rate for central Europe in 2012, 2.8 vs. 1.9 per 100,000
population respectively [15] and a small increase from the 1.8 for Poland in 2004 [10] (ﬁgure 1.5).
The adult (15-49) prevalence for Poland is 0.1% (95% CI 0.1-0.1) [1]. It is estimated that a
third of HIV positive individuals in Poland are unaware of their HIV status, with the number of
individuals living with HIV estimated to be as high as 30,000-35,000 [40,41].
HIV testing is available in Poland through medical, service initiated screening and patient
initiated facilities, such as Voluntary, Counselling and Testing (VCT) sites. Screening for HIV
is conducted at 300 laboratories across Poland and conﬁrmatory testing is available at 20
laboratories, the majority of which use western blot. Overall, within a year, around a million
HIV tests are conducted through blood blanks and a further 200-300,000 test through all other
facilities, testing information collected by European Centre for Disease Prevention and Control
(ECDC) shows an increase in the number of HIV tests over the past 7 years (ﬁgure 1.5) [15].
Although a large proportion of tests are conducted via blood banks, the large majority of positive
results are identiﬁed through diagnostic services or centres offering anonymous testing [40].
33Figure 1.5: Rate of new HIV diagnoses and number of HIV tests performed, Poland: 2004-2010.
Source: European Centre for Disease Prevention and Control [15].
34The distribution of persons newly diagnosed has changed over time with the primary route of
infection moving from PWID who, until recently, have accounted for 70% of all new diagnoses,
to sexual contact [10,42]. In a cross-sectional study of PWID entering a treatment program in
Warsaw between January and September 1993 the sero-prevalence was recorded as 45.9% [43].
This concentrated epidemic among PWID was largely due to high risk behaviours such as needle
sharing and a lack of needle exchange programme [43,44], among those in the cross-sectional
study, 24% reported borrowing and 37% reported passing on used syringes [43]. A needle
exchange programme for Poland was initiated in 1991 [41]. Other high risk behaviour reported
was sexual risk and among those PWID, who reported sexual contact (72%), 62% reported never
using a condom [45].
During 2000 - 2010 the number of new diagnoses attributable to injecting drug use fell by
90%, and the number of diagnoses among MSM, increased by 345% and among heterosexual
men and women, by 114% [10,39,40]. The number of diagnoses due to sexual contact, both sex
between men and women and MSM, overtook that of persons infected through injecting drug
use in 2008 [10] (ﬁgure 1.6).
There is considerable geographical variation across Poland, ﬁgures for 2010 ranged from
0.16 per 100,000 population in Swietokrzyskie to 4.55 per 100,000 population in Dolnoslaskie
(ﬁgure 1.7) [46].
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36Figure 1.7: Rate of HIV infections by geographical region per 100,000 population: Poland 2010.
Source: National Institute of Public Health - National Institute of Hygiene [46].
371.5 Countries and resources: Estonia
Estonia has a relatively new epidemic, although the ﬁrst case of HIV was identiﬁed in 1988,
the concentrated epidemic rose rapidly during 2000 reaching the highest HIV prevalence
(105.3 per 100,000 population) in the EU in 2001 [47]. Since then the incidence has been
gradually decreasing but diagnoses still remains high at 23.5 per 100,000 population in 2010 [15]
(ﬁgure 1.8), and was identiﬁed as one of three European countries presenting with an HIV rate
more than 20.0 cases per 100,000 population [15]. Estonia is still one of the three countries in
Eastern Europe and Central Asia in which an estimated HIV prevalence exceeding 1% of the
adult population (15-49 years), with 1.2% [1.0-1.5] [1]. By the end of 2010 the cumulative number
of new HIV diagnoses was 8377, with 390 AIDS diagnoses and 104 deaths among individuals
with AIDS [15].
Testing for HIV is accessible nationwide, with service initiated screening available in antenatal
settings, prisons and blood donor facilities. In 2011, over 200,000 tests were conducted on
147,000 individuals. The majority of tests (57%) were conducted in Tallinn, followed by Tartumaa
(29%) [Lutsar, Personal correspondence]. Studies among high-risk populations investigating
the uptake of HIV testing identiﬁed that 32% of MSM [48], 35% of Commercial Sex Workers
(CSWs) [49] and 38% of PWID had never had an HIV test [50]. Among the sample of PWID,
of those who were positive, 62% were unaware of their status [50]. It is estimated that in 2009
testing rates in high risk groups are still low, with 27% of MSM, 52% of CSWs and 47% of PWID
having had a test in the last 12 months and knew the result [1].
38Figure 1.8: Rate of new HIV diagnoses and number of HIV tests performed, Estonia: 2001-2010.
Source: European Centre for Disease Prevention and Control [15].
39Changes in the leading route of infection were instrumental to the rise of new diagnoses,
changing from sexual contact (both sex between men and women and sex between men) to
injectingdruguse. In2001thenumberofnewHIVdiagnoseshadpeakedat1,474,ofwhichPWID
accounted for 90% of diagnoses [51]. In more recent years the proportion attributable to PWID
has decreased (48% in 2009) [51] (ﬁgure 1.9), a positive outcome of the needle exchange projects
which were piloted in 2007 increasing from 13 sites to 36 in 2009 [51]. However prevalence
is high with studies conducted between 2002 and 2009 reporting the HIV prevalence among
PWID ranging from 45-56% [50,52,53], with estimated incidence reported as 20.9 per 100 person
years in 2005 and 2007 and 9.0/100 pyrs in 2009 [53]. In more recent years diagnoses among
heterosexuals have increased and in 2010 the number of diagnoses attributable to heterosexual
contact crossed that of PWID [10,51]. Information on MSM in Estonia is limited; however the
prevalence among a sample of 79 MSM in 2008 was 2.5% [48].
The rapid increase in HIV infections in 2000 initially occurred in the North Eastern region
of Ida-Virumaa, followed by the capital city Tallinn [51,54], with these regions still account for
the majority of new diagnoses representing 45% and 44% respectively in 2011 (ﬁgure 1.10) [55].
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Figure 1.10: Regional distribution of new HIV diagnoses in Estonia: 2011.
Source: Terviseamet Health Board, 2010 [55].
421.6 Focus of Thesis
TheaimofthisthesisistoidentifyandcharacterisenewHIVdiagnosesandrecentHIVinfections
in three counties within Eastern and Central Europe; Estonia, Poland and Ukraine. This is
addressed by introducing a relevant methodology for identifying recent infections and enhance
current surveillance methods to:
1. explore the distribution of persons newly diagnosed within in each country,
2. estimate robust incidence rates for each country,
3. validate methodologies for differentiating recent from long standing infections,
4. ascertain risk factors associated with onward transmission, and
5. assess the distribution of patients identiﬁed as recently infected.
Chapter one describes the distribution of HIV in Europe, and speciﬁcally in Estonia, Poland
and Ukraine. Chapter two outlines the different methods which have been used to estimate
HIV incidence and their limitations. Chapter three deﬁnes further the methods and deﬁnitions
behindtherecentinfectiontestingalgorithm,Chapterfourexploresthestatisticalmethodsused
toestimateincidenceandtheirlimitations. Chapterﬁvedescribesthedatasetsusedinthethesis,
methods for data collection and modiﬁcations applied. Chaptersix describes the characteristics
of persons newly diagnosed during the study period for each country and derives a number of
components needed for estimating incidence. Chapter seven describes the characteristics of
persons recently infected during the study period for each country, incidence estimates for each
country, the circulating HIV Subtype and the distribution of transmitted drug resistance among
those recently infected. Chapter eight discusses ﬁndings and methodologies with suggested
recommendations.
43Chapter 2
Methological Approaches to
Estimating Incidence
Using published literature I outline methodologies for estimating incidence, identifying studies
which have used these methodologies and present incidence estimates for the most recent ﬁve
years.
442.1 Introduction
Estimating HIV incidence is an essential public health monitoring tool, characterising those
at risk of HIV infection within a deﬁned population. Incidence estimates enable development
and evaluation of appropriate healthcare interventions, resource planning and allocation,
monitoringofcurrenttrendsintheepidemicandreducingonwardtransmission. Case-reporting
of HIV, already established in many European countries, enables estimates of the prevalence
of the disease to be made, establishing its magnitude within the population. However, this
prevalence rate does not necessarily reﬂect incidence patterns and cannot distinguish whether
the increase is due to onward transmission or a result of increased uptake of testing. This issue
arises from the time lag between when an individual is infected and subsequently diagnosed.
The long latent period for HIV means that an HIV-infected individual can live for many years
without knowing their HIV status. This is evident in the high proportion of individuals in Europe
who are diagnosed after a stage at which treatment should already have begun [10], by either
being newly diagnosed with a CD4 cell count less than 350 cell/mm3 or with an AIDS deﬁning
illness. This major limitation results in the prevalent snapshot failing to ascertain a true picture
of the current epidemiological situation. As a result, numerous methodologies have been
implemented and evaluated in an attempt to make robust incidence estimates to understand
HIV transmission patterns.
The main objectives of this literature review is to identify methodologies which have been
used for estimating incidence, and review studies which have applied and evaluated these
methods. Through reviewing papers, abstracts and national reports I have given a detailed
account of the most frequently used methodologies for estimating incidence and discuss the
performance and limitations which arise from each.
452.2 Literature Review Search Methodologies
I conducted a literature review using the PubMed electronic database, manual searches of
bibliographies and searching for grey literature through Google scholar, and abstracts from
three major conferences (International AIDS Society (IAS), the Conference on Retroviral and
Opportunistic Infections (CROI) and the Joint Statistical meeting (JSM)). Key words and search
criteria were used throughout the searches to ensure consistency and different combinations
were investigated to identify the most comprehensive search. Search criteria used (table 2.1)
were medical subject headings or Medical Subject Headings (MeSH) terms which are used
for indexing articles and words speciﬁcally identiﬁed in the Title and Abstract (TIAB). Two
separate searches were conducted in the PubMed electronic database, search a). HIV [MeSH]
and Incidence [MeSH] AND (recent [TIAB] OR incidence [TIAB]) and search b). HIV incidence
[All ﬁelds].
46Key Word Search Criteria Results
1. HIV MeSH 71,404
2. Incidence MeSH 145,619
3. Recent TIAB 565,859
4. Incidence TIAB 438,559
5. RITA TIAB 634
6. STARHS TIAB 39
7. Detuned Assay TIAB 13
8. HIV Incidence TIAB 1024
9. Incidence Estimation TIAB 57
10. Incidence Assay TIAB 9
11. BED TIAB 56,491
12. 1 AND 2 1086
13. 3 to 11 (OR) 1,031,222
14. 3 OR 4 OR 5 OR 6 OR 11 1,031,222
15. 1 AND 2 AND 14 676
16. 1 AND 2 AND 3 OR 4 689
17. HIV Incidence All Fields 890
Table 2.1: Search criteria used for identifying literature through the PubMed electonic database.
472.2.1 Pubmed Electonic Database
Two separate searches were conducted in the PubMed electronic database, search a) "HIV"
[MeSH] AND "Incidence" [MeSH] AND ("Recent" [TIAB] OR "Incidence" [TIAB]) and search
b) "HIV incidence" [All ﬁelds]. Although all the key words previously identiﬁed were included
in the initial development of search a, those key words that did not offer any further literature
were dropped; the key word manipulation can be seen in the table. Search b was conducted to
incorporate any possible literature which might have been missed through the search a.
The initial literature search identiﬁed 689 publications for search a and 890 for search b.
Titles and abstracts for these publications were appraised for inclusion, only English language
papers were reviewed. Final inclusion included 102 publications for search a (ﬁgure 2.1) and 105
for search b (ﬁgure 2.2).
2.2.2 Manual Bibliography Search
A manual bibliography search was conducted on all literature identiﬁed through the PubMed
electronic database search to identify any key publications which were not captured through the
initial search. Sixty publications were identiﬁed and included in the literature review.
2.2.3 Second Search
A second literature search was conducted in August 2013 using both methods indicated in
section 2.2.1 and section 2.2.2. 52 additional publications were identiﬁed and included in the
literature review.
2.2.4 Conference Proceedings
Amanualsearchwasconductedonallabstractsacceptedforeitheranoralorposterpresentation
atthe three conferences indicated previously (IAS, CROI andJSM) to identify any key workwhich
has not yet been published. Forty-six abstracts were identiﬁed and included in the literature
review.
482.2.5 Grey Literature
Google Scholar and the search engine Google were used to identify grey literature. The majority
of these documents were produced by multinational organisations including the World Health
Organisation (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) and the
European Union agency the ECDC previously EuroHIV. Three reports were identiﬁed and
included in the literature review.
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512.3 Methods for Estimating Incidence
I identiﬁed three main methods through reviewing the literature: longitudinal studies,
studies using serological testing, and studies using sero-positive data. Overall, I identiﬁed
328 publications which used one or more of the three methodologies, or discussed the
methodologies, with the majority using serological methods and, in particular, RITA. Within this
section I will discuss the different methods used to derive incidence estimates, and discuss the
limitations of each method and interpretation of derived results.
2.3.1 Longitudinal Studies
Longitudinal studies are a direct method for measuring incidence, whereby persons who are
initially without the disease of interest are followed-up over time. New infections are identiﬁed
during this time period through regular follow-up allowing time of infection to be estimated as
the midpoint between the last negative date and ﬁrst positive date. Incidence is, therefore, the
number of new infections per person-years at risk[N/PY].
Ideally a cohort would follow the population prospectively, starting with a sero-negative
population, and through regular follow-up or the patient returning for at least one follow-up
visit, new infections can be identiﬁed. This method allows incidence to be directly measured
and multiple exposures to be considered. However, this method is time consuming, expensive
and, depending on the level of incidence within the population, could require several years
in duration to collate meaningful estimates. A further issue is the representativeness of the
population; cohort studies are susceptible to loss to follow-up with those remaining under
follow-up having different experiences and, therefore, HIV incidence rates, from those lost to
follow-up. A study among MSM indicated that compared to MSM who remained in the study,
those who were lost to follow up were signiﬁcantly more likely to be risky and therefore have
higher incidence [56]. There may also be changes in behaviour among the participants as
information on risk reduction and prevention measures become available and are taken up by
them.
An alternative method is the retrospective cohort which uses information on all persons
52presenting for a test at a particular site regardless of their HIV status. For these persons, the
testing history either held at the testing site or self-reported by the individual is used to estimate
HIV incidence. However, with a retrospective cohort the appropriate denominator needed for
estimatingincidenceisnotknown. Inaddition, repeattesterscouldleadtoanover-estimationof
incidence, repeat testing because of high risk behaviour, or an under-estimation where engaging
with health services results in lower risks.
2.3.2 Sero-positive data
Indirect methods of estimating incidence are based on HIV diagnoses: by testing of populations
throughserialsero-surveys, andby use ofmathematicalmodels. Primarily based ondataalready
collected, these methods are much less costly.
Probably the most recognised use of sero-positive data is the Estimation and Projection
Package (EPP) used by UNAIDS and the WHO to calculate country speciﬁc short-term estimates
including incidence [57–65]. Estimates are generated by ﬁtting an epidemic model to the
observed prevalence data, with additional assumptions on survival, sex ratio, effects of HIV
on fertility, MTCT rates, age patterns and the effects and coverage of treatment [58]. Four
parameters are used to estimate the best ﬁt; 1. the rate of growth of the epidemic; 2. the fraction
of the population at risk of infection at the start of the epidemic; 3. the starting year of the
epidemic, and 4. a parameter that modulates recruitment to the at-risk population in response
tomortality-drivendeclinesinthepopulationovertime[58]. Thismodelhasbeenreviewedevery
two years since its introduction in 2003, with modiﬁcations allowing for movement between
populations [60], ﬂuctuations in prevalence [61]. More recently, modiﬁcations allowing for
incidence rates to vary over time with long running epidemics [64,65] and the use of population
based CD4 cell counts, estimates of MTCT and survival in children [66].
Alternative methods for estimating incidence include the use of prevalence data, through
consecutive surveys or ﬁxed populations [67–71]. Incidence estimates can be made through
linking two or more cross-sectional surveys; determining how many of those participating more
than once had seroconverted over time, using changes in sero-prevalence in a ﬁxed population
to reﬂect new infections or by dividing the difference in sero-prevalence between two surveys by
53the time between them. Prevalence in younger age groups, particularly among pregnant 15-24
year olds [72,73], provides an estimate of incidence as young age groups have had less time to
acquire an HIV infection sexually and, therefore, are likely to represent incident infections. If
the incidence is stable over time in the population of interest, the linear increase of prevalence
should reﬂect HIV incidence [67,74,75]. Finally, short-term incidence has been estimated using
mode of transmission (MOT) model, estimating the number of new infections occurring among
particular risk groups, using the population size of each group, current prevalence, and risk of
exposure [76–80].
The Back-calculation method uses temporal data on a disease end point to reconstruct
trends in the number of new infections underlying the observed end point time series. This
method has been used to estimate past trends in HIV incidence on the basis of temporal data
on AIDS diagnosis. The estimated HIV incidence can then been used to provide projections of
AIDS incidence [81–93]. In its simplistic form the back-calculation method relies on knowledge
of the incubation period between HIV infection and AIDS diagnosis and the number of observed
AIDS diagnoses over time. A number of developments to the model have addressed changes in
the incubation period with the introduction of treatment [92,93], test-seeking behaviours [88] ,
differences in populations and incubation periods such as age [89,90,94,95]. In particular, the
changes in the distribution of the incubation period following the introduction of Antiretrovirals
(ARVs) and the diminished relevance of the AIDS end point have impacted on the ability
to use this method and its usefulness, respectively. Amongst the various developments,
a recent formulation of the back-calculation uses HIV diagnosis as disease end point and
exploits information on CD4 counts around diagnosis to estimate past HIV incidence. Here
HIV progression through CD4 stages and testing uptake from the different disease stages are
simultaneously modelled [96–103].
Further mathematical models ﬁt age- and time-speciﬁc prevalence data using the maximum
likelihood method [70, 104–110]. This method extends the use of prevalence in younger age
groups to estimate incidence. A number of adjustments have meant numerous modiﬁcations
to the maximum likelihood model including inﬂuence of calendar time, changes in incubation
time overall and between risk groups, mortality and morbidity [111] and, in particular, the
effect of the "relative inclusion rate" among the infected and uninfected [104,106,107,109,110].
54Alternatively, a deterministic transmission dynamic model can be used, incorporating data on
HIVprevalence, demographicandbehaviouraldata[112]oraStochasticSimulationModel[113].
2.3.3 Serological Testing
Laboratory-based methods to differentiate recent from long-standing infections using the
maturing antibody response to the HIV infection have been developed since the early 1990s.
Unlike longitudinal studies which require signiﬁcant follow-up to identify recent infections,
this method uses a single sample of diagnostic serum taken at a single point in time. This
methodology is collectively known as RITA, previously the Serological Testing Algorithms for HIV
Seroconversion (STARHS), and refers to the laboratory assay and additional clinical information
required to estimate incidence. Each serological test uses key components of the antibody
response to the virus following infection to identify whether an individual has been recently
infected, including antibody concentration, response, reaction or proportion, isotype and
avidity (ﬁgure 2.3).
55Figure 2.3: Evolution of HIV after initial infection.
Source: Murphy et al Eurosurveillance 2008 [4]
56There have been eight laboratory methodologies developed, two among those pre-
seroconversion and six among the sero-positive population, table 2.2 gives an overview
of each method. Based on the biological marker, an optical threshold is derived from the
quantiﬁed result (Optical Density (OD)) of the anti-HIV immune response measured by the
assay deﬁning the point an individual stops being recent (i.e. has an OD below the threshold)
and becomes classiﬁed as an established infection (i.e. has an OD above the threshold). The
time an individual stays below this threshold is referred to as the "Mean Duration of Recent
Infection (MDRI)" "window period of recency", "duration of recency", "recency period" or
"seroconversion window". This period differs between individuals and between the serological
tests. Serially testing samples from individuals with known dates of seroconversion, the OD and
corresponding sample date (HIV infection duration) for each person is plotted to establish the
optimal threshold which will best deﬁne a recent infection. This is achieved through increasing
the OD by increments of time to maximise sensitivity and speciﬁcity, estimating the mean and
median OD by deﬁned time, reaction/response measured by time, linear or non-linear mixed
models, non-parametric survival analysis or using the proportion of recent infections among
seroconverters. The incidence estimates are then derived from a mathematical formula, details
are given in Chapter 4.
57RTIA Assay Overview of methdology
p24 antigen [114,115] Identifying the p24 antigen when negative or
intermediate for HIV antibodies
HIV RNA [116] Presence of HIV RNA in the absence of HIV antibodies
Sensitive/Less Sensitive EIA
(detuned) [117]
Uses one sensitive and one less sensitive assay to
identify rising antibody levels
IgG BED-CEIA [118] MeasurestheproportionofHIV-speciﬁcIgGantibodies
Avidity [119] Uses the avidity index (bond between antibodies and
antigen)
IDE-V3 EIA [120] Antibody concentration for identiﬁed antigens
IgG3 Isotype [121] Antibody response to speciﬁed antigens
INNO-LIA HIV I/II score [122] Antibody reaction to speciﬁed antigens
Table2.2: MethodologyoverviewoftheRITAassaysusedtodistinguishrecentfromlongstanding
infections and their limitations.
58There are 3 main frameworks used for estimating incidence: a cross-sectional sample, sentinel
surveillance, and through routine testing sites. Cross-sectional studies collect data on a study
population, representativeofthewholepopulationatagivenpointintime. Personsare included
using a sampling strategy or through convenience sampling based on accessibility using sexual
health clinics, bars or community groups. Sentinel surveillance allows detailed information to
be collected from a limited number of sites, which could be a population of particular interest
or a representative sample of the overall population. For both methods information is available
on both the sero-negative and positive population allowing HIV incidence to be estimated using
the approach described in Section 4.2.
RITA testing can also be introduced into already established surveillance systems. However,
for the majority of studies using surveillance systems data and samples are only available for
positive persons, requiring a different approach to estimating incidence (section 4.3).
Although RITA addresses the limitations surrounding longitudinal studies by removing the
need for repeat testing, there are still a number of limitations that need to be considered.
A fraction of long-standing infections could be classiﬁed as recent due to factors impacting
a person’s immune response. These factors include AIDS or a low CD4 cell count, a low or
undetectable viral load or being on treatment at the time of the test [123, 124]. A false recent
result could also occur if a person’s antibody response remains under the threshold for a
prolonged period of time [124, 125]. Further factors found to impact test characteristics are
pregnancy, co-infections and HIV sub-type [123,126–130]. Consideration must also be given to
the representativeness and size of the population being tested. These issues will be discussed
further in chapter 3.
For the majority of studies where an assay was used but incidence estimates were not derived,
the results were presented as the proportion identiﬁed as recent and were more likely to have
been conducted using only those identiﬁed as HIV positive. Alongside the introduction of new
methods for detecting a recent infection there has also been a shift from using a cross-sectional
framework for collecting data to introducing RITA testing to an already established national
surveillance system within the country.
592.3.4 Ambiguous Nucleotides
Also being investigated is the idea that genetic diversity of the virus sequence could be used
to deﬁne the age of infection. Although this method has not currently been used to estimate
incidence speciﬁcally, it has been considered as a method to differentiate recent from long-
standing infections. Much like many of the biological markers used by the serological test
(see section 2.3.3 and Chapter 3) such as the avidity index, genetic diversity, the proportion of
ambiguous bases in the HIV-1 pol sequence, increases from a single virus in early infection,
suggesting inference of a person’s age of HIV infection.
Four studies [131–134] have investigated the use of genetic diversity to differentiate recent
from long-standing infections, suggesting that a cut-off of 0.45-0.50% could distinguish an
infection ¸ 1 year from chronic (>1 year). However, although there appears to be a correlation
between age and genetic diversity, estimated at 0.2% per year [134], all studies found the
speciﬁcity to be around 70%, with Kouyos et al suggesting that genetic diversity may be more
helpful at accurately discriminating against chronic infections rather than recent [134].
As a simple and inexpensive method, particularly if transmitted drug resistance is already
being assessed this should be considered as a complementary approach to the serological test
(RITA), minimising misclassiﬁcation of long-standing infections as recent.
602.4 Overview of Published Incidence Estimates
Using the methods indicated in section 2.2, I identiﬁed studies which have estimated incidence
using one or more of the three methods discussed. Publications which included incidence
estimates were collated and grouped by study region. All incidence estimates were present by
100 pearson years (pyrs) at risk (or of follow-up). Methods were grouped into cohort, RITA and
other and populations of focus were grouped into high risk, testing population and other; the
distributionofthesegroupsareinappendix A.Studieswhichdidnotpresentincidenceestimates
were more likely to provide the proportion of persons recently infected and these studies are
discussed separately.
2.4.1 Incidence estimates per 100 person-years at risk.
In total I identiﬁed 230 studies published over a 20-year period (1994-2013), producing 767
incidenceestimatesfortheyears1984-2011. Thedistributionofthesestudiesareshowninﬁgure
2.4, with 91 studies within Americas, 55 and 60 in Asia/Australasia and Africa respectively and
24 in Europe (20 in Western Europe and 5 in Eastern Europe). I grouped the study populations
into 4 categories, high risk, Population Surveys or Surveillance, Screening and other, with
131, 80, 18 and 22 studies in each group, respectively. Sixteen studies reported estimates for
more than one population category and 29 used multiple methods to estimate incidence.
Predominately these studies used the cohort method (143) or serological test (105); only a
small number used mathematical models. Within these methodological groups, 118 cohorts
were prospective [56,68,105,114,125,135–245] and 30 retrospective [68,221,246–272]. For the
serological test the breakdown is as follows: Four studies used p24 antigen to identify recent
infections [68,114,190,241], 3 used HIV RNA [190,231,273], 43 used the concentration of HIV
antibodies (LS-EIA) [162, 232, 252, 256, 259, 274–311], 58 the proportion of HIV speciﬁc IgG
antibodies(BED-CEIA)[80,125,154,157,159,164,175,178,201,202,224,231,238,240,252,254,263,
273,284,299,307,309,312–346], 11 Avidity index [178,231,240,251,273,284,290,343,344,347,348]
and 3 used antibody response to antigens [349–351]. Details of these serological tests can be
found in chapter 3.
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62Methods differed by region with estimates for Africa more likely to be from a cohort study than
RITA (40 vs.17) whereas for Americas and Asia/Australasia there was little difference between
the two groups. Differences by country were also seen by study population. African studies were
more likely to be from population-based surveys compared to all other regions where the focus
was on high risk populations. These populations were representative of the distribution of those
at risk, with Americas and Western Europe having a higher number of studies among MSM,
Asian CSWs and Eastern Europe PWID.
Focusing on incidence estimates for the most recent ﬁve years (2007-2011), where
date was reported, 42 studies were included (table 2.5). Asia/Australasia had 13 and
Americas had 14 studies each [56, 80, 156, 157, 159, 159, 161, 169, 171, 185, 194, 207,
208, 213, 214, 226, 231, 255, 270, 301, 317, 318, 334, 336, 346], 11 from sub-Saharan Africa
[141,182,183,191,195,196,218,219,230,344,352]and8inEurope[113,223,227,254,258,348–350].
The majority of studies were among high risk populations (32), followed by Population Surveys
or Surveillance (14), Screening (3) and used the cohort method (31), RITA (15) or other (3).
The highest incidence estimates for Africa were among women in South Africa ranging from 5.5
per 100 pyrs [230][152] to 14.8/100 pyrs [195]. Incidence estimates among FSW in Kenya were 5.6
per 100 pyrs [191] and among discordant couples in Uganda 4.3 per 100 pyrs [182]. The lowest
incidence estimates were among Police Ofﬁcers in Tanzania with 0.84 and through community
based clinical trials in Zimbabwe and Tanzania with 0.91 and 0.78, respectively [196,344].
Incidence estimates for women in the USA were, as expected, much lower than in Africa
with estimates ranging from 0.13 per 100 pyrs to 2.52 [231]. The highest incidence estimates
were among MSM in New York with 5.7 per 100 pyrs [255]. PWID in Vancouver were estimated to
have incidence of 2.49 [161] and FSW in Honduras 0.23 [80]. Estimates for 50 US states and the
District of Columbia in 2009 were 0.019 falling from 0.023 in 2007 [346].
For Asia and Australasia, the majority of incidence estimates were calculated among the
three main risk groups MSM, PWID and FSW.PWID from Dehong Prefecture in China had
incidence estimates as high as 9.7 per 100 pyrs in 2007 falling to 4.3 in 2008 [318]. Estimates for
MSMrangedfrom8.09[207]to2.6per100pyrsinBeijing[185]andamongFSWestimatesranged
63from 4.4 per 100 pyrs in Yunnan [353] to 0.6 in Dehong Prefecture [318]. Discordant couples
had estimates of 7.2 per 100 pyrs in Dehong Prefecture [318] and pregnant women, pre-martial
couples and military personnel all had estimates below 0.25 per 100 pyrs [318,336].
MSM who had post exposure prophylaxis in Amsterdam had the highest estimates in Western
Europe with 6.4 per 100 pyrs [227] with the lowest in Italy with 0.601 per 100 pyrs [348]. Overall
estimates for PWID were low ranging from 0.043 to 0.577 per 100 pyrs in Italy between 2007
and 2008 [348]. The lowest estimates were among those newly diagnosed in Italy falling from
0.0208 in 2007 to 0.0199 in 2008 [348] and in France 0.017 per 100 pyrs [349]. Estimates for Easter
Europe were available for only one study investigating PWID in Russia and during the period
between 2005 and 2008 HIV incidence was 25.5 per 10 pyrs [254].
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692.4.2 Proportion identiﬁed as recent
I also identiﬁed studies which presented the proportion of recent infections within a population
[354–380]. The majority of these studies were focused on persons newly diagnosed with HIV,
following the introduction of testing for recent infections as part of the surveillance of HIV. As
this method in many cases only includes those persons newly diagnosed, estimating incidence
is much more complicated due to the limited information on the negative populations. The
populations recently infected among new diagnoses varied from 11% in the UK to 35% in
Australia (ﬁgure 2.6).
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Figure 2.6: Proportion of recent infections among newly diagnosed persons by country and year
of diagnosis.
712.5 Summary
Although most countries monitor their epidemics through sentinel or country based
surveillance, this method is limited to understanding HIV prevalence and retrospective
transmission patterns. To truly understand the dynamics of the current epidemic there is a need
for timely and robust incidence estimates.
Through published literature I identiﬁed three methodologies which have been used to
estimate HIV incidence: following a cohort of sero-negative individuals, sero-positive data
collected through routine surveillance and using the maturing response of the virus through a
laboratory test. It is important to note that there is no gold standard method for estimating HIV
incidence.
Following a cohort of sero-negatives is a direct method for estimating HIV incidence identifying
those who become sero-positive. Although direct, this method requires a long period of time
for follow-up, especially if the incidence rate is low, and a large amount of expenditure. Where
information on testing history is available it is possible to work backward using a retrospective
cohort of all individuals testing for HIV at an identiﬁed site. The time of infection is estimated
as the mid-point between an individual’s previous negative and ﬁrst positive test. Determining
the time of incident infection from previous testing history reduces the need for time and
money but introduces a number of biases. A person’s reason for repeat testing could result in an
over-estimation of incidence, testing because of high-risk behaviours or an under-estimation as
those who engage with health services maybe at lower risks of HIV.
Alternatively, using sero-positive data already collected is an indirect method to estimate
HIV incidence through serial surveys or mathematical models. These methods are relatively
inexpensive as they largely depend on data already collected. However, they are vulnerable
to changes in the epidemic, such as the introduction of treatment, and are dependent on the
assumptions of the mathematical model, which may lead to unreliable estimations.
Finally, the RITA assay which uses key components of the maturing antibody response to
the virus to determine whether an individual is recently infected or long-standing, has been a
practical alternative to prospective and retrospective cohorts. This method uses a serological
72test on a single serum sample taken at a single point in time, requiring no follow-up, and can be
introduced to surveillance and laboratory methodologies already in place. Although addressing
the limitations which arise through longitudinal and sero-prevalence methods, the RITA assay
has its own limitations. Ensuring the correct assay is chosen and that it has been validated for
use in the population of interest is extremely important. Furthermore, key components such as
the sampling framework, sample size and methods for limiting the possibility of misclassiﬁed
results need serious consideration which I discuss in Chapter 3.
In additional but not speciﬁcally for estimating incidence, is the use of genetic diversity
to differentiate recent from longstanding infections. Although there does appear to be a
proportional cut-off which indicates recent from longstanding infections, this methodology
currently is best used to discriminate those infections >1 year rather than those ¸ 1 year. Where
transmitted drug resistance is already being assessed this methodology should be considered
particularly in conjunction with the serological test.
Incidence estimates per 100 pyrs for the past ﬁve years were presented by geographical
region and population. Although the distribution of populations investigated reﬂect the
epidemic within each region, making comparisons between estimates is difﬁcult due to the lack
of consistency in the methods used to identify populations and statistical methods to estimate
incidence. The introduction of a test for recent infection to national HIV surveillance will allow
for a wider comparison between risk groups, regions and years. In the meantime, what could
be determined were the populations at greater risk of HIV within particular regions with higher
incidence estimates more likely to be among populations such as MSM, PWID and CSWs.
The introduction of RITA within HIV testing facilities was the technique used to estimate
incidence rates and understand the current transmission dynamics for the three countries
identiﬁed in this project. Although there is no gold standard of estimating incidence, this
technique will enable timely estimates to be made and to develop tailored prevention and
intervention efforts, reducing onward transmission in countries where the diagnostic rates are
the highest in Europe and to focus resource planning and allocation.
73Chapter 3
Serological Tests for Identifying
Incident Infections
Within this chapter, through literature identiﬁed in the methods section of chapter 2, I will
review the methods developed for distinguishing a recent infection using biological markers, the
corresponding limitations and the key components needed for estimating incidence.
743.1 Introduction
The initial serological method for differentiating recent from long-standing infections was
introduced in 1998 [117], leading to the development of multiple techniques, collectively
knownastheRITAortheSTARHS.Eachserologicalmethoduseskey componentsoftheantibody
responsetothevirusfollowinginfection,illustratedinﬁgure2.3,suchasantibodyconcentration,
proportion, isotype and avidity.
Following initial infection, HIV RNA and a protein component of the virus, p24 antigen,
are usually present for a short period of time before HIV antibodies are detected, after which
time only HIV RNA remains detectable. Antibody reactions follow with an initial peak and fall
in immunoglobulin M (IgM) followed by a gradual increase in immunoglobulin G (IgG). The
avidity index, the strength of the bond between antibody and antigen, also increases following
the development of HIV antibodies [4].
These initial components after infection may be broken down into six so called Fiebig
stages [381]: stage I RNA positive, stage II RNA and p24 antigen positive, stage III RNA,
p24 antigen and HIV IgM-sensitive EIA reactive, stage IV same as stage III but indeterminate
Western blot, stage V same as stage IV but Western blot reactive (excluding p31), and stage VI
same as stage V but full western blot reactive. Stages I-IV are estimated to have an average
time-frame of 3-5 days each, stage V 69.5 days and stage VI is open ended. As a result, the
identiﬁcation of particular markers or early levels of immune response can indicate a recent
infection.
753.2 Serological Tests for Identifying Incident Infections
I identiﬁed published literature on eight different methodologies developed for detection of
recent infection, which include both purposely developed assays and commercially available
diagnostic tests which have been modiﬁed for purpose. The principle central to each recent
HIV infection assay is that an optimal threshold and mean duration of recency are deﬁned and
used to determine whether or not an individual is likely to have been recently infected. These
thresholds are determined by the individual OD, the quantiﬁed result of the anti-HIV immune
response, as measured by the RITA assay, and the corresponding time since seroconversion
for each person. Among a population of individuals with a known date of seroconversion, the
OD and corresponding date of sample for each person is examined to establish the optimal
threshold which will best deﬁne a recent infection. Through deﬁning this threshold the mean
timefromseroconversiontowhenindividualsareestimatedtoreachthisthresholdisestablished
to determine the MDRI.
3.2.1 p24 antigen
Thep24antigenisoneoftheﬁrstserologicalmarkerspresentafterinitialexposuretoHIV,andits
evolution may be deﬁned by three stages [114,115]. Following initial exposure, a person will be
negative for both HIV antibodies and p24 antigen (stage 1), then negative for HIV antibodies and
positive for p24 antigen (stage 2) and, ﬁnally, test indeterminate for HIV antibodies and positive
for p24 antigen (stage 3). After these three stages, the person may or may not be positive for
p24 antigen but will test positive for HIV antibodies. Persons identiﬁed in either the second
or third stage are classiﬁed as recently infected. Brookmeyer et al estimated the duration of
stages 2 and 3 by examining serology from 15 patients who were positive for p24 antigen and
negative/indeterminate for HIV antibodies and approximated stage 2 to last for 3.5 days and
stage 3 for 19.0 days [115]. The main limitation of this method is the window period for detection
which due to the short time period, requires the sample size for the study to be large and if
possible from a population with high HIV incidence, ensuring a sufﬁcient number of persons
who have not yet seroconverted but have detectable p24 antigen are available.
763.2.2 HIV-RNA
Like the p24 antigen, the presence of HIV-RNA in the absence of HIV antibodies can be used to
identify a recent HIV infection. Although, HIV-RNA is present throughout a person’s infection,
for an estimated 28 days after initial infection HIV-RNA is present in the absence of any immune
response to the virus [116, 190]. Again like the p24 antigen, a large sample size is needed for
estimating incidence due to the short window period when RNA is present in the absence of
antibodies.
3.2.3 Sensitive/Less sensitive EIA or ‘detuned’
The sensitive/less sensitive enzyme immunoassay (LS-EIA) relies on the ability to identify the
rising concentrations of HIV antibodies using two versions of the Abbott 3A11 assay [117].
Through increased serum dilution (1:20,000) and shortened incubation times, the Abbott 3A11
assay was modiﬁed to be less sensitive to detecting lower concentrations of HIV antibodies.
Persons who are reactive to the Abbott 3A11 and non-reactive to the less sensitive Abbott assay
are identiﬁed as a recent infection. The OD or antibody concentration, for each sample is
standardised using formula 3.1.
(Sample OD - Negative control OD)
Positive control OD
(3.1)
Both plasma and serum samples from 104 seroconverters, were collected from 3 sources and
used to determine the duration of recency, with further samples collected from 268 persons
infected for 2.5 years without AIDS and 158 with AIDS to determine how long the test remained
reactive. The distribution of time between the last non-reactive results to the ﬁrst reactive result
for individuals were calculated using a mathematical model with varying cut-offs. The cut-off
value found to be most reliable in estimating the time between tests was 0.75 with a duration of
recency of 129 days (95% CI 109-149 days) (ﬁgure 3.1). Using this cut-off 0.4% of persons with
a longstanding infection without AIDS and 2.4% of those with AIDS were misclassiﬁed as being
recent.
77Figure 3.1: Distribution of seroconverters by days since seroconversion and optical density.
Source: Janssen et al JAMA 1998 [117]
78FollowingthelimitationoftheAbbott3A11-LSEnzymeImmunoassay(EIA)requiringspecialized
equipment and an FDA injunction in January 2000, a 2nd generation LS-EIA was developed,
speciﬁcally the Vironostika-LS EIA [382]. Initial correlation measures were tested using the
Abbott 3A11-LS EIA protocol, reporting a high degree of correlation between the Vironostika-LS
EIAand3A11-LSEIA,identifyingrecentfromlongstandingspecimens[382]. Furtherstudiesalso
found a high degree of correlation with >95% of specimens giving concordant results [282,383],
andintheUK,althoughagoodcorrelationbetweenthetwoassayswasreported,theVironostika-
LS assay classiﬁed a higher number of specimens as recent [384]. More recently, a less-sensitive
version of the diagnostic assay Vitros Anti-HIV 1+2 has been developed [385].
3.2.4 IgG BED CEIA
The BED-CEIA assay [118] measures the level of IgG antibodies in the person’s serum, allowing
the proportion of the total IgG which is HIV-speciﬁc to be calculated. As HIV-speciﬁc IgG is
estimated to increase for two years post seroconversion, persons with a low proportion of
HIV-speciﬁc IgG are likely to be recently infected. Unlike the LS-EIA, the BED-CEIA assay has the
ability to detect HIV speciﬁc antibodies from a wider selection of subtypes, as it uses a branch
peptide containing subtype B, E and D . The OD, the proportion of HIV-speciﬁc IgG, is calculated
using formula 3.2.
Mean Specimen OD
Mean Calibrator OD
(3.2)
To deﬁne the optimal threshold and duration of recency for the BED assay, more than 600
longitudinal specimens with a known seroconversion date were tested, the distribution can
be seen in ﬁgure 3.2. Sensitivity and speciﬁcity values were calculated for different assay and
recency duration thresholds, increasing the assay threshold in 0.1 increments between 0.5 and
1.5 and the duration of recency in increments of 10 days between 120 and 220 days. With 81.7%
sensitivity, and 89.1% speciﬁcity, the optimal thresholds identiﬁed were an OD of 1.0 within
160 days [118,386]. Alternatively, the duration of recency was estimated as 158 days (95% CI:
151-163) using a linear mixed effect model.
79Figure 3.2: Distribution of specimens with known seroconversion, with suggested optimal
thresholds.
Source: Parekh et al AIDS Research and Human retroviruses 2002 [118].
803.2.5 Avidity Index
The Avidity Index (AI), the strength of the bond between the viral protein (antigen) and the
HIV-speciﬁc antibody, can be used for determining incident infections [119,387,388], a method
already in use for the management of rubella and cytomegalovirus infection during pregnancy
[Eggers 2000, Jenum 1997, Matter 1997]. Like the antibody response, the AI increases during the
ﬁrstyearofinfection,beforestabilisingatavalueof1,withantibodieshavingalowavidityforthe
antigen within the ﬁrst six months of infection. The calculation for a person’s AI is determined
by formula 3.3.
Sample cut off ratio of the guanidine aliquot
(Sample cut off ratio of the phosphate - buffered saline aliquot)
(3.3)
The optimal threshold for distinguishing a recent infection was determined by using serum
samples taken from 47 persons with a known date of seroconversion. Using the distribution of
AI by time from seroconversion for these individuals (ﬁgure 3.3) a mean and median AI was
identiﬁed to be lower than 0.8 for those diagnosed within 6 months from seroconversion. The
diagnostic accuracy of the AI was investigated using ROC curves with a 79% sensitivity and 92%
speciﬁcity for those with an AI <0.8 [119].
These ﬁndings were conﬁrmed using a panel of samples for 1,075 days follow up, with an
AI cut off of · 0.75 equating to 125 days (85 to 164) and an AI cut off of · 0.80 equating to 142
days (107 to 183) [387].
Since the initial application of the AI using the AxSYM HIV 1/2gO assay to differentiate
recent from longstanding infections [119] there have been numerous applications, the two-well
avidity index EIA (AI-EIA), single well limiting antigen avidity EIA (LAg-Avidity EIA) [389,390], an
avidity modiﬁed version of the Vitros Anti-HIV 1+2 assay [385], a modiﬁed version of the Bio-Rad
Genetic Systems TM 1/2 plus O [391] and a bead-based multiplex assay using multiple avidity
measurements from multiple HIV antigens [392].
81Figure 3.3: The distribution of AI by months from seroconversion for specimens with a known
date of seroconversion.
Source: Suligoi et al Journal of Clinical Microbiology 2002 [119].
823.2.6 IDE-V3 EIA
The IDE-V3 EIA is a simple approach using an indirect enzyme-linked immunosorbent assay
for identifying recent infections [120]. This assay uses the antibody concentration without
the need of a commercially available assay; a limitation found with the avidity, detuned and
BED assays. Four HIV antigens were identiﬁed based on particular features, a. whether the
antigen was recognised in all patients, b. the antigen’s clade relationship, and c. the ability to
obtain and detect the antigen after seroconversion [120]. The four antigens chosen were the
immunodominant eptitope (IDE) of gp41, V3 peptides, Integrase (IN) p32 and p24. Using serum
for persons with known dates of infection, the antibody concentration was recorded for each
of the four antigens, and used to determine whether there was a distinction between persons
infected in the last 6 months (<180 days) and long standing infections (>180 days).
A deﬁnite distinction was identiﬁed in the median ratio for antibodies found in patients
with a recent infection compared with established infections using the antigens IDE and V3,
with a 20 fold difference for each [120]. The distinction between samples using IN and p24 were
much lower (10 fold) but with considerable overlap between the two groups to allow meaningful
separation between them (ﬁgure 3.4). Samples were classiﬁed into recent and long-standing
infections using the probability of being classiﬁed as long-standing based on the combination of
antigens. These probabilities were estimated using logistic regression with a probability of · 0.5
being classiﬁed as recent and >0.5 being classiﬁed as long-standing [120].
All possible combinations of the different antigens were tested to determine the best model
using ROC curves. The IDE alone or in combination with V3 was found to best differentiate
between recent and long-standing infections. The sensitivity and speciﬁcity using the IDE-V3
combination was 88.3% and 100% respectively [120].
83Figure3.4: Probabilitydistributionofbeingclassiﬁedasrecentlyinfected(·180days)byantigen,
among persons with a known date of seroconversion.
TS: Training Sample; VS: Validation sample; (VS used as an external validation of the parameters
estimated in the TS). Comparison was made for less than or equal to 180 days vs. greater than
180 days and longstanding infections with (AIDS) vs. without (chronic) symptoms.
Source: Barin et al Journal of Clinical Microbiology 2005 [120].
843.2.7 IgG3 Isotype
Another simple approach is examining whether antibodies generated in response to speciﬁc
antigens are indicative of a recent infection. This was achieved using an antibody isotype-
speciﬁc HIV-1 western blot which was further quantiﬁed using an antibody isotype-speciﬁc
enzyme-linked immunoabsorbant assay [121]. The response of three different biotinylated
secondary isotyping antibodies (IgG, IgG1 and IgG3) to HIV-1 speciﬁc antigens among persons
testing for HIV during and following seroconversion were examined. IgG and IgG1 resulted in a
wide range of HIV-1 speciﬁc antigens being detected, whereas IgG3 identiﬁed responses to p17
and p24 with transient responses to p66 and p32 (ﬁgure 3.5). When the anti-p24 response was
measured by densitometry it was found to be highest during 58 and 86 days after infection.
To quantify these results an IgG3-speciﬁc anti-p24 enzyme-linked immunoabsorbant assay
was applied to 17 seroconversion panels. In agreement with the western blot results each of the
17 panels recorded a positive IgG3 reaction towards p24. Plotting absorbance units by time since
seroconversion indicated that the optimal absorbance cut off of 0.5 would differentiate recent
from long-standing infections within a recency period of 34 to 120 days [121].
85Figure 3.5: Distribution of the antibody isotype-speciﬁc response to HIV-1 antigens by time from
infection among persons with a known date of seroconversion.
Source: Wilson et al AIDS 2004 [121].
863.2.8 INNO-LIA HIV I/II score
Another diagnostic tool modiﬁed to detect recent infections is the INNO-LIA HIV I/II score
assay [122]. Like the IgG3 isotype, the INNO-LIA uses antibody reactions to seven HIV antigens,
sgp120, gp41, p31, p24 and p17 for HIV-1, and sgp105 and gp36 for HIV-2, to determine a recent
infection. A modiﬁed scoring system of the antibody reactions classiﬁed the results into one of
six possible intensity scores (0, 0.5, 1, 2, 3 or 4). Using new diagnoses already classiﬁed as recent
or long standing, through symptoms of primary infection, testing history or laboratory evidence
of a seroconversion, different algorithms of INNO-LIA antibody patterns were investigated to
determine which best identiﬁed a recent infection (ﬁgure 3.6).
For each of the ﬁve HIV-1 antigens a low antibody score was found to be associated with
a recent infection. However, individually the antigens identiﬁed only a low proportion of
recent infections correctly with low sensitivity scores. When using the antigen bands in
combination, the proportion of recent infections correctly identiﬁed increased. The most
successful algorithms were identiﬁed as 11-13, with a sensitivity score of between 40-50%
and speciﬁcity score between 95-99%, using these algorithms 70% of recent infections were
identiﬁed correctly which was comparable to the 72% identiﬁed when using the BED-CEIA [122].
87Figure 3.6: INNO-LIA algorithms investigated to determine the most appropriate model for
detecting recent infections.
Source: Schupbach et al PloS ONE 2007 [122].
883.3 Mean Duration of Recency
The MDRI is the time from seroconversion until a person is no longer deﬁned as recent and can
be estimated using the following methodologies:
² Linear Mixed Model (LMM) which estimates the slope and intercept for each person. The
durationofrecencyisestimatedasthetimeintervalbetweentheslopeinterceptingtheOD
baseline and theOD cut-off for the assay [118,320].
² Non-Linear Mixed Model (NLMM) which uses the changing OD recorded at each
observation. Using iterations from the Markov Chain Monte Carlo method the MDRI is
estimated [393].
² Survival Analysis: The upper and lower bounds of recency duration are estimated using
intervals for seroconversion and the OD cutoff [393].
² Graphical: A graphical representation of OD by time since seroconversion allows the
sensitivity and speciﬁcity to be established by increasing the OD cutoff by time. This
method is previously shown in ﬁgure 3.2 [118].
² Proportion of recent infections among seroconverters: Among a population initially
negative at time 0 and then tested again at time T, the probability that an individual is
recent equals MDRI/T, with the MDRI estimated as recent/positive at time T [394].
A comparison of the above methods indicated that theNLMM had the lowest coefﬁcient of
variation and the greatest variation was in the graphical method [395].
893.4 Additional Factors impacting serological tests.
There are a number of limitations to be considered when using any of the RITA assays which
may be speciﬁc to one assay or applicable to all, as they may affect the accuracy of the incidence
estimates.
3.4.1 Antibody Response
Using a RITA assay on a specimen from an individual with established infection such as an AIDS
deﬁning illness, or low CD4 cell count could result in them being misclassiﬁed as recent. These
misclassiﬁcations are the result of decreasing antibodies due to a weakened immune system.
Apart from the Avidity assay, all of the RITA assays differentiate recent from long-standing
infections using the antibody response, with a low antibody response indicating a recent
infection. However, low antibody responses are also made by individuals diagnosed with AIDS
and low CD4 cell counts with rates of misclassiﬁcation varying between assays. Studies where
individuals with a current AIDS diagnosis were tested with a RITA assay reported the following
rates of misclassiﬁcation; for the Sensitive/Less sensitive assay, 2.9% of long-standing infections
were identiﬁed as recent using the 3A11 Abbott [117] and 2.4% using the Vironostika-LS [383],
for the BED-CEIA the rate was 2-3% [396] and for the IDE-V3 9% [120].
In addition, persons taking ART, and therefore with low/undetectable viral load, are likely
to be misclassiﬁed as recent [397]. This is due to the suppression of the viral replication resulting
in a low antibody response, much like persons with an established infection. When using the
IDE-V3 on samples from individuals treated with ART, the majority of samples which were
known to be from established infections were classiﬁed as recent [120]. Individuals on treatment
for two years or more were more likely to be misclassiﬁed as recent [397–399]. In two studies,
the proportion misclassiﬁed increased from 12.4% among treatment naive patients to 23.8%
among those on treatment for two years [397], and 11.2% to 56% respectively [399]. Further work
suggests that ART impacts the evolution of the AI in persons immediately taking up treatment by
minimising viral replication. In a small study of 13 persons with primary HIV infection, the AI in
those untreated increased whereas for those on treatment the AI was stable [400].
903.4.2 HIV Subtype
Although the subtype an individual is infected with does not directly affect the RITA assay, it
is known to inﬂuence the recency period (the period which an individual would be classiﬁed
as recent). Two studies comparing Subtype B with E, found in both cases that subtype B had
a shorter recency period than E, 155 days (125-189) vs. 270 days (187-349) [128] and 239 days
(208-287) vs. 356 days (318 vs. 402) [130]. The BED-CEIA attempts to minimise the impact of
different subtypes by using a branched peptide containing subtype B, E and D [118]. A further
study investigating seroconverter panels for subtypes A/D, B, C and E identifed that although
subtype B and E had shorter recency periods the 95% conﬁdence intervals for all the subtypes
investigated overlapped [128,401,402] (Figure 3.7).
91Figure 3.7: Window Period for the BED-CEIA (0.8 cutoff) by HIV subtype.
Source: Parekh et al HIV Diagnostics: New Developments and challenges 2005 [402].
923.4.3 False Recency Rate
Aside from AIDS, low CD4 count and treatment, a number of individuals maintain an optical
density below the assays threshold for long periods following seroconversion, and some may
never rise above it. This fraction of treatment-naive persons with long-standing HIV infection
but whom the assay identiﬁes as being recently infected is known as the False Recent Rate (FRR).
This fraction is obtained from panels of well characterised specimens from individuals with
long-standing infection from the population for which incidence is to be estimated, and used to
correct for misclassiﬁcation (discussed in chapter 4). Where additional clinical information on
AIDS, CD4 or treatment is not available for reclassifying recent infections as long-standing, the
FRR can be estimated for all individuals. In settings where it is not feasible to calculate the FRR,
samples from similar populations can be used, however as the FRR can differ signiﬁcantly across
settingsresultinginverydifferentincidenceestimates,carefulconsiderationmustbegivenwhen
identifying an appropriate FRR [125,403].
3.5 Sampling Strategy
There are 3 main frameworks used for estimating incidence: a cross-sectional sample, sentinel
surveillance and case-reporting through routine testing sites.
Cross-sectional studies collect data on a study population, representative of the whole
population at a given point in time. Persons are included using a sampling strategy or through
convenience sampling based on accessibility using sexual health clinics, bars or community
groups. Cross-sectional studies are a quick and easy method of collecting specimens with
limited follow-up time needed. However, using convenience sampling may not necessarily be
representative of the whole population, makes it difﬁcult to investigate incidence over time, and
difﬁculties arise in capturing hard to reach populations such as CSWs or PWID.
Sentinel surveillance allows detailed information to be collected from a limited number of
sites, which could be a population of particular interest or a representative sample of the overall
population. This methodology is less expensive with high quality data due to the focused design.
However, like using convenience sampling for cross-sectional studies, sentinel surveillance may
not be representative of the overall population. Methods for recruiting individuals may also
93inﬂuence incidence estimates with persons testing due to high risk behaviour or symptoms
making it difﬁcult for results to be generalisable beyond the survey population, and leading to
an overestimate of incidence.
Both cross-sectional studies and sentinel surveillance methodologies collect information
on both the sero-negative and positive population allowing HIV incidence to be estimated using
the approach described in section 4.2.
RITA testing can also be introduced into already established surveillance systems, developing a
better understanding of the current epidemic, allowing for temporal trends. However, changes
in testing behaviour through campaigns to promote testing will introduce bias in reporting of
HIV diagnoses, alongside persons seeking a test due to high-risk behaviour or symptoms of
primary infection inﬂating incidence estimates.
For the majority of studies using surveillance systems to identify recent infections, information
on only persons testing positive will be available. As the sero-negative population is not
available, an alternative method for estimating HIV incidence is described in section 4.3.
3.6 Sample Size
Incidence estimates are dependent on the number of persons included within the study, where
the sample size is generally larger than would be needed to estimate prevalence [404]. Sample
sizes are based on the anticipated incidence and estimated prevalence for the population of
interest, the duration of recency for the assay used and the expected proportion of false positives
amongthosewithalong-standinginfection, alsoknownastheFRR[405]. Thismethodestimates
the sample size required in a cross-sectional framework and includes data from both positive
and negative individuals. When introducing RITA as part of existing surveillance schemes, in
many cases the only information available will be on the HIV positive population. Centre for
Disease Control (CDC) recommends 300 HIV positive cases within the selected period and at
least 200 cases per stratum with 40 cases specimens tested and at least 10 recently infected
[Daniela De Angelis, Personal Communication, August 2013]. Where cost limitations arise,
consideration should be given to the sample size and sampling methodology.
94A key element of the incidence formula, using existing surveillance schemes, is estimating the
probability of testing within a year of diagnosis. This is achieved using either a patients testing
historywhereavailableorthetestingfrequenciesofthepopulation. Theseprobabilitiesarelikely
to differ for subpopulations such as age, sex or by risk factors, resulting in incidence estimates
being calculated for stratiﬁed populations. The sample size and sampling methodology is
therefore equally important to be considered for these subpopulations.
In the series of graphs within ﬁgure 3.8 the effect sample size has on the conﬁdence intervals
for HIV incidence using the cross-sectional methodology is illustrated. The ﬁve graphs show the
effect of between 1 and 5% HIV incidence on samples sizes ranging from 100 to 50,000 persons.
As the sample size increases, so does the level of certainty.
9596Figure 3.8: Effect of sample size on conﬁdence intervals for HIV incidence estimates of between
1 and 5%.
Source: European Centre for Disease Prevention and Control/WHO Regional Ofﬁce for Europe
2013 [406].
973.7 Summary
The distinct maturing anti-body response to HIV has enabled laboratory methods to be
developed to differentiate a recent from longstanding infection, requiring only a single
diagnostic sample taken at a single point in time. Currently, there are eight assays developed
and, although these methodologies use different biological markers, they all require a person to
be tested within a speciﬁed time after infection which is speciﬁc to the assay being used.
Initial methodology introduced used the presence of p24 antigen or HIV RNA in the absence
of HIV antibodies among individuals who had not yet seroconverted. The major limitation to
this was the short duration of recency, which required a large sample size to calculate incidence
estimates. Alternatively, assays for post seroconversion were introduced using titre, antibody or
avidity cut-offs or reactions between speciﬁed antigens and antibodies. Each of these biological
markershasbeendevelopedwiththeaimofdifferentiatingrecentfromlong-standinginfections.
However, there are distinct advantages and disadvantages which need to be considered when
designing an incidence study. The detuned assay has limited use beyond subtype B populations,
the INNO-LIA is expensive if not routinely used, whereas the IDE-V3 aand IgG3 are both inhouse
methodologies but are not yet commercially available. In addition, the IDE-V3 has a much lower
sensitivity than other assays and the IgG3 is still to be validated for use with different subtypes.
Finally, there is a limitation to their use because of misclassiﬁcation of long-standing infection
as recent. This is particularly high for the BED assay. Although the avidity assay is also prone to
misclassiﬁcation, it is much lower than has been found for the BED assay, is also commercially
available, and requires no additional laboratory equipment.
Addressing these limitations, particularly the misclassiﬁcation of long-standing results as
recent, is imperative to ensure appropriate incidence estimates are made. The misclassiﬁcation
of results is applicable to all assays, although with differing intensities. Using the assay in
conjunction with clinical information ensures individuals who have low antibody responses due
to AIDS or use of antiretrovirals are correctly classiﬁed as long-standing. Additionally, the FRR,
the fraction of treatment-naive individuals known to have a long-standing infection identiﬁed
as recent, is used to correct for misclassiﬁed results as part of the formula used to identify the
true population recently infected (see section 4.4.2) . This fraction can be used in addition to
clinical information for persons who will maintain an OD below the threshold for long periods
98of time with no evidence of treatment or AIDS or for all persons where clinical information is
not available. Importantly, where possible the FRR should be made among the population of
interest or a similar population.
Finally, the correct sampling framework is also essential, ensuring that samples tested are
representative of the overall populations from which they are drawn. Appropriate sample sizes
should be calculated before initiating testing and consideration should be made in regards to
the population being sampled so the most appropriate assay is chosen.
99Chapter 4
Statistical Methods for Estimating
HIV Incidence using Serological Tests
Within the following chapter, I present the different statistical methods used to estimate
incidence when using a serological test for recent infection, with both direct and indirect
methodologies to minimise the chance of misclassiﬁed results.
These methods include using a cross-sectional framework, focusing on a purposely recruited
population, or on data collected through national surveillance among a population choosing or
referred for testing.
1004.1 Introduction
Thestatisticalmethodologyusedtoestimateincidenceisdependentonthesamplingframework
used. However, the two key elements used in each methodology are:
² the number (or proportion) of sero-positives which are recent, and
² the duration of recency of the assay being used.
There are two fundamentally different designs. The ﬁrst design, a cross-sectional framework,
relies on data from a purposely-recruited probability sample of the population of interest. These
data include both HIV positive and negative individuals and may be directly generalisable to
the overall population. By contrast, the second design, introducing a test for recent infection
to HIV diagnoses only, relies on data from a population choosing to test, or being targeted for
testing, where only information on the sero-positive population is available. Incidence estimates
for a population undergoing HIV testing will be impacted by testing frequencies and testing
motivation. Symptoms of primary infection, high risk behaviours and concurrent Sexually
Transmitted Infection (STI) symptoms could lead to increases in testing rates and at earlier time
points [407,408].
Alongside choosing the appropriate methodology for the sampling framework, additional
considerations must be made to minimise the impact of misclassiﬁed results. Within this
chapter, through literature identiﬁed in the methods section of chapter 2, I will describe the
different methods for estimating incidence and discuss modiﬁcations to minimise the effects of
speciﬁc limitations.
1014.2 Estimating incidence using a cross-sectional framework
The cross-sectional framework requires population-based data with information from both the
sero-negative and positive population and is directly generalisable to the population sampled.
Populations where such information is regularly collated are antenatal screening and blood
donors.
The following terms/notations will be used within section 4.2.
N Total Population
I HIV Incidence rate
D Duration of disease
Nr Number classiﬁed as recent
Nn Number HIV negative
P HIV Prevalence
¹ Assay recency period (days)
We start with the relationship between incidence and prevalence, where prevalence can be
determined by the incidence rate and the duration of the disease, as seen in formula 4.1. This
interrelationship assumes that incidence is constant as is the duration of the disease. Any one of
these three measures can be derived when the other two measures are known.
P ¼ I £D (4.1)
Using this interrelationship with the assumption that the rate infected during the recency
period is constant, Brookmeyer and Quinn used formula 4.2 to estimate incidence [114]. To
determine incidence per year, the proportion of persons classiﬁed as recent within the recency
period is multiplied by a correction factor (365/recency period). Brookmeyer and Quinn used
the presence of p24 antigen in the absence of antibodies, which occurs on average 22.5 days
before seroconversion [114]. Therefore, the estimated incidence per-cent per year is equal to the
prevalence of recent infections (occurring 22.5 days before seroconversion) multiplied by the
correction factor 16.5 (365/22.5).
102(
Nr
NrÅNn
)£(
365
¹
)£100 (4.2)
Brookmeyer and Quinn [114], identiﬁed 15 persons of the 1241 seronegative who attended an
STI clinic in Pune, India between May 1993 and January 1994 and were p24 antigen positive,
resulting in an estimate of 19.6 percent per year.
(
15
1241
)£(
365
22.5
)£100
Æ19.6percentper year
Formula 4.2 was also used by Janssen et al [117] for the sensitive/less sensitive assay where
the duration of recency was 129 days resulting in a correction factor of 2.83. Among persons
donating blood for the ﬁrst time between 1993 and 1996 in 32 American Red Cross collection
regions, 69 of the 2 717 910 tested were identiﬁed as recent (478 were HIV positive but not
recent), resulting in an incidence estimate of 7.18 per 100 000 per year.
(
69
2717432
)£(
365
129
)£100
Æ0.00718percentper year
A further variation of formula 4.2 was applied by Parekh et al [118] when using the BED-CEIA
assay (section 3.2.4). Within formula 4.3 the correction factor for determining the number of
recent infections classiﬁed within a year is applied to the number classiﬁed as recent directly.
The recency period for the BED-CEIA assay is 160 days, with a correction factor of 2.28 (365/160).
The number of recent infections within a year is then divided by those at risk of HIV (including
both negative and recently infected persons) resulting in the incidence per-cent per year.
[(365
¹ )£Nr]
[NnÅ((365
¹ )£Nr)]
£100 (4.3)
Using data from Janssen et al [117] the following equation results in an incidence estimate of 5.8
per 100 000 per year.
103[(365
160)£69]
[2717432Å((365
160)£69)]
£100
Æ0.0058percentper year.
1044.3 Estimating incidence using sero-positives
Using data from sero-positives to estimate incidence differs from the cross-sectional framework
in two major areas. Whereas, for the cross-sectional method, data are available for both the
infected and uninfected populations, only data for those infected are available. Consequently,
the number of persons at risk which is used as the denominator within the cross-sectional
formula is not available. Furthermore, diagnostic reporting represents a population selected for
testing or choosing to test compared with a sample from a population recruited into a study
resulting in different testing frequencies among subpopulations. As a result, an alternative
method was introduced by Karon et al [409].
4.3.1 Inital approach to estimating incidence using sero-positives
The following terms/notations will be used within section 4.3.
N Total Population
I Incidence rate
t Reference Period (Duration of interest)
Nr Number classiﬁed as recent
Tr True number recent
¹ Assay recency period (days)
®A Shape parameter of the incubation period from infection to an AIDS diagnosis
¯A Scale parameter of the incubation period from infection to an AIDS diagnosis
q proportion of persons diagnosed with HIV and AIDS simultaneously
P Probability of testing and being classiﬁed as recent
P1 probability of having a HIV test within the reference period (t-year)
P2 probability of a conﬁrmed positive sample having a RITA result
Pw probability of being classiﬁed as recent (within ¹)
There are multiple variations to consider, the reference period throughout this chapter will refer
to 365 days and is assumed to be at least as long as the recency period. Pw varies depending
on the assay being used and P1 will differ from person to person. As each person has a unique
P1, P can be calculated separately for each person or as an average. There are also numerous
105assumptions to consider.
² Date of HIV infection and date of HIV test are independent.
² The test for recent infection is conducted on the sample obtained at the time of new
diagnosis.
² For persons with a previous negative date the infection date has a uniform distribution
between last negative and ﬁrst positive test.
² Persons testing for the ﬁrst time have a constant testing hazard after infection, and the
recency period and time from infection until AIDS diagnosis are independent.
² For repeat testers the testing behaviour has not changed during recent years.
The true number of recent infections within the population can be estimated by a function of the
probability that an individual is tested and classiﬁed as recent (P). This method for estimating
incidence has been adopted by both the United States [345,346,409,410], France [349] and Italy
[ [348] using the underlying formula 4.4.
T r Æ Nr/P (4.4)
In the formula the number of detected recent infections (Nr) equates to the number of HIV
positive individuals who have come forward for a diagnostic test and have been tested with a
test for recent infection assay and for whom the test indicated a recent infection. To establish
the true number of recent infections within the population (Tr), the number of diagnostic tests
identiﬁedasrecentlyinfectedisdividedbytheprobabilityofbeingtestedandclassiﬁedasrecent
(P), which is assumed constant across individuals or the average value is used.
For example, Karon et al [409] identiﬁed 908 recent infections and estimated P (the probability of
testing and being classiﬁed as recent) as 0.105, resulting in the true number of recent infections
estimated as 8648.
106908/0.105
Æ8648
Theﬁrstmethodofestimatingtheprobabilityofdetectionwascalculatedusingthreecomponent
probabilities [409].
² P1 probability of having an HIV test within the reference period
² P2 probability a conﬁrmed positive sample has a RITA result
² Pw probability of being within the recency period at the time of the RITA test
P ÆP1£P2£Pw (4.5)
Further methods estimated P using only P1 and Pw assuming P2 is equal to 1 as a result of
complete reporting of BED results or through imputation of the data [345,349].
P ÆP1£Pw (4.6)
The probability that an individual has a RITA result classifying them as a recent infection within
a year of infection (Pw) is estimated using formula 4.7, with the reference period, in this case 365
days, over the recency period. This equation assumes that the rate of new infections has been
steady over the reference period.
Pw Æ¹/365 (4.7)
The probability of a person being tested within the reference period (P1) is estimated separately
within three strata:
² persons with a known previous negative HIV test,
² persons with no testing history and newly diagnosed with symptoms (such as an AIDS
deﬁning condition), and
107² persons with no testing history and newly diagnosed without symptoms.
Persons with a known previous negative HIV test
The probability of testing within the reference period (P1) is estimated based on the time from
the person’s last negative test to their ﬁrst positive HIV test (T¤) in years. The probability that an
individual’s ﬁrst positive test is within the reference period is estimated for each individual as
min(1,1/T¤). All individuals are included regardless of whether they present for an HIV test due
to symptoms or not. Table 4.1, shows examples of P1 for repeat testers.
Diagnosis Date Date of last negative test Difference P1
14/08/2013 15/07/2004 9.1 0.11
27/09/2013 01/12/2008 4.8 0.21
04/04/2013 15/03/2000 13.1 0.08
17/09/2013 01/02/2013 0.62 1
07/10/2013 01/09/2011 1.1 0.91
Table 4.1: Example of the estimated probabilities for repeat testers based on the time between
the last negative and ﬁrst positive test.
Persons with no testing history
The probability of testing within the reference period (P1), for persons without testing history is
much more problematic and is estimated assuming a constant rate of testing.
An individual’s ﬁrst test after seroconversion can arise in either of two ways, and we denote the
time till the test by T1.
² TR the time from seroconversion to an individual coming forward at random for an HIV
test
² TA the time to testing due to an AIDS deﬁning illness
108T1 is therefore equal to the minimum of these two times, min(TA,TR). For a person to be tested
within the recency period T1 must be less than the recency period.
If T1= TA, diagnosed with both HIV and AIDS simultaneously, then T1 is the incubation
period in years (from infection to AIDS), which is assumed to follow a distribution determined
usingMarkovmodels,modellingthedifferentstagesorbiologicalmarkersofaperson’sinfection.
Alternatively, if T1= TR it is hypothesised that an individual’s ﬁrst test would have occurred
during the incubation period prior to symptoms. To estimate the distribution of TR we assume
an individual tests for HIV randomly over this time period following an exponential distribution
with the scale parameter deﬁned as.
1/¯ (4.8)
To determine ¯, the shape (®A) and scale (¯A) parameters of the incubation period until an
AIDS diagnosis, assuming a gamma distribution and the proportion of persons for whom T1=TA,
are required, a shape parameter of 2 and a scale parameter of 4 was proposed by Karon et
al [409],and speciﬁcally the scale parameter is taken to be:
¯Æ
[¯A]
[q¡1/®A ¡1]
(4.9)
Forexamplewithinapopulationwhere20%ofpersonsarenewlydiagnosedwithasimultaneous
HIV and AIDS diagnosis, ¯ = 3.2, with the estimated mean time from infection to ﬁrst test is
therefore 3 years and the probability of testing within a year of infection is 31% (formula 4.10).
109¯Æ
[4]
[0.2¡1/2¡1]
Æ3.2
1/¯Æ0.31
(4.10)
Forapopulationwith5%newlydiagnosedwithasimultaneousHIVandAIDSdiagnosis,thetime
from infection to ﬁrst test is 1 year or less with a much higher probability of 87% (formula 4.11).
¯Æ
[4]
[0.05¡1/2¡1]
Æ1.15
1/¯Æ0.87
(4.11)
1104.3.2 Modiﬁed approach to estimating incidence using sero-positives
The original calculation of the probability of testing and being classiﬁed as recent (P) was further
modiﬁed by Prejean et al in 2011. These modiﬁed methods for estimating P , allow for frequent
testers whose time between testing might be less than a year and considers that the duration of
recency for an individual could be greater than 1 year. As these assumptions are not considered
bytheKaronmethodology[409]theprobability oftestingwithinthereferenceperiodisbounded
by 1. Table 4.2 shows the differences in the probability of testing within a year of infection by the
two methodologies, where Prejean et al consider increasing time from negative test to positive
test in months, Karon et al consider this time in years. By considering that an individual will test
at yearly intervals a lower probability is estimated than if the time between tests is less than a
year, which leads to an overestimation of the number of true recent infections.
111Interval between negative
(month or year)
Probability of testing within a
year of infection
Probability of testing within a
year of infection
and positive test (where interval is months) (where interval is years)
1 0.996 1
2 0.984 0.50
3 0.937 0.33
4 0.869 0.25
5 0.794 0.20
6 0.726 0.167
7 0.662 0.143
8 0.603 0.125
9 0.550 0.110
10 0.502 0.100
11 0.462 0.091
12 0.428 0.083
13 0.398 0.077
14 0.372 0.071
15 0.349 0.067
16 0.329 0.063
17 0.310 0.059
18 0.294 0.056
19 0.279 0.053
20 0.265 0.050
21 0.253 0.048
22 0.242 0.045
23 0.231 0.043
24 0.444 X 12/(difference in months) 0.042
Source: Prejean et al PLoS ONE 2011 [346].
Table 4.2: Probabilities of testing within the reference period by HIV test interval (year or month)
between last negative and ﬁrst positive test, for repeat testers.
112Furthermore,theoverallprobability(P)isboundedbytheprobabilityofbeingclassiﬁedasrecent
(Pw) estimated by the recency period over the reference period (ﬁgure 4.1). Figure 4.1, shows this
limitation by comparing the expected probability of testing and being classiﬁed as recent with
increasing time since a person’s last negative test using the Prejean method (blue line) with the
calculated probability using Pw, Karon’s method, where P is bounded by Pw estimated as ¹/365.
As a result, P is calculated directly as follows, preventing an underestimation of P .
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114The following terms/notations will be used within section 4.3.2.
Pi Probability of testing and being classiﬁed as recent for person i
P Average probability of testing and being classiﬁed as recent across all repeat testers
n Number of repeat testers
Ti number of months between last negative and ﬁrst positive test for person i
Sw(t) Probability of a person being classiﬁed as recent at time t after infection
SA(t) Survival function for the AIDS incubation period (as previously discussed)
Persons with a known previous negative HIV test (Direct Calculation)
For each person, Pi is estimated as the probability of a person being classiﬁed as recent (Sw(t))
at the time of their test since infection, over the distribution of possible infection time, which
is assumed uniform between the last negative and ﬁrst positive test. For each individual we
consider the time in months between their last negative test and ﬁrst positive test and assume
that their date of seroconversion in uniformly distributed within this time frame. The probability
of testing and being classiﬁed as recent for that individual (Pi) is the sum of each possible date
of seroconversion within the time frame between the negative and positive date. The overall
probabilityoftestingandclassiﬁedasrecent(P)isthentheaverageofeachperson’sPi. Therefore,
ifapersonhadapositivetest10monthsaftertheirlastnegativetest, wecanassumethatthedate
of seroconversion occurred at some point during those 10 months, the probability of testing and
being classiﬁed as recent is then estimated for each of the 10 months and the overall Pi the sum
of these 10 probabilities.
Pi Æ
1
T i
Z Ti
0
Sw(t)dt (4.12)
4.3.3 Persons with no testing history (Direct Calculation)
The assumption for ﬁrst-time testers is the same as previously with a constant testing rate
until AIDS from infection, where the rate can be estimated based on the proportion of persons
115diagnosed with a simultaneous HIV and AIDS diagnosis referred to as q.
¯Æ
[¯A]
[q¡1/®A ¡1]
(4.13)
P is estimated by the weighted sum of the probability that a person tests within the recency
period and the probability that the test occurs before AIDS.
P Æ
Z 1
0
Sw(t)SA(t)
1
¯
e-t/¯dt (4.14)
Table 4.3 lists estimated probabilities by proportion testing late as published by Prejean et al.
116Proportion of persons diagnosed
simultaneously with HIV and
AIDS
Probability
of testing
within a year
of infection
Proportion of persons diagnosed
simultaneously with HIV and
AIDS
Probability
of testing
within a year
of infection
0.01 0.575 0.26 0.099
0.02 0.452 0.27 0.095
0.03 0.383 0.28 0.092
0.04 0.336 0.29 0.089
0.05 0.301 0.30 0.086
0.06 0.274 0.31 0.083
0.07 0.252 0.32 0.080
0.08 0.234 0.33 0.077
0.09 0.218 0.34 0.075
0.10 0.204 0.35 0.072
0.11 0.192 0.36 0.070
0.12 0.182 0.37 0.068
0.13 0.172 0.38 0.066
0.14 0.163 0.39 0.063
0.15 0.156 0.40 0.061
0.16 0.148 0.41 0.059
0.17 0.142 0.42 0.058
0.18 0.136 0.43 0.056
0.19 0.130 0.44 0.054
0.20 0.125 0.45 0.052
0.21 0.120 0.46 0.051
0.22 0.115 0.47 0.049
0.23 0.111 0.48 0.047
0.24 0.106 0.49 0.046
0.25 0.103 0.50 0.044
Source: Prejean et al PLoS ONE 2011 [346].
Table 4.3: Probabilities of testing within the reference period by proportion of persons diagnosed
simultaneously with HIV and AIDS.
1174.3.4 Conﬁdence Intervals
Two methods have been used to determine conﬁdence intervals for incidence estimates using
the sero-positive method, bootstrapping [348, 411] and the delta method [346, 349, 409]. The
bootstrapping methodology resamples the original data to create a deﬁned number of samples
from which the outcome is estimated and the range of these estimates deﬁned. For these data
both the interval from the last negative and ﬁrst positive test for repeat testers and the CD4
count at diagnosis for ﬁrst-time testers are resampled 1000 times to produce 1000 probabilities
required for each sample population. These 1000 probabilities give a range within which we
can be 95% conﬁdent the true probability will lie. Whereas for the delta method the derivation
of the incidence estimator variance, var(log(incidence)), is obtained and used to approximate
the variance of a function, in this case 1/x, of one or more random variables in terms of their
respective variances and covariance.
4.3.5 Testing Patterns
When using sero-positive data to estimate incidence, the main component is presenting for
an HIV test. Therefore, differences in testing frequencies will result in different estimates of
incidence with populations testing more frequently having a higher probability of testing within
the reference period than those testing less frequency. As these probabilities inform the true
number of recent infections within a population, an incorrect probability will result in over or
under estimating incidence. To correct for heterogeneous testing patterns, when investigating
subpopulations the methods described in section 4.3 should be applied to each sub-population
of interest. Sub-populations to consider are age groups, sex and exposure category.
Previous literature indicated high rates of repeat testers among MSM and PWID [271, 412],
persons participating in high risk behaviours [271, 407, 408, 412, 413] and older individuals
[412,414]. Four studies investigated testing among sexual health clinic attendees [414–416] and
attendees of a same day HIV testing clinic [417] in the USA and the UK. Among attendees of a
sexually transmitted disease clinic in the United States, a third of individuals had had a previous
HIV negative test [414]. Among attendees of a same day HIV testing clinic in the UK, one in four
118MSM and two in ﬁve heterosexuals were repeat testers [413]. Investigating MSM speciﬁcally, two
studies identiﬁed that MSM had, on average, 1.6 tests per year, with 43% having more than 1 test
within one year [416], and a third re-attend within a year for a HIV test, with 50% of re-attendees
retesting within 12 months and 75% retesting within in 24 months [415]. Among PWID, data
from the USA reported tha 49% had a previous negative test [417]. In Canada 56% had an HIV
test within the past 12 months [418].
4.4 Minimising False Recent Infections
In section 3.4, I discuss the limitations to using RITA to estimate incidence with the possibility
of long standing infections being classiﬁed as recent. These misclassiﬁed results occur either
due to factors impacting the immune response (AIDS, low CD4, HIV treatment or undetectable
viral load) or among persons whose quantiﬁed result of what is being measured by the assay
never crosses the critical threshold to differentiate a recent from long standing infection. To
address these inaccurate results the following methods have been used. These methods are
used to complement each other with the direct approach correcting results arising from clinical
indicators indicative of a long-standing infection and the indirect approach correcting for long-
standing infections which appear to be recent due to slower progression.
4.4.1 Direct approach
Thedirectapproachtakesintoconsiderationpatient-basedinformationtoidentifylongstanding
infections regardless of the assay result. These data include evidence of a CD4 cell count <200 or
an AIDS-deﬁning condition at time of sample date, previous HIV positive test results or evidence
that the individual is on ART or has an viral load <400 copies/ml (ﬁgure 4.2). This method helps
to reclassify those with a long-standing infection and minimise, but not eliminate, the false
recent rate. This direct method with the assay result is known as the Recent Infection Testing
Algorithm or RITA.
119Figure 4.2: Suggested approach for minimising the risk of misclassiﬁcation.
Source: World Health Organisation 2011 [405].
120An alternative algorithm would include the use of more than one test for recent infection
assay. This Multiassay Algorithm (MAA) has been incorporated in multiple studies with results
suggesting increased accuracy [231,343,419,420]. Each study used the BED-CEIA and Avidity
index as part of the algorithm and suggested the process in ﬁgure 4.3, authors indicated that this
method was also successful if CD4 cell counts are not available.
121Figure4.3: Multi-assayapproachforminimisingmisclassiﬁcationofrecentinfectionsusingmore
than one test for recent infection.
Source: Laeyendecker et al J Infect Dis 2013 [343].
1224.4.2 Indirect approach
The indirect approach applies a correction factor to the incidence formula derived from the
fraction of persons who remain non-reactive and under the threshold for time > Sensitivity +
Short-term Speciﬁcity (>¹1 + >¹2) or 1-long-term speciﬁcity referred to as the FRR (ﬁgure 4.4).
To determine the FRR, samples from persons known to have been infected for a time period
equal to twice the recency period (>¹1 + >¹2) are classiﬁed using RITA, which is applied to the
appropriate incidence formula. This fraction, or FRR, (samples classiﬁed as recently infected
which are in fact long-standing) is removed from the number of samples classiﬁed as recently
infected using RITA. Before calculating the FRR, it is necessary to ensure the same algorithm (see
section 4.4.1) for identifying recent infections is also used on those known to have been infected
for greater than one year.
Initially, the correction factor was estimated using the sensitivity (¾), short-term speciﬁcity
("1) and long-term speciﬁcity ("2) of the test as seen in formula 4.15 and 4.16 [202]. Using the
following 3 assumptions; recent infections are randomly distributed, the window period for "1 is
equal to the window period for ¾ and the window period for "2 is more than the window periods
for ¾ and "1. To calculate ¾ and "1 samples are required from persons with a known date of
seroconversion and for "2 samples are required from persons known to have been positive for
greater than a year.
f NR
f NRÅ!NN
(4.15)
f Æ
(
NR
NP
)¡"2
(
NR
NP
)(¾Å"1¡2"2)
(4.16)
123Figure 4.4: Survival curve representing the proportion of samples RITA positive by time since
seroconversion.
Source: McWalter et al PLoS ONE 2009 [421].
124Formula 4.17 removes the correction factor, suggesting it is only necessary to calibrate 1-"2 or "
because ¾ ¼ "1, where " is estimated from samples known to have been positive for greater than
a year [320].
NR¡"NR
NRÅ!N ¡"(NPÅNN)
(4.17)
Formula 4.18 has been derived from the mathematical relationships between sensitivity, short-
term speciﬁcity and long-term speciﬁcity [421–424]. McWalter and Welte indicate that not all
individualswillprogressoverthethresholdfordifferentiatingarecentinfectionfromnon-recent,
moving from ﬁgure 4.5a to 4.5b. Therefore being under the threshold and alive does not reach
0 and is ﬂat for time >¹1 + ¹2 as seen in ﬁgure 4.4, the long-term speciﬁcity. The assumptions
for formula 4.18 are modiﬁcations of those previously deﬁned by McDougal: being under the
threshold and alive is ﬂat for time >¹1 + ¹2, and progressing individuals under the threshold
are distributed during 0,¹1 + ¹2; infection times are uniformly distributed and with the same
intensity as for time ¹1 + ¹2 and survival is the same for progressing and non-progressing
individuals [421–424].
125a.
b.
Figure 4.5: Time since infection, a). Where all individuals cross the threshold from recent to
non-recent b). Where a proportion of individuals remain under the threshold and therefore are
misclassiﬁed as recently infected.
Source: Wang et al JAIDS 2009 [425].
126With these assumptions McWalter and Welte [421–424] indicate that ¾-"1+"2=1 or ¾-"1=1-"2. As
a result ¾ and "1 are no longer required, much like formula 4.17.
NR( "
1¡")(NP¡NR)
!NN
(4.18)
For formula 4.17 and 4.18 the advantage of only using " is that it is estimated through follow
up intervals which are greater than ¹1 + ¹2, whereas ¾ and "1 need specimens from individuals
where the time from infection can be conﬁdently determined [320,421–424]. What this model
doesnotaccountforisfalsepositiveresultsarisingfromestablishedinfectionswithlowantibody
response, due to an AIDS deﬁning illness or ARVs, assuming that all individuals progress in one
direction from being identiﬁed as recently infected to being identiﬁed as long-standing. Further
limitations considered are the assumptions that survival expectation is the same between
progressing individuals and non-progressing individuals and the regional variability for the
correction factors.
Formula 4.18 was found to agree with the maximum likelihood estimator [425] concluding
that characterising the proportion of those individuals who remain under the threshold for time
>¹1 + ¹2 is essential [425].
Table 4.4 shows variations in incidence estimates using the different incidence formulas
previously described. Data was taken from a longitudinal population-based study collected by
the Africa Centre for Health and Population Studies, South Africa [125], where the HIV incidence
was measured as 3.09 per 100 people per year, adjusting for sex and age. Incidence estimates
which corrected for long-standing infections classiﬁed as recent were comparable to those
measured longitudinally.
This correction factor was also used when estimating the true number of recent infections
among new HIV diagnoses [349] as discussed in section 4.3.
NR¡N"
1¡"
(4.19)
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1284.5 Minimising False Long-standing Infections
Alongside minimising the risk of misclassiﬁcation of long-standing as recent infections,
consideration should also be given to minimising the risk of recent infections which have been
classiﬁed as long-standing. Like the FRR the rate of long-standing infections which have been
misclassiﬁed should also investigated, however this is much more difﬁcult to calculate, as a
population known to be recently infected would need to be identiﬁed. Other methods for
reducing misclassiﬁed results include information on previous negative tests within the past 6
months, a previous documented HIV RNA or p24 positive result whilst antibody negative within
thelast6months,usingclinicalsymptomsrepresentativeofaseroconversionorusingmorethan
one RITA assay.
4.6 Further Considerations
Using case-based reporting as the sampling framework is also subject to reporting delays,
underreporting of variables, the ability to eliminate duplicate reports and the ability to identify
which diagnoses are new. Furthermore, the formula used for case-based reports is used to
calculate the probability of an individual testing within the recency period by either using testing
history or assuming a constant rate of testing, where the date of infection is independent of
the testing date. Information on testing history is limited as it may be subject to recall bias
and the assumption of a constant testing rate is impacted by changes in frequency due to
testing motivations such as risky behaviour or symptoms. In addition to changes in testing
frequencies,arechangestotestingbehaviours. Theintroductionofspeciﬁcpreventionstrategies
or behavioural interventions may result in an increase in testing rate among those at risk.
These changes impact the ability to investigate temporal trends. Finally, certain subgroups
maybeunderreportedduetosocialstigmaanddiscriminationrelevanttothecountryestimating
incidence. Underreporting of particular ﬁelds will make estimating robust estimates difﬁcult, an
underestimation of the population size will result in an overestimation of incidence.
4.7 Summary
The interrelationship between incidence, prevalence and duration of a disease enables any one
ofthesethreevariablestobeestimatedbasedoninformationfromtheothertwo. Theavailability
129of such information, however, is largely dependent on the sampling framework of the study,
with the two main designs being cross-sectional and sero-positive. The fundamental difference
between these two designs is the availability of information from the negative population.
Initial work used the cross-sectional design testing of samples with an incidence assay from a
purposely-recruited probability sample of the population of interest. This allowed investigators
to estimate incidence based on the prevalence of recent infection among that population, and
the recency period deﬁned by the incidence assay. More recently, a sero-positive famework has
been developed estimating incidence using a test for recent infection as part of routine HIV
surveillance within a particular country, which is both cheaper and easier to implement.
Unlike the cross-sectional methodology, the sero-positive methodology extrapolates the
true number of incident infections from those observed in persons newly-diagnosed based
on the testing frequency of that population. In the sero-positive methodology published
by Karon et al [409], the extrapolation process was based on an approximation formula to
estimate the probability a person will test and be classiﬁed as recent. This formula included
the likelihood the person tests close to their infection, and the likelihood they test recent by the
incidence assay. However, estimating these components separately leads to an artiﬁcial upper
boundary of the probability a person will test and be classiﬁed as recent. A further issue of this
methodology is deﬁning a person’s minimal inter-test interval to be one year, which may not
be appropriate. These limitations to Karon’s [409]methodology led to the probability of testing
and being classiﬁed as recent being underestimated. This in turn, resulted in the extrapolation
methodology overestimating the true number of recent infections and, therefore, incidence.
As a result, the method for estimating the probability of testing and being classiﬁed as recent
for extrapolation was modiﬁed [346] to consider the decreasing likelihood of being a recent
infection based on increasing time from infection.
Misclassiﬁcation of longstanding infections as recent, arising from changes in the antibody
response or slow antibody maturation, is an important limitation to consider when estimating
incidence. Ignoringthislimitationresultsinanoverestimationofthenumberofrecentinfections
within a population. Correcting for misclassiﬁed results includes using clinical data indicative
of either a recent or longstanding infection, such as viral load and CD4 count. This is followed
by a correction factor of the proportion of longstanding infections that appear recent even after
130correcting for clinical data. This correction fraction, known as the false recent rate, adjusts for
the fraction of non-recent infections which are misclassiﬁed as recent in incidence estimates.
Failure to adjust for these results in incidence eing overestimated.
Finally, it is important to consider the impact of testing patterns when estimating incidence
using the sero-positive methodology, if the inter-test interval differs by sub-population. Among
populations for whom the inter-test interval is short, the probability of testing and being
classiﬁed as recent will be much higher than for populations with a longer interval. Therefore,
theprobabilityoftestingandbeingclassiﬁedasrecentisneededbysub-population, withshorter
intervals more likely among high risk populations such as MSM.
To characterise populations presenting with a recent infection in each country, the sero-positive
frameworkwillbeimplemented,withatestforrecentinfectionusedonresidualsamplesfromall
new diagnoses. Therefore, the sero-positive framework, which requires a number of parameters
to be estimated, and to investigate testing behaviours by sub-populations. Although the issues
surrounding Karon’s methodology have been discussed within this chapter, I intend to use the
methodpublishedbyKaronetal [409]andthemodiﬁedmethodbyPrejeanetal [346]toestimate
the true number of recent infections within the population. By using both methodologies I will
review the difference in incidence estimates and establish the impact the limitiations from the
original method has on the outcome.
131Chapter 5
Study Methodology
The methods I undertook for data collection are found in the following chapter. I describe
how the data were collected and the processes I implemented to adapt collection techniques. I
indicate what further data were required and methods of data collection.
I present how I validated and characterise the data, procedures chosen for identifying recent
infections, and statistical methods involved in characterising recent infections and estimating
incidence.
1325.1 Introduction
Existing testing services within each country were used to identify newly diagnosed individuals.
Data were collected as an extension of the current surveillance methods. Ethics approval for
the study was received from the ethics committee in each country, and from University College
London (UCL) research ethics committee (see appendix B). Patients seeking an HIV test did
not experience any additional procedures and no extra blood was taken. Any additional data
introduced were dependent on the data already collected by each surveillance system. Table 5.1
lists the data required and availability for each country before starting this work.
Laboratory-based methods to differentiate recent from long-standing infections using the
maturing antibody response to the HIV infection were introduced and conducted on samples
conﬁrmed as newly diagnosed. Results from Consortium for the Evaluation and Performance of
HIV Incidence Assays (CEPHIA) [Gary Murphy, personal communication, March, 2013], initiated
to provide technical guidance and validate the different RITA assays, were used to identify an
appropriate assay.
All additional testing was conducted once all samples had been conﬁrmed as HIV-positive.
All persons tested for HIV country-wide in Estonia and persons attending one of the 30 VCT
facilities in Poland between January 2013 and January 2014 were included and persons attending
for an HIV test at any one of the four infectious disease clinics known as the AIDS centres in Kiev
between April 2013 and March 2014. Patient results and collected data were matched using a
unique patient identiﬁcation number which was used throughout and, where possible, year of
birth and sex. Data for Estonia and Ukraine were available throughout the study, whereas data
for Poland would not be available until September 2014.
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1345.2 Ethics Statement
The study was part of CASCADE within EuroCoord (www.EuroCoord.net) funded by the
European Union Framework Programme VII. Ethics approval was given by the University College
London, Institute of Epidemiology Kiev, The University of Tartu, Estonia and the National
Institute of Public Health National Institute of Hygiene, Poland (appendix B).
5.3 Project logistics
During the three years of my PhD, I was the project coordinator with the task of setting up the
study to characterise recently acquired HIV infections within Estonia, Poland and Ukraine. As
part of this project I worked with partners to ensure project ownership within each country.
Collaborators involved were Ruslan Malyuta for Ukraine, Magdalena Rosinska and Janusz Janiec
for Poland, and Irja Lutsar and Pilleriin Soodla for Estonia.
I was involved in all aspects of the project which included but was not limited to; overall
organisation and administration of the project, writing documentation for the project and
ethics committees applications, design and implementation of a new system in Ukraine, sample
management, data extraction and manipulation, statistical analysis and incidence estimation.
Figure 5.1 and 5.2, shows how the project developed over the three years. In brief, during
the ﬁrst year, I ﬁnalised the project protocol and gained ethics committee approval from UCL
for the overall project and within each country separately. I established the parameters for
estimating incidence and worked with each team to identify what data already existed and what
was additionally required, which included developing a new system for Ukraine.
135Figure 5.1: Gantt chart of the data processes within the project from September 2011 - December
2012.
136Figure 5.2: Gantt chart of the data processes within the project from January 2013 - September
2014.
137Data collection and storage of residual samples took place in 2013 for both Poland and Estonia,
and during the ﬁrst quarter of the same period I developed and piloted the new system for Kiev.
Thisinvolveddevelopingthedatacollectionformforuseonahandheldtablet,whichwentlivein
April. Data collection and storage of samples for Kiev took place from April 2013 and throughout
2014. Although the project was overseen in the speciﬁc countries by the collaborators, I was able
to review the data for Kiev monthly downloading the data directly allowing for feedback to the
clinics. I also visited the testing facilities including the laboratories during the summer of 2013.
In October 2013 I was invited to attend the WHO incidence working group meeting in Rome,
where I initiated a collaboration with CDC, to conduct the training of the LAg avidity EIA the
chosen assay. The training took place in February 2014, where CDC and a laboratory technician
from each country spent a week within a laboratory at Public Health England in London. During
this time it was agreed that UCLH would conduct all the molecular epidemiology for samples
from newly diagnosed persons in Kiev. Because of unrest in Ukraine, all samples including those
to be tested with the LAg avidity EIA were shipped to the UK.
Data for Poland and Estonia were collated by the collaborators, whereas I worked on the data
collected for Kiev City throughout, cleaning and validating the data. I match the demographical
datatothetestresults, RITAresults, andviralloadmeasurements, anddeterminedtheindividual
subtype and resistance mutations using the sequences received from UCLH. Probabilities for
repeat testers were estimated following data collection in 2014, whereas for ﬁrst-time testers
late diagnosis estimates for probabilities were collated from Estonia and Ukraine during 2013.
Testing patterns were investigated for Kiev and Estonia using data collected during the project,
and from previous years for Poland. The origins of data used are seen in table 5.2.
138Country Data Source Year
Poland
New Diagnoses VCT Sites 2013
Repeat Testers VCT Sites 2008-2010
Estonia
New Diagnoses All Testing Facilities Sites 2013
Repeat Testers Laboratories 2013
Late Diagnoses HIV Database 2010-2012
False Recent Rate HIV Database
Kiev, Ukraine
New Diagnoses AIDS Centre 2013-2014
Repeat Testers AIDS Centre 2013-2014
Late Diagnoses PatientNotes(AIDSCentre) Q1: 2013
False Recent Rate AIDS Centre
Table 5.2: Data Sources for each variable and country.
1395.4 Data Collection
5.4.1 Ukraine
Existing country-wide testing services were used to identify newly diagnosed individuals. At the
timeofanindividual’sinitialHIVtestinthesouthernregionofOdessa, thefollowinginformation
was collected, together with a serum sample: patient’s name or clinic number, year of birth, area
of residence, and reason for test (appendix C). Further demographic and clinical information,
including HIV risk factors, are available on individuals who attend for care at an AIDS centre.
However, it is estimated that 20% of positive individuals would be lost to follow up and no extra
information would be available for them.
Working with the non-governmental organisation Perinatal Prevention of AIDS Initiative
(PPAI), I worked to modify current data collection methods to introduce data needed to
adequately characterise the newly-infected population and to estimate incidence. I designed
a detailed anonymous questionnaire to be completed at the initial consultation (appendix C),
whichincludedallthenecessaryﬁelds. Demographicinformationtocharacterisethepopulation
into sub-populations, test history to correctly classify results and testing history and reason
for testing for determining the method of estimating incidence and understanding testing
motivations and frequencies.
Data were collected directly from the patient, and risk factor information was collected by
asking patients whether they have ever participated in activities known to be risk factors for
HIV infection, rather than using labels. For example "have you ever had sex with another man?"
rather than "are you a homosexual man?"
The anonymous questionnaire was piloted in ﬁve facilities during July and August of 2012
to assess acceptability from both medical workers and individuals attending for an HIV test.
The completion of ﬁelds varied, demographic information (year of birth, sex, residence and
citizenship) and reason for test were completed for ¸96% of individuals. Information of whether
the individual had been tested previously was 93% complete when completed by the health care
worker and 98% complete when completed by the individual. However, the date of previous test
was only recorded by the patient. Of the 81 individuals who answered "do you think you have
140been at risk of HIV?" only 7 answered "yes", although 29 individuals ticked one or more of the
risk factors listed. No information was recorded on whether the individual had any evidence of
symptoms.
Following the pilot, further modiﬁcations were made to the anonymous questionnaire.
The ﬁnal data ﬂow is outlined in ﬁgure 5.3, with the anonymous questionnaire introduced
during the patient’s initial consultation. No identiﬁable information would be collected on
the questionnaire and the clinic code would be used to link the reference list, blood sample
and anonymous questionnaire when entered at the laboratory. No additional processes were
added, with the anonymous questionnaire and RITA results entered onto the sample database.
Remaining sera from individuals conﬁrmed as new diagnoses would be stored and available for
RITA testing.
141Figure 5.3: Data ﬂow between testing site, laboratory and the Perinatal Prevention of AIDS
Initiative (PPAI) in Odessa, Ukraine.
142Following the Ukraine parliamentary election in October 2012, the Central Virology and
Immunology Laboratory (CVIL) was dissolved. As a result, the project was moved to the Ukraine
capital Kiev, where data processes and information collected at initial consultation were similar
to those of Odessa. Persons attending at any one of the four Kiev City AIDS centres were the
focus of the study (ﬁgure 5.4) with the same anonymous questionnaire introduced at initial
consultation.
However, unlike Odessa, the patient completed the questionnaire electronically using a
handheld device. A review of ﬁve different methods of data collection identiﬁed that tablet
computers closely resembled the use of paper for data collection, whilst gaining the beneﬁt of
computer-based approaches [426]. A study comparing paper with tablet computers found that
patients were positive about using the tablet, concluding that electronic tablets were a valid
methodology for collecting data [427]. Furthermore, the use of the electronic tablet ensured that
patients maintain anonymity regards sharing information on their risk factors.
All electronic questionnaires were managed by me at the Medical Research council (MRC).
Medical staff at the testing centre did not have access to patients’ answers to the questionnaires.
The patient’s sample and test request form followed the normal process with the institute of
microbiology, Kiev AIDS Centre storing all positive samples for RITA testing. The modiﬁed data
ﬂow can be seen in ﬁgure 5.5, with a timeline of processes in ﬁgure 5.6.
143Figure 5.4: Testing sites in Kiev city oblast.
Source: Googlemaps 2013.
144Figure 5.5: Data ﬂow for Kiev City, Ukraine.
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Figure 5.6: Flow of processes and communication within Ukraine.
146Preliminary work to classify recent infections in Odessa were conducted before this study on
all new HIV diagnosis between May and December 2009. The BED-CEIA assay was used where
adults with a standard optical density in a conﬁrmatory test of ·0.8 were classiﬁed as recent and
this >0.8 as long-standing [396]. I analysed there data as part of this thesis.
1475.4.2 Poland
Persons attending one of the 30 VCT facilities for an HIV test were used to identify newly
diagnosed individuals (ﬁgure 5.8). At initial consultation information is collected from the
patient through a detailed pre-test questionnaire and self-reported questionnaire, alongside a
test referral form which is sent with the patient’s blood sample to the laboratory. Variables
collected using the pre-test and self-reported questionnaires are listed within appendix C. The
pre-testandself-reportedquestionnairesareforwardedtothenationalAIDScentrefordataentry
and all information is collated at the National Institute of Public Health - National Institute of
Hygiene (NIZP-PZH). Paper forms are forwarded to the national AIDS centre at the end of each
year to be processed and data are only accessible in September of the following year.
148Figure 5.8: Distribution of VCT sites in Poland.
Source: Googlemaps 2013.
149The patient’s blood sample and test referral form (appendix C) are sent to screening laboratories
and those identiﬁed as positive are sent to one of two conﬁrmatory laboratories. Variables
collected on the test referral form include initials or password, year of birth, sex, nationality, and
probable route of infection. Test results are sent back to the testing facilities and surveillance
laboratory reports are available at NIZP-PZH within 30-90 days.
Patients with a conﬁrmed positive result can attend for HIV-related care at one of 15 specialised
clinics in each of the major cities in Poland. Further specialised test are offered including CD4
and viral load counts and access to ARVs.
Working with NIZP-PZH, I identiﬁed that no modiﬁcations to how patient information is
collected is required. However, the question "Number of negative tests within the previous two
years" was added to the pre-test questionnaire. All data and results will be collated and matched
by staff at NIZP-PZH. The ﬁnal data ﬂow and project timeline can be seen in ﬁgure 5.9 and ﬁgure
5.10.
150Figure 5.9: Data ﬂow between testing site, laboratory and the National Institute of Public Health-
National Institute of Hygiene.
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Figure 5.10: Flow of processes and communication within Poland.
1525.4.3 Estonia
Existing country-wide testing services were used to identify newly diagnosed individuals.
Following laboratory conﬁrmation, patient’s results are sent back to the testing facility and
patient’s with a conﬁrmed HIV positive result are referred to one of ﬁve hospitals offering
HIV-related care; these include Tartu University (SATUK), West-Tallinn Central Hospital (LTKH),
Narva Hospital, IDA-VIRU Central Hospital (IVKH) and East-Tallinn Central Hospitall (ITKH). At
these centres, information on the patient is collected through the NAKIS HIV report linked to
the Estonian health board and the HIV database, both forms of data collection are web-based.
Before information is entered onto the HIV database informed consent is required from the
patient. Variables collected using the NAKIS HIV report form and the HIV database are listed
within the appendix C.
All Estonian citizens have a unique ID code which is recorded for all conﬁrmatory tests
and linked to the patient’s unique HIV code. Double registration of the unique ID code is not
allowed. All results and information collected on each patient is linked to the HIV code. The link
between ID and HIV code is kept conﬁdential.
Working with the Institute of Microbiology, I identiﬁed that no modiﬁcations to how patients’
information is collected is required. However, information on previous testing history were
collated from conﬁrmatory laboratories. The data ﬂow and timeline are outlined in ﬁgure 5.11
and ﬁgure 5.12.
153Figure 5.11: Data ﬂow between testing site, laboratory and infectious disease clinic.
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Figure 5.12: Flow of processes and communication within Estonia.
1555.5 Data Validation and Characterisation
Data cleaning and validations were completed by the data management team initially in Poland
and Estonia. I conducted further validations to categorise probable route of exposure, reason
for test and testing history, detailed below. For Kiev, I conducted all cleaning and validations,
initially de-duplicating records using year of birth, sex, clinic and clinic identiﬁcation number
and removing any incomplete records, where year of birth, sex or date of diagnosis were
incomplete. Information from duplicate records were merged, where information differed
records were sent back to the laboratory and records were merged based on the results. From
each dataset, records were removed where the previous positive result was reported as positive,
as these persons cannot be classiﬁed as newly diagnosed.
Data are presented for adults, persons aged 16 years and over for Ukraine and Poland and
18 years and over for Estonia.
Probable route of exposure was reported directly for Kiev City and Estonia, whereas for
Poland probable route of exposure was assigned using data collected through the pre-test
questionnaire. PWID was assigned where risk was identiﬁed as injecting drug use, person
reported sex under the inﬂuence of drugs by injection and/or sharing a syringe. MSM was
assigned if the sexual orientation was homosexual, and for males reporting male sexual contacts,
a male partner ever, passive anal sex and/or reporting a homosexual partner. Heterosexual
contact included reporting heterosexual contact, reported vaginal sex, having the opposite sex
as a sexual partner and/or reporting a heterosexual partner. Other risks were reviewed and
where no information was available person’s risk was classiﬁed as not known. For each country,
probable route of exposure was allocated according to a hierarchical order, where persons with
more than one reported risk were classiﬁed by the risk most likely (PWID, MSM followed by
heterosexual contact).
Reason for test was grouped into the following four categories: clinical indication (persons
presenting with symptoms), high risk population (those regarded to have high risk behaviour
including injecting drugs, contact of a known positive, diagnosed with a sexually transmitted
infection, individuals who experienced an occupational HIV risk and sex with multiple partners)
and general screening (blood, organ and tissue donors, before surgical interventions, women
156screenedthroughantenatalservices, recruitmentintothearmy, prisonersandpersonsrequiring
HIV due to regulations or policy, e.g. for employment or visa procurement).
For the data collected through the previous study in Odessa, information was available on:
basic demographic information such as name, year of birth, residence, and reason for test. No
information was available on previous AIDS diagnosis or prior use of ART. However, HIV positive
individuals were referred to a clinical centre for HIV/AIDS, available in each province, where HIV
care is provided. Further information on HIV disease stage and whether persons had previously
been on ART was available for individuals who took up the referral.
I grouped reason for test into the following four categories: clinical indication (individuals
presenting with an illness suspected to be due to HIV infection, and those who had died and an
autopsyrevealedHIVinfection),highriskpopulation(thoseregardedtohavehighriskbehaviour
including sex with a prostitute and ”multiple partners”, diagnosed with a sexually-transmitted
infection, and individuals who experienced an occupational HIV risk), general public screening
(blood, organ and tissue donors, women screened through antenatal services, recruitment into
the army, prisoners, and persons requiring HIV testing due to regulations or policy, e.g. for
employment or visa procurement), and other (foreign citizens and anonymous testing).
5.6 Deﬁning Recent and Non-Recent Infections.
A recent HIV infection was identiﬁed using the SediaTM HIV-1 LAg Avidity EIA, an in vitro
quantitative Limiting Antigen (LAg) avidity enzyme immunoassay [389, 390, 428]. The LAg
avidity EIA is a CDC developed assay which uses the avidity index, the strength of the bond
between the viral protein (antigen) and the HIV-speciﬁc antibody (section 3.2.5), to differentiate
recent from longstanding infections (section 3.2.5). A high concentration of antigen results
in binding from both high- and low- avidity antigens, by decreasing the concentration of the
antigen coated on the well, means that only the high avidity antibodies ,the long-standing
infections, are able to bind. The avidity result is measured by the concentration of the bound
antibodies [390], with a low avidity representing a recent infection, whereas a long-standing
infection would have a high avidity. Using the procedure described in ﬁgure 5.13, an optical
density is measured with those measuring below 1.5 being classiﬁed as "recent".
157The LAg Avidity EIA was performed according to manufacturer’s instructions (Sedia Biosciences
Corportaion, Portland, Oregon) [429], shown in ﬁgure 5.13. The normalised optical density is
estimated by dividing the optical density of the specimen by the mean optical density of the
calibrator. A recent infection is equal to an optical density of <1.5 and a mean duration of recent
infection of 130 days (95% CI: 118-142) [429]. Initial testing requires all samples to be tested
once, and for samples with an ODn · 2.0 to be tested in triplicate for conﬁrmation. As the LAg
Avidity EIA uses well plates no specialised machinery is required.
158Figure 5.13: LAg-Avidity EIA procedures.
Source: Sedia HIV-1 LAg-Avidity EIA insert [428].
159The LAg Avidity EIA was one of the TRI being evaluated by CEPHIA, residual samples from
persons with particular clinical characters were used in a qualiﬁcation panel to estimate the
MDRI, FRR, the coefﬁcient of variation (CoV) and the reproducibility. When evaluating the
performance of the LAg, CEPHIA identiﬁed that LAg produced the lowest FRR of 0.9% (95CI: 0%-
4.7%), however like all of the TRI evaluated the LAg performed poorly on specimens with a low or
undetectable viral load and/or currently on treatment [Gary Murphy, personal communication,
March, 2013]. Therefore a viral load was required for all samples with an OD <1.5, where a viral
load <1000 was classiﬁed as longstanding (ﬁgure 5.14).
Samples collected in Kiev City were transported to the UK for testing with the LAg Avidity
EIA conducted at Public Health England and Viral loads at the University College London
Hospital. For both Poland and Estonia, all testing were conducted in the corresponding country.
160Figure 5.14: Recent Infection Testing Algorithm (RITA).
1615.7 Molecular Epidemiology
The circulting HIV subtype and prevalence of transmitted drug resistance (TDR) among persons
classiﬁed as recently infected were ascertained using residual samples from persons presenting
for an HIV test. Samples were collected as described in section 5.4.
For Poland and Estonia testing was conducted in the respective laboratories conducting
the test for recent infection, for Kiev, Ukraine samples were transferred for testing at the
University College London Hospital (UCLH). The deﬁnitiion of drug resistance mutuations was
taken from a standardised list used for genotypic surveillance of TDR [430]. Speciﬁc mutations
were identiﬁed from sequences, as was viral load (copies/ml) and HIV subtype.
5.8 Incidence Estimation
I describe the newly-diagnosed population overall and by sub-populations including age at
diagnosis, sex, reason for testing and risk factors. I further describe those identiﬁed as recently
infected overall and by sub-populations, exploring the association between testing recently and
key variables collected at the patient’s initial consultation using logistic regression models.
HIV incidence was estimated using the stratiﬁed extrapolation method published by Karon
et al, and later modiﬁed by Prejean et al, described in Section 4.3. Brieﬂy this method uses the
observed number of recent infections and the probability that a person will present for a test and
have a recent infection to estimate the true number of recent infections in the study period. The
probability of testing and being classiﬁed as recent, is the product of the probability of testing
within a year of infection (P1) and the probability the result is recent within a year of infection
(Pw). P1 is estimated separately for persons who have tested previously and for persons where
this test is their ﬁrst. For persons with testing history the probability of testing within a year is
estimated as the time between the persons last negative and ﬁrst positive test, whereas among
persons testing for the ﬁrst time the time between infection and diagnosis is estimated using
the proportion of persons who do not test until late within their infection, deﬁned as a CD4 cell
count <200 and/or and AIDS diagnosis within 3 months of initial diagnosis. Pw, the probability
that a test will be classiﬁed as recent is equal to the annualised mean recency period, dividing
the reference period (365 days) by the MDRI (130 days), which results in a probability of 0.356.
162For Kiev and Poland testing history was self-reported by the patient and in Estonia information
on testing history within the previous two years will be collected from laboratories. Persons were
classiﬁed as a repeat tester if there was evidence of at least one previous HIV test. Previous test
was coded as not known if no date or result of the previous test was reported, or the previous
test result was equivocal and where the previous test was within a month of the current test. For
Estonia and Kiev city data on previous test was collated from the population of interest, however,
for Poland, I used data from persons testing at a VCT between January 2008 and December
2010. The data for each year are collated separately and cannot be de-duplicated because data
is collected anonymously; therefore persons with a previous test occurring during the three year
period and conducted at a VCT clinic were also excluded.
The proportion of persons diagnosed late was not derived directly from the study population.
Data on patients’ clinical status and CD4 cell count were collected from patient notes during
the ﬁrst quarter 2013 in Kiev city, and for Estonia these data are available on the HIV database
for patients who take up a referral for care. Data from reports of newly diagnosed HIV and
AIDS cases reported to the provincial sanitary-epidemiological stations were readily available
for Poland, whereas data on CD4 cell counts were stored by the HIV clinics. Late diagnosis
was deﬁned as an AIDS diagnosis and/or a CD4 cell count <200 within 3 months of initial HIV
diagnosis.
Differences in testing frequencies among sub-populations were also investigated, to determine
whether probabilities for testing within a year would differ by these subpopulations. For each
population using the data collected of testing history I explored the association between a repeat
test and key variables collected at the patient’s initial consultation using logistic regression
models.
Because there were missing data I used a multiple imputation method. The STATA program MI
(MultipleImputation)wasused,whichisasimulationstatisticaltechniquewhere20imputations
were generated using a logistic regression imputation model. Using the variables ID, diagnosis
date, sexandage, whichwerecompleteforeachindividualtheimputationmodelwasperformed
separately for each imputation and later pooled into a single multiple-imputation result from
163which the missing value was replaced. Variables which were imputed were residence, HIV test
result, probable route of exposure, Reason for test, previous testing history and evidence of a
recent infection.
Conﬁdence intervals were estimated using bootstrapping methodologies where the original data
were resampled 1000 times to create 1000 datasets from which the probabilities for testing and
being classiﬁed as recent were estimated to give the upper and lower estimates where 95% of the
time the point estimate will fall within these limits.
Rates per 100,000 population were calculated for tests, diagnoses and incidence estimates.
Population denominators were based on 2012 data published by the statistical ofﬁce of the
European Union, Eurostat [431]. Region speciﬁc denominators for Kiev City were based on data
collected through the government census [432]. Rates were calculated by dividing the number of
tests, diagnoses or estimated number of recent infection for the calendar year by the population
denominator and multiplied by 100,000. Incidence rates per year will be calculated for each
country overall and by age and sex using population estimates as the denominator. Where
available population estimates on subpopulations at risk of HIV were collated, however for hard
to reach and stigmatised populations such as PWID and MSM in Eastern Europe these data are
unlikely to be available.
ForUkraine,theAIDSAlliance[433],publishedpopulationestimatesformostatriskpopulations
(MARPs) by region. Estimates for 2012 indicate that in Kiev City there were an estimated 41,500
MARPs, of which 23,400 were PWID and 9,400 Men who have sex with men. These ﬁgures
are estimated using the method of ’anonymous friend’, where persons are asked to list the
behaviours of friends, data from behavioural studies conducted among at risk populations and
sociological surveys of young people aged 14-24 years and of adults aged 25-49 years, further
details are within the analytical report based on sociological study results Estimation of the
Size of Populations Most-at-Risk for HIV Infection in Ukraine in 2009 [434]. MSM population
estimates derived from the European MSM internet survey (EMIS) were also used [435],
which considered the diagnosed population for a country, survey members and the diagnosed
survey members. The proportion estimated to be MSM for the Ukraine represented 0.3% of
themalepopulation,withthe’best’estimatewithtruncationforoutliersincreasingto0.7%[435].
164Statistical analyses were performed using STATA version 12 (STATA Corp, College Station,
TX, USA).
165Chapter 6
Determining Components for
Estimating HIV Incidence
Within the following chapter I characterise persons newly diagnosed within each country for
whom residual samples are available for RITA. For Estonia this includes new diagnoses from
all testing centres across the country, for Poland new diagnoses from all 30 VCT sites, and
for Kiev, persons testing at the four HIV testing sites Kiev City oblast. I estimate a number of
parameters required for estimating incidence, and investigate differences in testing behaviours
by sub-populations.
1666.1 Characterising persons newly diagnosed with HIV
6.1.1 Kiev City
A total of 6370 adults (3425 men and 2945 women) were tested for HIV at any one of the four
HIV testing sites, known as the Kiev AIDS Centres in the Kiev City Oblast between April 2013 and
March 2014. This equating to a crude testing rate of 293.2 tests per 100,000 population (aged
¸16 years) (345.8 for men and 249.1 for women) (Table 6.1). The median age at test was 30 years
(IQR: 26-36), with the majority testing due to symptoms (table 6.2). HIV test results could not be
linked for 353 specimens. Of the remaining 6017 tests with a result, 467 (7.8%) were HIV positive,
equivalent to a diagnosis rate of 21.5 per 100,000 persons (table 6.1). The completion rate for
questionnaires was 99.4% with only 39 persons not providing any further information.
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168Probable route of exposure to HIV was available for 5986 of the 6017 (99.5%) individuals with a
test result, the majority (4803; 80%) reported heterosexual contact, and 191 (3.2%) identiﬁed as
MSM (table 6.2). Of the 4803 reporting heterosexual contact, 519 (11%) reported contact with
PWID, with a higher proportion for women (417/2587, 16%) compared to men (101/2216, 4.6%).
A further 377 persons (7.8%) reported paying for sex or reported that they themselves were paid
for sex.
The median age among those newly-diagnosed was higher than those testing (32 years;
IQR: 28-36), and HIV prevalence among those testing was highest among persons aged 31-35
years, males, PWID and MSM (table 6.2). The proportion of persons newly-diagnosed among
those in the heterosexual contact exposure category was low and similar for men and women.
For PWID, the proportion newly-diagnosed was somewhat higher for women compared with
men (21.4% vs. 17.1% respectively).
After excluding those who were not resident within Kiev City, both the testing and new
diagnosis rate were lowerat265.6per 100,000 and17.9, howeverthe proportionofpersonsnewly
diagnosed by subpopulations remained unchanged.
169HIV test Test result known Newly Diagnosed
n = 6370 N = 6017 N = 467 %
Age (years)
16-25 1466 1381 64 4.6
26-30 1795 1698 120 7.1
31-35 1456 1376 154 11.2
¸36 1653 1562 129 8.3
Sex
Male 3425 3224 303 9.4
Female 2945 2793 164 5.9
Residence
Kiev (city) 5771 5457 391 7.2
Kiev area (small town) 412 384 53 13.8
Kiev area (village) 111 108 10 9.3
Another area of Ukraine 46 43 7 16.3
Not Reported 30 25 6
Probable route of exposure
Persons who inject drugs: Male 835 801 137 17.1
Persons who inject drugs: Female 198 191 41 21.5
Men who have sex with men 201 191 46 24.1
Heterosexual contact: Male 2370 2216 114 5.1
Heterosexual contact: Female 2728 2587 122 4.7
Not reported 38 31 7
Testing history
Repeat tester 1413 1365 84 6.2
First-time tester 4787 4499 349 7.8
Not Reported 170 153 34
Reason for test
Clinical Indicators 3166 2336 257 11.0
High Risk Behaviour 2427 2977 163 5.5
General Public Screening 735 668 40 6.0
Not Reported 42 36 7
Table 6.2: Distribtution of all persons testing for HIV and persons newly diagnosed at any one of
the four HIV testing sites between April 2013 - March 2014 in Kiev City, Ukraine.
1706.1.2 Poland
Preliminary results for 2013, indicate that 32,306 persons presented for an HIV test at one of the
30 VCT centres across Poland, with 17,986 tests among men and 14,320 among women. Table 6.3
shows the corresponding rates with 99.9 tests per 100,000 population (aged ¸16 years) (116.3 for
men and 84.9 for women).
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172381 persons were newly diagnosed giving an HIV prevalence of 1.2% with, with the majority
(89%; 338) of new diagnoses among being men. 264 (69%) reported sex between men as their
risk, followed by 22% reporting heterosexual contact and 9.2% identifying as PWID (table 6.4).
Information on overall testing ﬁgures were not available by risk group.
173HIV test Newly Diagnosed
n = 32,306 N = 381 %
Age (years)
16-19 1413 4 0.3
20-29 16,495 171 1.0
30-39 10,275 143 1.4
¸40 4123 63 1.5
Sex
Male 17,986 338 1.9
Female 14,320 43 0.3
Probable route of exposure
Persons who inject drugs: Male 24
Persons who inject drugs: Female 11
Men who have sex with men 264
Heterosexual contact: Male 50
Heterosexual contact: Female 32
Table 6.4: Distribtution of all persons testing for HIV and persons newly diagnosed at a VCT site,
Poland: 2013.
1746.1.3 Estonia
A total of 320 persons (¸ 18 years) (199 men and 121 women) were newly diagnosed with HIV
in Estonia during 2013, equating to a crude diagnosis rate of 29.7 per 100,000 population (40.5
diagnoses for men and 20.7 for women) (table 6.5). The median age at diagnosis was 32 years
(IQR: 27-41), with the majority being diagnosed within the capital Tallinn, and testing being due
to symptoms or high risk behaviour (table 6.6).
175Characteristics Population [437] New HIV diagnoses Diagnosis rate
Total 1,076,483 320 29.7
Age (years) 18-24 119,352 41 34.4
25-30 115,161 97 84.2
31-35 90,519 51 56.3
¸36 751,451 131 17.4
Sex Male 490,847 199 40.5
Female 585,636 121 20.7
Source: Eurostat [437].
Table 6.5: HIV diagnoses rates (per 100,000 population) for persons newly diagnosed in Estonia
during 2013.
176Risk factor information was available for 210 (66%), the majority of whom were infected through
heterosexual contact (66%). For the 110 perons with no reported risk factor information, 73
(66%) were men.
Among those testing due to screening (n=79), 27 were screened because of incarceration,
19 because of pregnancy, 4 were blood donors and for 29 the screening reason is not known.
These persons were excluded from further analysis as testing frequencies and incidence
methodologies differ from populations testing due to self initiation, given that population size
of those screened are known.
After exclusions, 241 diagnoses were included in analysis, the distribution was similar to
that for all diagnoses with a median age of 34 years (IQR: 28-43) (table 6.6).
177Characteristics New HIV Diagnoses New Diagnoses (excluding persons
testing due to screening)
n= 320 n= 241
Age (years)
18-24 41 24
25-30 97 64
31-35 51 40
¸36 131 113
Median (IQR) 32 (27-41) 34 (28-43)
Sex
Male 199 156
Female 121 85
Probable route of exposure
Heterosexual Male 64 48
Heterosexual Female 75 52
Persons Who Inject Drugs 65 40
Men Who have Sex with Men 6 6
Not Reported 110 95
Testing history
Repeat testers 59 44
Reason for Test
Clinical Indicators 85 85
High Risk Behaviour 61 61
General Screening 79
Other 6 6
Not Reported 89 89
IQR, Inter Quartile Range.
Table 6.6: Characteristics of persons newly-diagnosed with HIV during 2013 in Estonia.
1786.2 Testing Patterns
The chosen sample framework for this study using existing national surveillance methods within
Estonia, the four HIV testing sites in Kiev City and and all VCT sites in Poland will be affected
by the test seeking behaviours of individuals. As identiﬁed by Remis et al, symptoms of primary
infection, high risk behaviours and concurrent STI symptoms could lead to increases in testing
rates and within an earlier time frame [407,408].
Such factors could lead to an overestimation of incidence and will be more prominent within
certain subgroups. Furthermore, different test seeking behaviours will inﬂuence the probability
of testing within one year of infection, a component needed for incidence estimates within the
sampling framework, with populations testing more frequently having a greater probability of
testing within one year of infection than those testing less frequently (Chapter 4).
There is little to no information regarding testing frequencies and behaviours in Kiev City,
Estonia or Poland. Using data collected as part of the study for Kiev City and Estonia and
through new diagnoses within the VCT sites between 2008 and 2010 for Poland, I examined
testing frequencies by subpopulations, to understand factors associated with repeat testing in
those countries.
Data regarding previous HIV tests for each country were used to quantify HIV testing rates
among the overall population, stratifying by socio-demographic data collected for each
individual.
6.2.1 Kiev City
Data described in section 6.1.1 of 6370 adults (16 years and older) attending for an HIV test at
any one of the four HIV testing sites in the Kiev City Oblast between April 2013 and March 2014
were analysed. Socio-demographic information, risk factors and testing history were collected
using a pre-test questionnaire, discussed in section 5.4.1. Persons reporting a previous test were
classiﬁed as repeat testers. Persons were excluded if no date of previous test was reported (n=6),
the previous test was within one month of the current test (n=45), where the previous test result
was not known (n=91). After exclusions, 6200 had information on testing history available, of
179whom 1413 (23%) were identiﬁed as repeat testers.
Table 6.7 shows the distribution of testing history among persons attending for an HIV test
during April 2013 to March 2014. The median age among all persons was 30 years [IQR: 26-36];
30 years [25-36]; among ﬁrst-time testers, and 31 years [27-36] among repeat testers.
180Characteristics Attendees
First-time testers
(n= 4787)
Repeat testers
(n= 1413)
n= 6200 n % n %
Age (years)
<30 2787 2252 81 535 19
¸30 3413 2535 74 878 26
Median (IQR) 30 (26-36) 30 (25-36) 31 (27-36)
Sex
Male 3326 2543 76 783 24
Female 2874 2244 78 630 22
Residence
Kiev City 5637 4320 77 1317 23
Outside Kiev City 561 466 83 95 17
Not Reported 2 1 50 1 50
Probable route of infection
Heterosexual Contact 5012 4017 80 995 20
PWID 985 640 65 345 35
MSM 196 123 63 73 37
Not Reported 7 7 100 0 0
Reason for test
Clinical Indicators 3092 2429 79 663 21
High Risk Behaviour 2365 1671 71 694 29
General Public Screening 729 682 94 47 6
Not reported 14 5 36 9 64
IQR, Inter Quartile Range.
Table 6.7: Testing history among persons attending the Kiev AIDS centre for an HIV test during
the period April 2013 - March 2014.
181In univariate logistic regression models, repeat testers were more likely to be older, MSM or
PWID, and testing due to high risk behaviour, compared with ﬁrst time testers (table 6.8). As the
interaction between sex and probable route of exposure was found to be signiﬁcant (p=0.004), I
re-categorised these two variables to create a new variable (MSM, Heterosexual contact: Female,
Heterosexual contact: Male, PWID: Female, and PWID: Male). After adjusting for all other
variables, probable route of exposure/sex remained an independent predictor for repeat testing.
Compared to heterosexual women, MSM and PWID (males and females) were more likely to
repeat test [Odds Ratio (OR): 1.87; 1.37-2.55 and 1.93; 1.62-2.30 and 1.40; 1.00-1.96, respectively],
and heterosexual men were less likely to repeat test [OR=0.78; 0.68-0.91]. Furthermore, repeat
testing was signiﬁcantly more likely with increasing age [OR=1.28 per 10 year increase, 1.19-
1.39] and among those engaging in high risk behaviour [OR=1.55; 1.37-1.76] compared with
those testing due to clinical indicators. Repeat testing was less likely among those testing as
part of screening [OR=0.28; 0.20-0.38] and those resident outside the City [OR=0.66; 0.52-0.84]
(table 6.8). Heterosexual women reporting high risk behaviour (high risk partner or sex work)
had a higher proportion of repeat testers than heterosexual men overall (25%; 135/539 vs. 19%;
72/374), led predominately by women with partners who inject drugs (28%; 119/420).
182Univariate Multivariate †
OR (95% CI) P value OR (95% CI) P value
Age (per 10 year increase) 1.21 (1.12-1.30) <0.001 1.28 (1.19-1.39) <0.001
Area of residence
Kiev City 1 <0.001 1 <0.001
Outside Kiev City 0.67 (0.54-0.85) 0.66 (0.52-0.84)
Probable route of exposure
Heterosexual contact: Female 1 <0.001 1 <0.001
Heterosexual contact: Male 0.81 (0.70-0.93) 0.78 (0.68-0.91)
MSM 2.16 (1.59-2.93) 1.87 (1.37-2.55)
PWID: Female 1.52 (1.09-2.12) 1.40 (1.00-1.96)
PWID: Male 2.10 (1.77-2.50) 1.93 (1.62-2.30)
Reason for test
Clinical Indicators 1 <0.001 1 <0.001
General Public Screening 0.25 (0.19-0.34) 0.28 (0.20-0.38)
High Risk Behaviour 1.52 (1.34-1.72) 1.55 (1.37-1.76)
† Adjusted for all variables in table.
Table 6.8: Factors associated with repeat testing among persons attending the Kiev AIDS centre
for an HIV test during the period April 2013 - March 2014.
183These ﬁndings were further supported when investigating the number of tests individuals
reported having in the past 2 years, with persons reporting sexual contact with the opposite sex
more likely to report 1 test in the past 2 years, whereas MSM were more likely to report 2 or more
(table 6.9).
184Characteristics Repeat
testers
Numberoftestsinthelast2years
(n=1413) 1 2 3 ¸4
Age (years)
<30 535 289 119 55 29
¸30 878 445 205 85 52
Sex
Male 783 411 184 72 51
Female 630 323 140 68 30
Residence
Kiev City 1317 676 313 134 73
Outside Kiev City 95 58 11 5 8
Probable route of infection
Heterosexual Contact 995 531 205 86 54
PWID 345 182 104 34 12
MSM 73 21 15 20 15
Reason for test
Clinical Indicators 663 373 140 44 30
High Risk Behaviour 694 326 177 94 47
General Public Screening 47 32 4 2 3
Table 6.9: Number of tests reported in the past two years by repeat testers attending the Kiev
AIDS centre for an HIV test during the period April 2013 - March 2014.
1856.2.2 Poland
I investigated testing frequencies among persons presenting at a VCT site within Poland through
analysing data collected by the National AIDS Centre, Warsaw, Poland between January 2008
and December 2010. These data were of all persons newly diagnosed as positive and a random
sample of 1000 negative tests from each year.
Data were collected at a person’s initial presentation for an HIV test through a pre-test
questionnaire and a self-reported questionnaire. Variables collected using the pre-test
questionnaire includes socio-demographic information, risk factors and testing history.
Variables collected using the self-reported questionnaire includes education, marital status,
employment, economic status, and self-health assessment, further details of data collections are
found in section 5.4.2.
Data for 3588 adults (16 years and older) attending for an HIV test at one of 30 VCT centres in
Poland between 2008 and 2010 were analysed. Persons reporting a previous test were classiﬁed
as a repeat tester. Persons were excluded if no information on testing history was reported
(n=52), if the previous test was positive (n=63) or equivocal (n=27), if the previous test result was
not known (n=175), the date of the previous test was not known (n=295) or where the previous
testwaswithinthesamemonthasthediagnostictest(n=49). Toensurepersonsareonlycounted
once, I excluded anyone who reported a previous date between 2008 and 2010 and indicated that
the test was performed at the VCT (n=370). After exclusions, 2557 had testing history available,
of whom 381 (15%) were identiﬁed as repeat testers.
Table 6.10 shows the distribution of testing history among persons attending a VCT clinic
between 2008 and 2010. The median age among all persons was 27 years [IQR:23-33], 26 years
[23-32] among ﬁrst-time testers, and 30 years [26-35] among repeat testers.
186Characteristics Attendees † First-time testers
(n= 2176)
Repeat testers
(n= 381)
n= 2557 n % n %
Age (years)
<27 1229 1121 91 108 8.8
¸27 1313 1042 79 271 21
Not reported 15 13 2
Median (IQR) 27 (23-33) 26 (23-32) 30 (26-35)
Sex
Male 1416 1167 82 249 18
Female 1137 1005 88 132 12
Not reported 4 4 0
Area of residence
City 2220 1866 84 354 16
Outside City 224 208 93 16 7.1
Not reported 113 102 11
Probable route of exposure
Heretosexual Contact 2055 1801 88 254 12
Persons who inject drugs 125 90 72 35 28
Men who have sex with men 351 261 74 90 26
Not reported 26 24 2
† Data were of all persons newly diagnosed as positive and a random sample of 1000 negative
tests from each year.
Table 6.10: Testing history among persons attending for an HIV testing at a VCT clinic between
2008 and 2010: Poland.
187In univariate logistic regression models, repeat testers were more likely to be older, resident in a
city, MSM or PWID compared with ﬁrst-time testers (table 6.11). After adjusting for all factors,
probable route of exposure remained an independent predictor for repeat testing. Compared
to heterosexual contact, MSM and PWID were more likely to repeat test [Odds Ratio (OR): 2.29;
1.69-3.12) and OR: 2.77 (1.81-4.25) respectively]. Furthermore, repeat testing was signiﬁcantly
more likely with increasing age [OR=1.29 per 10 year increase, 1.15-1.43]. Repeat testing was less
likely among those resident outside a city [OR=0.45; 0.27-0.76] (table 6.11).
188Characteristics Univariate Multivariate †
OR (95% CI) P Value OR (95% CI) P Value
Age (per 10 year increase) 1.27 (1.14-1.41) <0.001 1.29 (1.15-1.43) <0.001
Sex
Male 1 <0.001 1 0.19
Female 0.61 (0.48-0.77) 0.84 (0.65-1.09)
Area of residence
City 1 <0.001 1 0.001
Outside City 0.42 (0.25-0.71) 0.45 (0.27-0.76)
Probable route of exposure
Heterosexual contact 1 <0.001 1 <0.001
Persons who inject drugs 2.86 (1.88-4.36) 2.77 (1.81-4.25)
Men who have sex with
men
2.46 (1.86-3.25) 2.29 (1.69-3.12)
† Adjusted for all variables in table.
OR, Odds Ratio.
Data were of all persons newly diagnosed as positive and a random sample of 1000 negative
tests from each year.
Table 6.11: Predictors for repeat testing among persons attending for an HIV test between 2008
and 2010: Poland.
1896.2.3 Estonia
Amongthe241personsnewlydiagnosedduring2013withinEstoniaasdescribedinsection6.1.3,
data on a previous test within the past 2 years was requested from conﬁrmatory laboratories
using the citizen ID, with a negative test within the past 2 years reported for 35 (15%) newly
diagnosed in 2013. The distribution of persons testing negative in the past two years are within
table 6.12 with younger adults, women and persons testing because of high risk behaviour
more likely to test in the past two years. Adjusting for all variables, there were no independent
predictors identiﬁed.
190Characteristics New Diagnoses (excluding persons A negative test in the
testing due to screening) past 2 years
n = 241 n = 35 %
Age (years)
18-24 24 8 33
25-30 64 15 23
31-35 40 6 15
¸36 113 6 5.3
Median (IQR) 34 (28-43) 28 (25-33)
Sex
Male 134 19 14
Female 63 16 25
Probable route of exposure
Heterosexual Men 48 6 13
Heterosexual Women 52 9 17
Persosn Who Inject Drugs 40 7 18
Men Who have Sex with Men 6 0
Not Reported 95 13 14
Reason for Test
Clinical Indicators 85 8 9.4
High Risk Behaviour 61 11 18
Other 6 0
Not Reported 89 16 18
IQR, Inter Quartile Range.
Table6.12: Distributionofpersonswithanegativetestreportedinthepasttwoyearsofdiagnosis,
Estonia 2013.
1916.3 Determining Key Parameters for Estimating HIV Incidence
As described in section 4.3, when information on the negative population is not available, the
true number of recent infections needs to be estimated using the probability of testing and being
classiﬁed as recent (P).
For repeat testers, this probability is estimated by the time between a person’s last negative
and ﬁrst positive test. For ﬁrst-time testers, the proportion of persons diagnosed late (with an
AIDS diagnosis and/or CD4 cell count <200 cells/mm3) is used to derive that probability.
The methodology by Karon et al [409] estimates the probability of testing and being classiﬁed as
recent using equation 6.1.
P ÆP1£P2£Pw (6.1)
where P1 is the probability of having an HIV test within the reference period, P2 is the probability
of being tested with a TRI and Pw is the probablity of being classiﬁed as recent. For repeat testers
P1 equals 1/T with T representing the time between a person’s last negative and ﬁrst positive
result. For ﬁrst-time testers, P1 equals 1/¯, with ¯ representing the mean time from infection
to test. ¯ is estimated using equation 6.2 where q is the proportion diagnosed late and ®A and
¯A are the shape and scale parameter, respectively, of the incubation period from infection to an
AIDS diagnosis.
¯Æ
[¯A]
[q¡1/®A ¡1]
(6.2)
Prejean’s [346] method, described in section 4.3.2 modiﬁes this formula by estimating the
probability of testing and being classiﬁed as recent directly using equation 6.3 for repeat testers
and 6.4 for ﬁrst-time testers. Here Sw(t) is the probability of a person being classiﬁed as recent
at time t after infection and SA(t) is the survival function for the AIDS incubation period. These
modiﬁcationsremovetheupperlimitPw placedontheprobabilityoftestingandconsidersthata
person’s inter-test interval could be less than 1 year. I will estimate the probability of testing and
being classiﬁed as recent using both methodologies to compare the incidence estimates.
192P Æ
1
n
T X
iÆ1
1
T i
Z Ti
0
Sw(t)dt (6.3)
P Æ
Z 1
0
Sw(t)SA(t)
1
¯
e-t/¯dt (6.4)
6.3.1 Method A: Karon et al: Repeat testers
Kiev City
Using data described in section 6.1.1 and section 6.2.1, for persons attending the Kiev AIDS
centre for a test between April 2013 and March 2014, testing history was available for 6200, of
whom1413(23%)wereidentiﬁedashavingarepeattest, ofwhom482(34%)hadre-testedwithin
a year of their negative test. Among those subsequently diagnosed as HIV positive, the respective
ﬁgures were as follows: 433, 84 (19%) and 17 (20%). The probability of testing within a year of
infection for all repeat testers was 0.70, and for those HIV positive 0.566 (table 6.13). These two
probabilities were also estimated for the key characteristics identiﬁed as predictors for repeat
testing (section 6.2.1) which are needed to control for any heterogeneity in testing frequencies.
Populations with a greater probability of testing within a year of infection were: men (0.607),
age 16-25 years (0.693), and MSM (0.650) (table 6.13). These probabilities are estimated as the
average of 1/T for each repeat tester (see section 4.3.1), with T equal to the interval between
the person’s last negative test and ﬁrst positive test. Figure 6.1 shows the distribution of these
probabilities for repeat testers newly diagnosed during the time period.
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Figure 6.1: Distribution of the probability of testing within a year of infection for repeat testers
newly diagnosed at the Kiev AIDS centre April 2013 and March 2014.
195To estimate the true number of recent infections within the population (Tr), the number of
diagnostic tests identiﬁed as recently infected is divided by the probability of being tested and
classiﬁedasrecent(P).Thisprobabilityisthefunctionoftheprobabilityoftestingwithinayearof
infection (P1 equal to 0.566) and the probability of testing recent (Pw). The probability of testing
recent or Pw, is equal to ¹/365 (see formula 4.7) which is equal to 130 days/365 resulting in a Pw
of 0.356. Using formula 6.1, assuming that all new diagnoses have been tested with LAg Avidity
EIA, the probability of testing and being classiﬁed as recent (P) is equal to 0.201. Therefore,
for every one recent infection identiﬁed, this probability suggests the true number of recent
infections is 4.9, suggesting a further 3.9 recent infections are within the population currently
undiagnosed. Figure 6.2 shows both the probability of testing within a year of infection (blue
line) and the probability of testing and being classiﬁed as recent (red line). This ﬁgure illustrates
how the probability of testing and being classiﬁed as recent is bounded by the probability of
being classiﬁed as recent, with the blue line reaching a probability of 1 for those who test at
yearly intervals with the overall probability (red line) reaching a maximum of 0.356.
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Figure 6.2: Distribution of the probability of testing within a year of infection for repeat testers
(blue line) and the probability of testing and being classiﬁed as recent (red line) newly diagnosed
at the Kiev AIDS centre April 2013 and March 2014.
197Poland
Using data from 2008-2010, described in section 6.2.2, testing history and a diagnosis date were
reported for 2503 persons, of whom 372 (15%) were repeat testers, of whom 63 (17%) had re-
tested within a year of their last negative test date. Among those subsequently diagnosed as
HIV positive, the respective ﬁgures were as follows: 344, 77 (26%) and 8 (10%). The probability
of testing within a year of infection among those diagnosed HIV positive was 0.375 (table 6.14).
Probabilities were also estimated for the key characteristics identiﬁed as predictors for repeat
testing(section 6.2.2)tocontrolforheterogeneityintestingfrequencies. Although,olderpersons
(¸ 27 years) were more likely to repeat test , the probability of testing within a year of infection
wasgreaterforthoseage20-29years(table6.14),withahigherprobabilityoftestingwithinayear
of infection among MSM compared to those reporting heterosexual contact. These probabilities
are estimated as the average of 1/T for each repeat tester (see section 4.3.1), with T equal to
the interval between the person’s last negative test and ﬁrst positive test. Figure 6.3 shows the
distribution of these probabilities for repeat testers newly diagnosed during the time period.
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Figure 6.3: Distribution of the probability of testing within a year of infection for repeat testers
newly diagnosed at a VCT site across Poland during 2013.
200To estmate the true number of recent infections within the population (Tr), the number of
diagnostic tests identiﬁed as recently infected is divided by the probability of being tested and
classiﬁedasrecent(P).Thisprobabilityisthefunctionoftheprobabilityoftestingwithinayearof
infection (P1 equal to 0.375) and the probability of testing recent (Pw). The probability of testing
recent or Pw, is equal to ¹/365 (see formula 4.7) which is equal to 130 days/365 resulting in a Pw
of 0.356. Using formula 6.1, assuming that all new diagnoses have been tested with LAg Avidity
EIA, the probability of testing and being classiﬁed as recent (P) is equal to 0.134. Therefore,
for every one recent infection identiﬁed, this probability suggests the true number of recent
infections is 7.5, suggesting a further 6.5 recent infections are within the population currently
undiagnosed. Figure 6.4 shows both the probability of testing within a year of infection (blue
line) and the probability of testing and being classiﬁed as recent (red line). This ﬁgure illustrates
how the probability of testing and being classiﬁed as recent is bounded by the probability of
being classiﬁed as recent, with the blue line reaching a probability of 1 for those who test at
yearly intervals with the overall probability (red line) reaching a maximum of 0.356.
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Figure 6.4: Distribution of the probability of testing within a year of infection for repeat testers
(blue line) and the probability of testing and being classiﬁed as recent (red line) newly diagnosed
at a VCT site across Poland during 2013.
202Estonia
UsingdatafromnewdiagnoseswithinEstoniaduring2013, 18%(44)hadapreviousnegativetest
reported. Duetothenatureofhowthesedatawerecollected,themajority(80%)ofthesenegative
tests occurred in the past two years. As a result, the probability of testing within a year is high at
0.685 (table 6.15), stratiﬁed by subpopulations there was little difference in these probabilities
(table 6.15). All probabilities were much higher than for Poland and Kiev City. Like for Poland
and Kiev City these probabilities are estimated as the average of 1/T for each repeat tester (see
section4.3.1), withTequaltotheintervalbetweenthepersonslastnegativetestandﬁrstpositive
test. Figure 6.5 shows the distribution of these probabilities for repeat testers newly diagnosed
during the time period.
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Figure 6.5: Distribution of the probability of testing within a year of infection for repeat testers
newly diagnosed across Estonia during 2013.
205To estimate the true number of recent infections within the population (Tr), the number of
diagnostic tests identiﬁed as recently infected is divided by the probability of being tested and
classiﬁedasrecent(P).Thisprobabilityisthefunctionoftheprobabilityoftestingwithinayearof
infection (P1 equal to 0.685) and the probability of testing recent (Pw). The probability of testing
recent or Pw, is equal to ¹/365 (see formula 4.7) which is equal to 130 days/365 resulting in a Pw
of 0.356. Using formula 6.1, assuming that all new diagnoses have been tested with LAg Avidity
EIA, the probability of testing and being classiﬁed as recent (P) is equal to 0.244. Therefore,
for every one recent infection identiﬁed, this probability suggests the true number of recent
infections is 4.1, suggesting a further 3.1 recent infections are within the population currently
undiagnosed. Figure 6.6 shows both the probability of testing within a year of infection (blue
line) and the probability of testing and being classiﬁed as recent (red line). This ﬁgure illustrates
how the probability of testing and being classiﬁed as recent is bounded by the probability of
being classiﬁed as recent, with the blue line reaching a probability of 1 for those who test at
yearly intervals with the overall probability (red line) reaching a maximum of 0.356.
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Figure 6.6: Distribution of the probability of testing within a year of infection for repeat testers
(blue line) and the probability of testing and being classiﬁed as recent (red line) newly diagnosed
across Estonia during 2013.
2076.3.2 Method A: Karon et al: First-time testers
Kiev City
During the ﬁrst quarter of 2013, 311 persons who were newly-diagnosed with HIV in the Kiev
City oblast region attended the Kiev AIDS Centre for care. WHO clinical stage was available for
all persons accessing HIV care, 300 (96%) of whom also had a CD4 cell count. Of those with a
CD4 cell count reported, 130 (43%) were diagnosed with a CD4 cell count <200 cells/mm3and/or
classiﬁed as clinical stage IV. Formula 6.5 from section 4.3.1 was used to estimate the probability
of testing within 1 year of infection (1/ ¯).
where ¯Æ
[¯A]
[q¡1/®A ¡1]
)¯Æ
[4]
[0.43¡1/2¡1]
) ¯Æ7.6
) 1/¯Æ0.132
(6.5)
The 43% diagnosed late (q) resulted in an estimated mean time between infection and HIV
testing (¯) of 7.6 years, and the probability of a person within this group presenting for an HIV
test within 1 year of infection (1/ ¯), equal to 0.132.
Estonia
Between 2010 and 2012, 656 persons were newly-diagnosed and took up a referral for care in
Estonia (248, 240 and 168 for 2010, 2011 and 2012, respectively). CD4 cell count was reported for
158, 176 and 128 persons respectively of whom 36% (57), 27% (46) and 37% (48) had a CD4 cell
count <200 cells/mm3 within three months of HIV diagnosis. Five persons were diagnosed with
AIDS within 3 months of HIV diagnosis, of whom one person diagnosed in 2011 had a CD4 >200
208cells/mm3.
The average proportion of persons newly-diagnosed and accessing HIV-related care with a
CD4 cell count <200 cells/mm3 and/or an AIDS diagnosis within 3 months of diagnosis between
2010 and 2012 was 33% (table 6.16).
where ¯Æ
[¯A]
[q¡1/®A ¡1]
)¯Æ
[4]
[0.33¡1/2¡1]
) ¯Æ5.36
) 1/¯Æ0.187
(6.6)
Therefore, the estimated probability of testing within 1 year of infection, for those without
testing history (1/ ¯), is equal to 0.187.
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2106.3.3 Method B: Prejean et al
Alternatively,theprobabilityoftestingandbeingclassiﬁedasrecentcanbeestimateddirectlyfor
both repeat and ﬁrst-time testers using the methodology described in section 4.3.2. For repeat
testers, the probability of testing and being classiﬁed as recent (P) was estimated as 0.305, 0.192
and 0.368 for Kiev City, Poland and Estonia respectively, and for ﬁrst-time testers 0.044 for Kiev
City and 0.075 for Estonia. Data for Poland are not currently available for ﬁrst-time testers. The
probability of testing and being classiﬁed as recent (P) for all repeat testers newly diagnosed and
bysubpopulationsareshownintable6.17forKievCity,table6.18forEstoniaand 6.19forPoland,
with the distribution shown in ﬁgures 6.7, 6.8 and 6.9.
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Figure 6.7: Distribution of the probability of testing and being classiﬁed as recent among repeat
testers newly diagnosed at the Kiev AIDS centre April 2013 and March 2014.
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Figure 6.8: Distribution of the probability of testing and being classiﬁed as recent among repeat
testers newly diagnosed at 30 VCT sites across Poland during 2013.
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Figure 6.9: Distribution of the probability of testing and being classiﬁed as recent among repeat
testers newly diagnosed in Estonia during 2013.
217Using the modiﬁed method by Prejean et al [346] the probabilities of testing and being classiﬁed
as recent are estimated directly. However, with the initial methodology this probability is the
function of two probabilities; the probability of testing within a year of infection, estimated in
section 4.3.2, and the probability of being classiﬁed as recent, estimated by dividing the MDRI
for the assay over the reference period. For this study, the MDRI for the LAg Avidity EIA is 130
days and the reference period is 365 days, resulting in a probability of 0.365. Table 6.20 gives
the probability of testing and being classiﬁed as recent using the two methodologies, with those
estimated using the Prejean method higher than those using the Karon method [346,409].
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2196.4 Discussion
An HIV prevalence of 7.8% was estimated for persons presenting for an HIV test in Kiev City,
equivalent to 21.5 diagnoses per 100,000 population, and an overall testing rate of 293.2 per
100,000 population. For the ﬁrst time, detailed information on HIV risk behaviour was available,
indicating that MSM and PWIDs were disproportionately affected by HIV. Furthermore, given
the proportions among newly-diagnosed female heterosexuals reporting sexual contact with
PWID, there is further evidence of bridging in risk between PWID and their sexual partners. The
diagnosis rate for Estonia was 24.9 per 100,000 population and, although heterosexual contact
was the leading route of infection, a third of persons newly diagnosed did not have a risk factor
recorded, the majority of whom were men. Finally, preliminary data for Poland indicate that the
diagnosis rate for persons attending a VCT site in Poland in 2013 is 1.2 per 100,000 population,
with the majority reporting their risk as MSM.
Although, the diagnosis rate for Kiev City of 21.5 is lower than that for Ukraine as a whole
(37.1 per 100,000), it is however, substantially higher than rates for Western and Central Europe
(6.6 and 2.1, respectively) [15]. Even though ECDC suggest testing rates are higher for countries
in Eastern Europe, the testing rate for Kiev City was one of the lowest in Europe with only Greece
reporting a lower rate with 190 per 100,000 population [15].
For the ﬁrst time detailed information on HIV risk behaviour was available, indicating that MSM
and PWID were disproportionately affected by HIV. Although the majority of persons presenting
for an HIV test reported heterosexual contact, one in ﬁve MSM and PWID testing for HIV were
diagnosed positive. Using MSM population estimates discussed in section 5.8 [434, 435], the
diagnosis rate for MSM ranged from 490.6/100,000 to 1548.3/100,000. This is substantially
higher than the diagnosis rates of 76.6 to 241.7/100,000 suggested by the 152 MSM diagnosed
in Ukraine overall [15], though the prevalence of MSM may differ between Kiev and the rest of
Ukraine.
Interestingly, there was little difference in the diagnosis rates between men and women
reporting heterosexual contact. Due to high rates of stigma and discrimination within Ukraine
I had anticipated non-disclosure of homosexuality to be high, with men more likely to report
they were a heterosexual male, leading to a higher rate of HIV diagnosis in heterosexual men.
220However, this was not reﬂected in the data, suggesting that non-disclosed homosexuality among
men is unlikely to be substantial. However, ﬁndings were in agreement with previous ﬁndings
suggesting a bridging between high risk individuals and their partners with an estimated one in
six heterosexual women reporting contact with a PWID.
Testing patterns among persons presenting for an HIV test in Kiev City are consistent with
current literature [271, 407, 408, 412–414], with those at high risk of HIV more likely to test
frequently, with probable route of exposure (MSM and PWID) and reason for test (high risk
behaviour) all being independently associated with repeat testing. Age was also associated with
repeat testing, which may, in part, be due to younger persons having had less time to test than
those who are older. Around one in three MSM and PWID reported a previous test compared
to one in ﬁve among heterosexuals, indicating that persons at risk have some awareness about
testing. This was also evident among heterosexual women with partners who inject drugs.
This increase in testing is likely to result in a person presenting for a test closer to their date of
HIV infection, and has a direct impact on the probability of testing within a year of infection,
highlighting the importance of controlling for these difference among subpopulations when
estimating incidence at a sub-population level.
This probability of testing within a year of infection as described in section 4.3, uses the
testing frequencies of persons who have tested more than once or the population for those
presenting for a test for the ﬁrst-time, to establish whether the number of recent infections
collated through new diagnosis is a true reﬂection of the number of recent infections within
the population. Among repeat testers, the more frequently a person tests the more likely they
are to be diagnosed when recently infected. Among those self-identifying as a repeat tester by
reporting a previous negative test in Kiev City, one in ﬁve tested positive within a year of their
last negative test. The respective probability of testing within a year of infection was 0.566,
suggesting that a high proportion of persons recently infected will have presented for an HIV
test close to their time of infection, and that the number classiﬁed as recent is close to the true
number recent. The probability of 0.566 suggests that for every 1 recent infection a further 0.8
recent infections have not yet been diagnosed.
Alternatively, among ﬁrst-time testers, the proportion of the population who test because
221they have had their infection for many years is used to estimate the likelihood this population
will test close to infection. A population with a low proportion of persons diagnosed late (CD4
cell count <200 cells/mm3) suggests a shorter average time between infection and diagnosis
than a population with a high proportion of late diagnosis. The proportion diagnosed late within
Kiev City was estimated to be 43%, suggesting an 8 year gap between infection and diagnosis
and a probability of testing within the ﬁrst year of 0.132. This proportion will be much higher if
persons reporting a previous negative test were removed from the population, with a longer gap
between infection and diagnosis.
Data on CD4 and clinical stage at diagnosis are not widely available within Ukraine, and
the data used were collected from patients’ notes for the ﬁrst quarter of 2013. Although data are
reﬂective of the study period, it is not possible to state whether they are typical of recent years.
In Europe on average, where CD4 completion was >75% for each country, the average CD4 cell
count <200 cells/mm3 at diagnosis, for countries within the EU/EEA was 26%, whereas among
non-EU/EEA countries this proportion was much higher at 43% [15]. This high proportion
among non-EU/EEA countries was comparable to that in Kiev City. Furthermore, the probability
of testing within a year of infection 0.132 was also comparable to those for the USA [409] and
Italy [348] with 0.240 and 0.136 respectively. This lower probability indicates that for every
person with no testing history who is classiﬁed as recent there are 6.6 more recent infections.
As previously discussed, because of differences in testing patterns among subpopulations,
I estimated the probability of testing within a year of infection for repeat testers separately
by age group, sex and probable route of exposure. Where the probability of testing within a
year was higher than the overall population, such as for males and MSM with 0.607 and 0.650,
respectively, the incidence estimate would be overestimated if the overall 0.566 probability was
used. Likewise, as this probability lower for females and persons diagnosed aged ¸ 36 years
(0.487 and 0.397, respectively) their incidence estimate would be an underestimate. Like the
repeat testers, the proportion diagnosed late and, therefore, the probability of testing within a
year, is likely to differ by subpopulations. Higher rates of testing among MSM and PWID suggests
that MSM are less likely to be diagnosed late compared to persons exposed through heterosexual
contact [15], leading to a higher number of undiagnosed heterosexuals compared to MSM.
However, these data are not currently available within Kiev City.
222The probability of testing and being classiﬁed as recent (P) can be estimated directly using
the methodology in section 4.3.2, rather than estimating the probability of testing within a year
and the probability of being classiﬁed as recent separately. The probability of testing in the ﬁrst
year was consistently higher among repeat testers, rather than ﬁrst-time testers as expected,
with a higher probability among men (0.332), MSM (0.328) and PWID (0.322). Estimating this
probability directly allows repest testers to have an inter-test interval of less than a year and
allow for a recency period of greater than a year, preventing an underestimation of P . This is
shown when comparing Karon’s P of 0.201 for repeat testers and 0.047 for ﬁrst-time testers with
Prejean’s of 0.305 and 0.056, respectively.
The 24.9 per 100,000 population diagnosis rate for Estonia with 320 persons newly diagnosed in
2013, was consistent with the 2012 diagnoses rates published by ECDC (23.5 per 100 000) [15].
Data for Estonia, are collected initially through the Estonian Health board and then through the
HIV database once persons attend for care. As all new diagnoses within Estonia were collected
this meant there was data for those self-initiated testing and for those being screened. These
testing populations are very different, and use very different methods for estimating incidence,
which is why persons testing through screening were excluded from any further analysis.
Among those persons who presented for a test, excluding those testing due to screening,
two thirds reported their probable risk of HIV as heterosexual contact, however a third of
persons newly diagnosed did not have a risk factor recorded, of which the majority were men.
With the distribution of sex for Estonia mirroring that of Kiev with 3 in 5 new diagnoses being
among men, but with a higher proportion of diagnoses among MSM and PWID, we can consider
that those without a risk factor could later report these risk groups.
Data on whether a person has tested previously were collected directly from 5 out of the
6 major laboratories within Estonia which represent an estimated 80-90% of the total tests
performed [Pilleriin Soodla, personal communication, August, 2014]. Although these negative
tests are more reliable than self-reported information, the majority of data only reﬂect the past
two years. As a result, the probability of testing within a year among these persons was much
higher with 80% re-testing within 2 years and 25% within 1 year. There was little difference by
223subgroup, with a higher probability among men (0.756), persons aged 25-30 (0.772) and PWID
(0.826). However, there were no independent predictors for repeat testing.
To estimate the proportion of persons diagnosed late in Estonia, I used data available from
the previous 3 years (2010-2012). Where a CD4 cell count was available (70%), on average a third
of persons were diagnosed with a CD4 less than 200 cells/mm3, resulting in a probability of
testing and being classiﬁed as recent of 0.077. As indicated previously, the average proportion of
persons diagnosed late in EU/EEA regions was 26%, lower that the 30% for Estonia. Although,
among the repeat testers men had a higher probability of testing within a year of infection,
this population also had a higher proportion of late diagnosis compared with women resulting
in a lower probability of testing and being cllassiﬁed as recent of 0.063 compared with 0.111.
This difference could be due to antenatal screening among women resulting in women being
diagnosed earlier in their infection.
Finally, due to data processing procedures within Poland (a commercial company is tasked
with data entry) a completed dataset is not available until the end of the following year. However,
preliminary data indicate that the diagnosis rate for persons attending a VCT site in Poland in
2013 is 1.2 per 100,000 population, lower than the 2.8 reported for the whole of Poland in 2012.
However, this difference is likely to reﬂect the difference in populations, with this study only
including persons testing at a VCT. From the preliminary data, the distribution of persons at
risk differed signiﬁcantly from that of Kiev City and Estonia, with nine of ten persons newly
diagnosed at a VCT being male, with the majority of diagnoses being among MSM.
Data from persons testing at a VCT site from previous years (2008-2010) were used to understand
testing patterns and estimate the probability of testing within a year of infection among repeat
testers. Testing patterns were also consistent with published literature [271,407,408,412–414],
with both MSM and PWID more likely to repeat test, and with higher odds of testing with
increasing age. The probability of testing within a year of infection for repeat testers was much
lower than in Kiev City, Italy and the USA [346,348], with only 1 in 10 persons re-testing within a
year of their last negative test.
Estimating the probability by subpopulation was consistent with testing patterns with MSM
224having a higher probability of testing within a year compared with heterosexuals (0.410 vs.
0.295). However, although increasing age was associated with repeat testing, the highest
probability was found among those aged 20-29 years. This indicates that repeat testing and age
is a factor of how long they have had to repeat test and does not necessarily reﬂect how regularly
they test. Of note, re-testing was less likely among persons living outside cities, which could
suggest that testing facilities are less accessible outside cities, or a lower understanding of the
importance of testing among persons in those settings.
225Chapter 7
Estimating Incidence
Within the following chapter I present the distribution of persons classiﬁed as recent within each
country. I estimate HIV incidence for all persons and for sub-populations where information
is available. I explore differences in incidence, based on the availability of data components
identiﬁed for estimating incidence, and testing behaviour.
Through nucleotide sequencing I investigated the distribution of HIV subtype and evidence
of transmitted drug resistance among persons newly diagnosed with HIV, in particular those
recently infected.
2267.1 Characterising Persons Recently Infected
7.1.1 Odessa
I analysed data from an initial study conducted within Odessa during 2009, where residual
samples from all newly-diagnosed HIV positive individuals (¸ 16 years) across Odessa city and
province between May and December 2009 were tested for evidence of recent infection using
the laboratory assay known as the BED-CEIA. See section 5.4.1 for methods.
1,315 persons aged ¸ 16 years were tested with the BED assay, of whom 2 were excluded as
they were subsequently discovered to be HIV negative. Of the remaining 1,313, 321 (24%) were
classiﬁed as recent. Median age at HIV diagnosis was 32 years [inter quartile range (IQR): 26-39],
with men accounting for 54% of diagnoses. The majority of persons tested for HIV were part of
general public screening (42%) or due to clinical indications (36%) (table 7.1).
Table 7.1 shows the distribution of newly-diagnosed individuals and the number identiﬁed
as recently-infected. Younger adults appeared to be more likely to be identiﬁed as recently-
infected (p<0.001), as did women (p=0.013). Those resident in the city of Odessa were less likely
to be identiﬁed as recently-infected (p=0.019). The interaction between sex and residence was
found to be signiﬁcant (p=0.015). I, therefore, re-categorised and created a new term of sex and
residence.
227New HIV diagnoses Recently infected p-value
n %
Age at HIV diagnosis (years)
<25 209 87 42
25-30 343 91 27 <0.001
31-40 488 87 18
>40 273 56 21
Sex
Male 709 154 22 0.013
Female 604 167 28
Residence
Odessa: City 692 149 22
Odessa: Rural 550 156 28 0.019
Non-resident in Odessa 54 15 28
Not Reported 17 1 5.9
Reason for test
Clinical Indicators 404 93 25
High Risk Behaviour 341 88 24 0.78
General Public Screening 557 138 25
Other 11 2 18
Total 1,313 321 24
Table 7.1: Characteristics of persons newly-diagnosed with HIV and the proportion identiﬁed as
recent by the BED assay in Odessa, Ukraine: May-December 2009.
228Findings were largely conﬁrmed in multivariable logistic regression models (table 7.2). Age
remained an independent predictor for recent infection with increasing age being associated
with a lower probability (OR=0.70 per 10-year increase, 95% CI= 0.60-0.82). Compared to men
residing in Odessa city, women in rural Odessa (1.85, 1.26-2.71) and non-resident men (2.83,
1.15-6.97) were more likely to be recently-infected. Reason for test was not independently
associated with recent infection.
Among those with testing history, none of the persons who reported a negative test within
a year of their diagnosis were classiﬁed as recent. Of those who were classiﬁed as recent four out
of the ﬁve reported their negative test within two years of their diagnosis.
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230By May 2011 of the 1,313 newly-diagnosed individuals, 819 (62%) had presented at an HIV/AIDS
centre, and information on clinical status was available on 809 of whom 322 (40%) were
diagnosed with AIDS and 181 (22%) were known to have died (table 7.3). Among the 321 who
were identiﬁed by the RITA assay as recently-infected, 209 (65%) presented at an HIV/AIDS
centre, 207 of whom had information on clinical status. Of these, 32 (15%) had been diagnosed
with AIDS and 23 (11%) were known to have died. Among those deemed to have been recently-
infected, 21 (66%) of those diagnosed with AIDS, and 15 (65%) of those known to have died, had
had an HIV test due to clinical indications.
When I excluded the 404 individuals who were tested due to clinical indications, 228 (25%)
of the remaining 909 were classiﬁed as recent. Findings from the logistic regression analyses
remained qualitatively unchanged with older age being associated with lower probability of
testing as recently-infected (OR=0.69 per 10 year increase, 0.56-0.84).
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2327.1.2 Kiev City
The LAg avidity EIA was conducted on residual samples from persons newly diagnosed with
HIV at any one of the four HIV testing sites in Kiev City between April 2013 and March 2014.
Figure 7.1 shows the data ﬂow used to classify whether a person has been recently infected. For
21individualsasamplewasnotavailablefortesting,oftheremaining446,39(8.7%)wereinitially
classiﬁedasrecentwithanavidityindex<1.5ODn. Additionalinformationonviralloadwasused
tominimiseriskofmisclassiﬁcationoflongstandinginfectionsasrecent. Ofthosewithanavidity
score of <1.5, 10 had a viral load <1000 copies/ml and were not considered as recent, resulting in
29 (6.5%) recent HIV infections, 6.6% among repeat testers and 6.5% among ﬁrst-time testers.
233Figure 7.1: Flow of data from presenting for an HIV test four testing sites to being classiﬁed as a
recent HIV infection, in Kiev City: April 2013 and March 2014.
234Median age among those recently infected was 30 years [IQR:24-34], similar to that among all
new diagnoses, with men accounting for two thirds of recent infections. Table 7.4, shows the
distribution of persons classiﬁed as recently infected in Kiev City. Recent infections were more
likelytobeidentiﬁedamongyoungeradultsandmenwhohavesexwithmen,withthoseresident
outside Kiev City less likely to be identiﬁed as recent.
235Newly Diagnosed Available Sample Recent classiﬁcation
N = 467 % N = 446 N = 29 %
Age (years)
16-25 64 4.6 61 8 13
26-30 120 7.1 115 10 8.7
31-35 154 11.2 144 8 5.6
¸36 129 8.3 126 3 2.4
Sex
Male 303 9.4 288 23 8.0
Female 164 5.9 158 6 3.8
Residence
Kiev (city) 391 7.2 373 28 7.5
Kiev area (small town) 53 13.8 51 1 2.0
Kiev area (village) 10 9.3 10 0 0
Another area of Ukraine 7 16.3 6 0 0
Not Reported 6 6
Probable route of exposure
Persons who inject drugs: Male 137 17.1 130 3 2.3
Persons who inject drugs: Female 41 21.5 40 1 2.5
Men who have sex with men 46 24.1 43 14 33
Heterosexual contact: Male 114 5.1 109 5 4.6
Heterosexual contact: Female 122 4.7 117 5 4.3
Not reported 7 7 1
Testing history
Repeat tester 84 6.2 76 5 6.6
First-time tester 349 7.8 338 22 6.5
Not Reported 34 32 2
Reason for test
Clinical Indicators 257 11 248 20 8.1
High Risk Behaviour 163 5.5 154 8 5.2
General Public Screening 40 6 37 1 2.7
Not Reported 7 7
Table 7.4: Characteristics of persons newly-diagnosed with HIV and the proportion identiﬁed as
recently infected using the LAg Avidity EIA, Kiev City, Ukraine: April 2013 - March 2014.
236Adjusting for all variables in a multivariable logistic regression model indicated that the only
independent predictor for being a recently infected was risk, with MSM more likely to present
risk compared with persons reporting heterosexual contact (table 7.5).
Where exposure category was reported, MSM accounted for 50% (14/28) of recent infections
with heterosexual men accounting for 18% (n=5) and heterosexual women 18% (n=5). The
majority of MSM classiﬁed as recent fell into the age group 26-30 years (57%; 8/14) and tested
due to high risk behaviour (71%; 10/14). Persons who inject drugs represented 14% (n=4) of
recent infections, of whom the majority (75%) were male.
Of the 17 persons reporting a negative test within a year of their HIV diagnosis none were
found to be recently infected suggesting that the probability of testing within a year of infection
for repeat testers is an overestimation which will underestimate the true number of recent
infection for that population.
The proportion of persons who maintain an optical density below the assay threshold for
greater than a year of infection after correcting for viral load was estimated using residual
samples from 109 persons known to have had HIV infection for greater than a year. Initial
classiﬁcation using the LAg Avidity assay, indicated that 6.4% (n=7) were misclassiﬁed as recent,
dropping to a false recent rate of 3.7% (n=4) after correcting for a viral load <1000 copies/ml.
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2387.1.3 Estonia
The LAg Avidity EIA was conducted on residual samples from persons newly diagnosed within
Estonia during 2013; persons tested due to screening were excluded from analysis. Figure 7.2
shows the data ﬂow used to classify whether a person has been recently infected, for 23
individuals a sample was not available for testing, and of the remaining 218, 95 (44%) were
initially classiﬁed as recent with an avidity index <1.5 ODn. Of those with an initial recent
infection a viral load was available for 35, of which 2 had a viral load <1000 copies/ml.
239Figure 7.2: Flow of data from presenting for an HIV test to being classiﬁed as a recent HIV
infection, Estonia: 2013.
240Median age among those recently infected was 32 years [IQR:27-42], with men accounting for
two thirds of recent infections. Table 7.6, shows the distribution of persons initially classiﬁed
as recently infected in Estonia. Recent infections were more likely to be among men and those
reporting heterosexual contact. Adjusting for all variables in a multivariable logistic regression
model there were no independent predictors for being a recent infection.
Five persons reported a seroconversion illness, who were all classiﬁed as recent (three had
a negative HIV test within the previous year). The 11 persons with a negative test within one year
of HIV diagnoses were all correctly classiﬁed as recently infected.
The proportion of persons who maintain an optical density below the assay threshold for
greater than a year of infection after correcting for viral load was estimated using residual
samples from 85 persons known to have had HIV infection for greater than a year. Initial
classiﬁcation using the LAg Avidity assay, indicated that 16% (n=14) were misclassiﬁed as recent,
dropping to 8.2% (n=7) after correcting for a viral load <1000 copies/ml. Two further persons
were identiﬁed as elite controllers with a viral load <1000 or 0 and normal CD4 cell count over
the years [Pilleriin Soodla, personal communication, August, 2014], resulting in a ﬁnal false
recent rate of 5.9% (5/85).
241Characteristics New Diagnoses † Available Sample Initial LAg Avidity score <1.5 ‡
n=241 n=218 n=95 %
Age (years)
16-24 24 23 17 74
25-30 64 58 24 41
31-35 40 35 20 57
¸36 113 102 34 33
Median (IQR) 34 (28-43) 32 (27-42)
Sex
Male 156 138 58 42
Female 85 80 37 46
Probable route of exposure
Heterosexual Men 48 39 18 46
Heterosexual Women 52 51 24 47
Persons Who Inject Drugs 40 38 17 45
Men who have Sex with Men 6 5 2 40
Not Reported 95 85 34 40
Testing history
Repeat testers 44 40 30 75
Reason for Test
Clinical Indicators 85 75 33 44
High Risk Behaviour 61 57 28 49
Other 6 5 1 20
Not Reported 89 81 33 41
† Excluding persons testing due to screening.
‡ Not yet corrected for viral load.
IQR, Inter Quartile Range.
Table 7.6: Characteristics of persons newly-diagnosed with HIV and the proportion initially
identiﬁed as recently infected using the LAg Avidity EIA: Estonia 2014.
2427.1.4 Poland
The LAg Aividity EIA was conducted on residual samples from all persons newly diagnosed with
HIV at a VCT centre across Poland during 2013. Figure 7.3 shows the data ﬂow used to classify
whether a person has been recently infected. For 135 individuals a sample was not available
for testing, and of the remaining 246, 73 (30%) were initially classiﬁed as recent with an avidity
index <1.5 ODn. Additional information on viral load was not yet available to minimise the risk
of misclassiﬁcation of long standing infections as recent.
243Figure 7.3: Flow of data from presenting for an HIV test at a VCT centre to being classiﬁed as a
recent HIV infection, in Poland: 2013.
2447.2 Incidence Estimates
7.2.1 Kiev City
HIV incidence was initially estimated using the original methodology by Karon et al where
the true number of recent infections are extrapolated from the observed number using the
probability of testing and being classiﬁed as recent (P). This methodology estimates P as a factor
of the probability of testing within a year of infection and the probability of being classiﬁed
as recent. I estimated incidence before and after correcting for viral load and used a 20-fold
imputation method to address where LAg result and testing history were missing from the data.
Before correcting for viral load, 799 new infections were estimated to have occurred in
Kiev City between April 2013 and March 2014, based on the 36 persons classiﬁed as recent
with testing history. These new infections resulted in an incidence estimate of 36.8 per 100,000
(table 7.7). After correcting for viral load, the number of estimated new infections decreases to
576, equivalent to 26.5 per 100,000 population (table 7.8).
After correcting missing testing history and LAg Avidity result, the estimate using the Karon et al
methodology was 562 new infections, equivalent to 25.9 new infections per 100,000 population.
The incidence estimate is calculated by dividing the number of new diagnoses classiﬁed as
LAg recent by P (the probability of testing and being classiﬁed as recent), where P is the product
of P1 by P2 by Pw.
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247I also applied the modiﬁed methodology by Prejean et al where the probability of testing and
being classiﬁed as recent (P) is estimated directly to ensure that the number of new infections is
not overestimated as a result of an underestimated P (see section 4.3.2). For repeat testers P is
equal to 0.305 compared to 0.201 using the Karon et al Method and 0.056 vs. 0.047 for ﬁrst-time
testers.
I calculated the same results as previously, by dividing the number of new diagnoses classiﬁed
as LAg recent by P , this resulted in 643 new infections before correcting for viral load, equating to
29.6 new infections per 100,000 (table 7.9), and 462 (21.3/100,000) after correcting for viral load
(table 7.10).
After the imputation procedure the ﬁnal estimates for Kiev City were 466 new infections
equating to 21.5 new infections per 100,000 population.
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250Using the modiﬁed method by Prejean et al, I estimated incidence for subpopulations. Although
a higher proportion of recent infections were identiﬁed among persons aged 16-25 years,
incidence estimates were highest among those aged 26-30 years and 31-35 years (both with 72.5
per 100,000). Men had the highest incidence estimates with 34.3 for men compared with 10.2 for
women.
Using population estimates for MSM and PWID (discussed in section 5.8), incidence was
estimated to be between 2289.6 and 6868.7 per 100,000 MSM and for PWID 350.4. These
incidence estimates were signiﬁcantly higher than that for the overall population. Groups with
incidenceestimateslowerthantheoverallpopulationwerewomenwith10.2per100,000women
and persons ¸36 years at 4.3 (table 7.11).
To address for differences in testing patterns as discussed in section 4.3.5, I used population
speciﬁc probabilities in table 6.20. Although information on testing history was available
for all subpopulations allowing for population speciﬁc probabilities, the distribution of late
diagnosis to determine population speciﬁc probabilities for ﬁrst-time testers is not. Therefore,
I used the overall probability of testing and being classiﬁed as recent for ﬁrst-time testers for
subpopulations to estimate the true number of recent infections. Where the proportion of late
diagnosis is greater than the overall population, this probability will underestimate the number
of new infections among ﬁrst-time testers, and overestimate if the proportion is less.
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2527.2.2 Estonia
The same methodologies were used to estimate incidence for Estonia. Viral loads were not
available for correcting misclassiﬁed results, therefore incidence estimates were based on the 95
diagnoses initially classiﬁed as recent using the LAg Avidity EIA.
Incidence estimates for Estonia in 2013, before correcting for misclassiﬁcation of long-standing
infections as recent, was 126.1 per 100,000 population using the original method with 1357 new
infections in 2013 and 95.0 using the direct method of estimating P with 1023 new infections
(table 7.12). Incidence estimates for men were signiﬁcantly higher than among women with
170.9 vs. 44.1 respectively.
Methods for estimating incidence are the same as Kiev City, where the number classiﬁed
as recent is divided by the probability of testing and being classiﬁed as recent (P).
253Repeat testers First-time testers
New diagnoses 40 178
LAg Recent (n) 30 65
Original Method
P1 0.685 0.185
P2 0.909 0.904
Pw † 0.356 0.356
P 0.222 0.06
True recent infections 135 1092
(95% CI) (122-152) (849-1295)
Incidence estimate 1357
(95% CI) (1073-1600)
Incidence rate ‡ 126.1
(95% CI) (99.7-148.6)
Modiﬁed Method
P 0.368 0.077
True recent infections 82 844
(95% CI) (69-98) (657-985)
Incidence estimate 1023
(95% CI) (802-1197)
Incidence rate ‡ 95
(95% CI) (74.5-111.2)
†130/365 = 0.356
‡Per 100,000 population.
CI, Conﬁdence Interval. Conﬁdence intervals were calculated using bootstrapping methologies
described in section 4.3.4.
Table 7.12: Incidence estimates before correcting for misclassiﬁcation of long-standing
infections as recent, Estonia, 2013. 2547.3 Molecular Epidemiology
7.3.1 Circulating HIV Sub-type
Kiev City
As of September 2014, genotyping, based on the ampliﬁcation of the HIV-1 pol region, was
complete for 118 specimens of the 467 new diagnoses identiﬁed in Kiev City between April
2013 and March 2014. The majority (n=116) had a RITA result, of which 15 were among those
classiﬁed as recently infected, and 101 long-standing.
Using the REGA subtyping tool [438], the majority (92%; 109) of those newly diagnosed
persons were infected with subtype A, with the remaining nine classiﬁed as subtype B. Table 7.13
shows the distribution of subtype among those newly diagnosed. Eight of the nine persons
infected with subtype B were male, of whom 3 reported their risk as MSM, 3 as heterosexual
contact and 1 as PWID.
255Characteristics Subtype A Subtype B
n=109 n=9
Sex
Male 73 8
Female 36 1
Probable route of exposure
Persons Who Inject Drugs 41 1
Men who have Sex with Men 17 3
Heterosexual Men 20 3
Heterosexual Women 27 1
Not Reported 4 1
Recent HIV infection
Yes 13 2
No 94 7
Not Known 2 0
Table 7.13: Subtype distribution for newly diagnosed persons for whom an HIV nucleotide
sequence was available: Kiev City April 2013 - March 2014.
256When evaluating the LAg avidity EIA, CEPHIA reported a higher FRR than the recommended 2%
when using specimens with Subtype A1, and a longer MDRI of 211 days compared to the 130
days as per the test insert [Gary Murphy, personal communication, March, 2013]. This longer
MDRI would increase the probability of beingclassiﬁed as recentand therefore reduce incidence
estimates
2577.3.2 Transmitted Drug Resistance
Resistance of HIV to antiretroviral drugs is one of the most common causes for therapeutic
failure in people infected with HIV. Identifying whether a person has a resistant virus to a
particular antiretroviral is an important part of managing HIV, ensuring that the individual is
managed in the most effective way possible. Resistance to a particular antiretroviral drug is the
result of the random mutations in their genetic structures during the reverse transcriptase stage
when the virus is not completely suppressed under the particular treatment conditions. This
could be as a result of poor adherence, but also, as there are no current treatment regimens that
are completely effective in halting viral replication, the emergence of drug-resistant HIV variants
is a common occurrence.
Transmitted Drug Resistance (TDR), identiﬁed in patients recently infected and drug naive,
suggests their infection was likely to have been acquired through contact with an individual
already aware of their infection and undergoing HIV treatment. These data can be used to
highlight current high risk behaviours among persons living with HIV. Studies in North America
and Europe, investigating TDR in recently infected persons, reported the prevalence to be
between 8 and 27% [439–450]. Nucleoside reverse transcriptase inhibitors (NRTI) resistance was
consistently the most common mutation reported in newly infected patients [439–443, 445].
However, increase resistance rate against non-nucleoside reverse transcriptase inhibitors
(NNRTI) and protease inhibitors (PI) have also been identiﬁed [441,443,445].
Kiev City
Of the 118 persons for whom an HIV sequence was available (as of September 2014), 3 (2.5%)
had evidence of TDR according to the Stanford algorithm []. All three were women classiﬁed as
long-standing. Table 7.14 indicates the mutations identiﬁed, both NNRTI mutations result in
high level resistance to Nevirapine (NVP) and Efavirenz (EFV). The NRTI mutations L74V and
M184V are the most common among person’s receiving Lumiviudine (3TC) and Emtricitabine
(FTC), with L74V resulting in high level resistance to didanosine (ddI), and M184V, 3TC and FTC.
the mutation K219E reduces susceptibility to Zidovudine (AZT).
258Sample PI NRTI NNRTI
1 G190S
2 L10I L74V, M184V K101A/E/P/Q, G190S
3 K219E
Table 7.14: Resistant mutations identiﬁed among persons newly diagnosed with HIV between
March 2013 and April 2014 in Kiev City.
2597.4 Discussion
Residual samples from persons described in chapter 6 were tested with a TRI to determine the
distribution of persons recently infected, and using key components (see Chapter 6) I estimated
HIV incidence for Kiev City and Estonia. Persons newly diagnosed comprised all persons
attending a VCT clinic across Poland, persons presenting for an HIV test at four testing sites in
Kiev City and across all testing facilities within Estonia.
Between April 2013 and March 2014, HIV incidence for Kiev City was estimated at 21.5
new infections per 100,000 population, resulting in an estimate of 466 new infections. The
distribution of those recently infected by risk further demonstrates the disproportionate
distribution of HIV among MSM, with a third classiﬁed as recently infected. Using the same
population estimates as described in section 5.8, incidence was estimated to be between 2289
and 6868 new infections per 100,000 MSM and 350 for PWID. These ﬁndings are similar to those
reported for the USA using the same methodology, where the overall incidence estimate was
19.0, with over half of recent infections attributable to MSM.
The incidence rate of 21.5 was estimated using the modiﬁed methodology as described in
section 4.3.2, where the probability of testing and being classiﬁed as recent used to extrapolate
the true number of recent infections from the observed number of recent infections is estimated
directly. The direct method of estimating this probability ensures the probability of testing and
being classiﬁed as recent is not underestimated and therefore overestimating the number of
new infections. This underestimation was identiﬁed as part of the original method by Karon et
al where the inter-test interval is limited to 1 year and this probability is also bounded by the
probabilityofbeingclassiﬁedasrecent. Asaresult, theoriginalmethodoverestimatesincidence,
with 25.9 per 100,000, resulting in an estimated 562 new infections. This original methodology
has also been used to estimate incidence for France with 17.0 per 100,000 and 19.9 for the Italian
region of Lazio, which although appear similar to that of with Kiev City, are likely to be lower if
the same methodology was used.
The incidence estimate of 21.5 was extrapolated from persons where a recent infection was
classiﬁed using RITA, where 6.2% of persons newly diagnosed at four testing sites in Kiev
City were recently-infected. Initial classiﬁcation of recent infections before correcting for
260misclassiﬁed results was 8.4%, as 10 persons had a viral load <1000 copies/ml at diagnosis
which has been identiﬁed as factor for a long-standing infection being classiﬁed as recent.
Current work by CEPHIA evaluating TRIs indicated that treatment and a low viral load resulted
in a high proportion of false recent infections [Gary Murphy, personal communication, March,
2013, [451]], rather than a low CD4 or AIDS diagnosis as previously thought. This change in
methodology makes it difﬁcult to compare ﬁndings already published, where recent infections
identiﬁedamongpersonsnewlydiagnosedcorrectingforCD4andAIDSatdiagnosisrangedfrom
11% in the UK to 35% in Australia. Alongside correcting for misclassiﬁed results, it is important
to correct for longstanding infections that appear recent because a person may maintain an
optical density below the assay’s threshold for long periods following seroconversion. Within
Kiev City, the FRR was estimated at 3.7%, higher than the suggested 2% by CEPHIA [Gary
Murphy, personal communication, March, 2013]. However this is closer to the 2.7% FRR CEPHIA
estimated for person with subtype A1 [Gary Murphy, personal communication, March, 2013],
which is prominent in Ukraine.
Probable route of infection was found to be the only independent risk factor for testing as
recent, with MSM at higher odds of testing recent compared to persons reporting heterosexual
contact. Data on probable route of exposure is not extensively collected in Ukraine, which
makes targeting at risk populations in terms of awareness, prevention and testing difﬁcult.
This disproportionate distribution of HIV among MSM indicates that onward transmission in
this group is high, and highlights the need for tailored prevention and intervention strategies.
Furthermore, the lack of risk information across Ukraine means that the true scale of the
problem among these high risk groups is unknown.
Preliminary estimates for Estonia suggest the incidence rate among those self-initiating testing
during 2013 was 95 per 100,000 population, considerably higher than estimates in Europe and
the USA. The 1023 recent infections estimated to have occurred during 2013 were extrapolated
from the 95 classiﬁed as recent using the LAg avidity EIA. Data on viral load were not available
to correct for misclassiﬁed results, and with nearly half (44%) of persons diagnosed classiﬁed as
recent we can assume this is an overestimation. In addition to correcting for viral load, a further
factor for consideration is the recombinant form CRF06_cpx which is the predominate subtype
across Estonia. It is unknown how the LAg Avidity EIA reacts with this recombinant form and
261whether this interaction produces an artiﬁcially high proportion of recent infections. Further
suggestions that this proportion is an overestimation is the high proportion of persons known
to be longstanding but are classiﬁed as recent. Even after correcting for viral load, the FRR for
Estonia was 5.9% considerably higher than the suggested 2% target. However, even though there
is uncertainty in the number of those classiﬁed as recent, all persons with laboratory evidence of
a negative test within 1 year were classiﬁed as recent, as were those reporting a seroconversion
illness.
Initial results for Poland before correcting for viral load suggest the proportion of recent
HIV infections in Poland was 30%. Although, I have not been able to correct for misclassiﬁed
results, previous work in Poland showed that when using multiple TRI the proportion classiﬁed
as recent fell from 47% to 22%. This high proportion of recent infections is likely to reﬂect the
population using VCT sites for testing, with the majority of new diagnoses among MSM. As
discussed previously MSM have been found to contribute a high proportion of recent infections
compared with other risk groups. For France, Kiev City and the USA, half of recent infections
were among MSM.
I also analysed previous work in Odessa using the BED-CEIA, indicating that approximately
one in four persons with a conﬁrmed new HIV diagnosis between May and December 2009,
were recently-infected. This proportion is considerably higher than that found in Kiev City.
Such a difference in part results from the limitations of the earlier study, with no data available
to address misclassiﬁcation of long-standing infections. Furthermore, the assay used was
the BED-CEIA, which has been found to have a higher false-recent than the LAg Avidity EIA,
with incidence estimates using the LAg Avidity assay much closer to modelled estimates than
when the BED-CEIA was used [451]. Data from Odessa indicated that age was an independent
risk factor for testing as recent, with a higher probability with decreasing age, consistent with
ﬁndings from studies in the UK, France and Germany [378,452,453]. I also found evidence to
suggest that women resident in the city and rural Odessa were more likely to test recent than
their male counterparts. These ﬁndings may reﬂect the change in the current epidemic with the
predominant route of infection in the Ukraine shifting from injecting drug use to heterosexual
contact [1,23], which was also evident in Kiev City (section 6.1.1).
262Finally, as of September 2014 genotypic data were available for 25% persons newly diagnosed
at the four testing sites in Kiev City suggesting a low level of transmitted drug resistance,
considerably lower than published ﬁgures [440,441,445,449]. Mutations identiﬁed were linked
to NRTI’s and NNRTI’s, with two out of the three individuals with resistance to Nevirapine (NVP)
and Efavirenz (EFV) both commonly used in ﬁrst-line treatment and preventing mother to child
transmission (PMTCT) suggesting that these persons were not newly diagnosed. This low-level
TDR maybe because treatment coverage is low across Ukraine, estimated to be between 22 and
28%, rather than low onward transmission among persons who know their status.
Using the same data, I investigated the circulating subtype among those newly diagnosed within
Kiev City. Consistent with published literature the majority were subtype A1. This subtype
distribution is commonly identiﬁed among Eastern European countries and in particular is
linked to PWID [454,455]. The alternative MDRI as indicated by CEPHIA [Gary Murphy, personal
communication, March, 2013] would reduce the incidence estimate for Kiev City. This signifys
how the incidence rate is impacted by the probability of being classiﬁed as recent when using
the initial methodology by Karon et al [409], and the difﬁculty in establishing the true number of
recent infections.
263Chapter 8
Discussion
This chapter summarises the main ﬁndings of the study, discusses how these outcomes
contribute to research and compare with current literature. I identify limitations to the study
and what further work is needed, and think about implications for policy and practice.
264To better understand the spread of HIV in three Eastern European countries, Poland, Estonia,
and Ukraine, a serological test for recent infection (TRI) was introduced to existing country
surveillance to differentiate recent from non-recent infections. By identifying those who test
close to their infection I was able to identify those at current risk of HIV and, for the ﬁrst time,
estimate HIV incidence for Estonia and the Ukrainian region of Kiev City.
Alongside the introduction of a TRI, laboratory, demographic, and clinical information was
required to enable the population to be characterised and to correct for overestimation of recent
infections. In Poland and Estonia, HIV surveillance is more developed but data collection within
Ukraine consisted of basic information on the person’s year of birth, sex, area of residence,
and reason for test. Therefore, in addition to introducing a TRI within Ukraine, I successfully
introduced a anonymous method of data collection, where persons would feel comfortable
disclosing their risk factor information, with >99% acceptance rate. The collection of such
information, through an anonymous questionnaire, enabled populations at risk to be identiﬁed,
which has signiﬁcant implications for policy, guidelines and funding.
HIV incidence for Kiev City (21.5 per 100,000 population) was similar to that reported for
the USA using the same methodology [346], and signiﬁcantly lower than estimates in Africa,
where overall for Tanzania, Zimbabwe, and the South African regions of Soweto and Vulindlela
incidence, was 1600 per 100,000 population [344]. Although incidence estimates were lower
than expected, the diagnosis rate for Kiev City (21.5 per 100,000 population) was higher than the
majority of countries within Europe, with only the overall rates for Ukraine and Estonia being
higher at 37.1 and 23.5 per 100,000 population, respectively. Both new diagnoses and recent
infections indicated a disproportionate distribution of HIV among MSM and PWID. Current data
collection methods within Ukraine make it difﬁcult to determine the distribution of persons at
risk of HIV, with <1% diagnosed in 2012 known to be MSM [15]. Among those diagnosed in Kiev
City, the data collected through this study suggest this proportion of MSM is higher (10%). If the
proportion of MSM diagnosed overall in Ukraine was the same as Kiev City then the number of
diagnoses increases from 152 to 1687 for 2013.
These results indicate the importance of a comprehensive surveillance system providing
an accurate picture of those at greatest risk of HIV. Recommendations from ECDC suggest that
265interventions should be relevant to national and local epidemiology, with surveillance data
for Eastern Europe indicating that interventions for prevention and treatment should focus on
PWID and their sexual partners [15].As described previously, the surveillance data for Ukraine is
minimal with risk ascertained through reason for test. However, from the data collected within
Kiev City, this would result in a key population being missed, a population where the majority of
recent infections were identiﬁed.
Using published estimates to deﬁne the population at risk with Ukraine, incidence estimates
for MSM ranged between 2289 new infections per 100,000 MSM based on 0.9% of the male
population being MSM and 6868 if this proportion was 0.3%. These alarmingly high incidence
rates compared with those for the overall population are similar to France [349] (1006 among
MSM vs. 17 among the total population) and Los Angeles county [334] (493 vs. 23 respectively).
Work in the UK on the likely sources of onward transmission in this subpopulation suggests
that high incidence among MSM is driven by condomless sex and would be even higher without
the introduction of antiretroviral therapy [113]. ART coverage in Ukraine is one of the lowest in
the world (between 22 and 28%) [456] and EMIS indicated that MSM in Ukraine are not being
reached by prevention efforts, and have minimal understanding of HIV and its prevention [435].
This could be the result of MSM being less likely to identify as such because of stigma and
discrimination but also due to the inadequate surveillance within Ukraine. Not understanding
the risk factor distribution of HIV positive individuals makes appropriate and targeted public
health interventions problematic. As there was little difference in the diagnosis rate between
heterosexual men and women suggests non-disclosure among MSM in Kiev City was minimal;
however it is difﬁcult to determine how the population within the capital city reﬂects that of
other regions in Ukraine.
Incidence estimates for PWID was also signiﬁcantly higher than that for Kiev City overall. Like
MSM, PWID are a hard to reach population, with underlying tension between law enforcements
and those involved in public health [457]. Diagnosis ﬁgures for Ukraine (section 1.2) show
sexual contact between men and women exceed that of injecting drug use to become the
leading route of infection; however incidence estimates suggest that PWID are still an important
subpopulation. UNAIDS indicates that harm reduction programmes are available in all regions
266of Ukraine, but reaches only a third of those at risk, and <10% are accessing treatment [458].
Work modelling the effectiveness of medication-assisted treatment for opioid dependence
(MAT), ART and syringe exchange programmes (SEP) among PWID, estimated that as high as
40% of HIV among PWID could have been avoided [37]. What has also become evident is a
bridging between those who inject drugs and their sexual partners (section 6.1.1), with a much
higher proportion of heterosexual women reporting an injecting partner compared to men.
Preliminary results in Estonia suggest an incidence rate of 95 per 100,000 population, although
data were not yet available to correct for misclassiﬁcation. These results are considerably higher
than the incidence rate for Kiev before correcting for viral load, even though these countries
have similar diagnosis rates. Of particular interest is how the LAg Avidity assay interacts with
the recombinant subtype CRF06_cpx. The proportion of incorrectly classiﬁed recent infections
according to the LAg avidity assay among persons known to be long-standing after correcting
for viral load was considerably higher than what has been previously identiﬁed [Gary Murphy,
personal communication, August, 2014], suggesting the assay performs differently with the
CRF06_cpx subtype.
Estonia has a very similar HIV picture to Ukraine, with one of the highest rates of diagnosed HIV
in Europe, where national surveillance suggests those at risk of HIV are predominately PWID or
heterosexuals. The diagnosis rate for those tested during 2013 was consistent with that reported
for 2012 (24.7 vs. 23.5 per 100,000 population), with the majority of those reporting a risk
reporting heterosexual contact. With a similar distribution of sex, with 3 in 5 diagnosed among
men, it is interesting to note that the proportion of diagnoses among men identiﬁed as MSM is
much lower in Estonia than in Kiev City (6.7% vs. 15% respectively), with 6 men reporting their
risk as MSM compared to 46 through the anonymous questionnaire in Kiev. It is possible there
is non-disclosure of MSM with just over a third of diagnoses in Estonia with unknown risk, of
which two thirds were men. However, unlike Kiev City where the majority of recent infections
were identiﬁed among MSM, the distribution of recent infections appears to be similar across
all risk groups. Although these results have not been corrected with viral load to give the true
distribution of those with an observed recent infection the distribution is similar to Kiev City
with a higher proportion among younger individuals and with the majority of recent infections
among those with a negative test within 2 years of their initial diagnosis.
267In Poland, preliminary results suggest the proportion recently infected was 30%, although
viral load were not available for correction purposes. Whereas Estonia and Ukraine have the
highest diagnosis rates in Europe, Poland has one of the lowest (2.8 per 100,000) at 1.2 for VCT
attendees. The high proportion of recent infections is likely to reﬂect the distribution of those
newly diagnosed, with the majority of new diagnoses among MSM. For Kiev City, France and the
USA, over half of the recent infections identiﬁed were attributable to MSM [346,349]. Incidence
estimates were not available for Poland, the probability of testing and being classiﬁed as recent
for ﬁrst-time testers not currently available.
8.1 Limitations
There are several limitations worthy of discussion. Firstly, the data required to estimate the
probability of testing and being classiﬁed as recent are prone to error. For repeat testers this is
based on the time between the last negative test and their diagnostic test, which is therefore,
reliant on these data to be reported. In Kiev City, as is likely in most surveillance systems,
the availability of these data is based on self-reporting. In Estonia, on the other hand, where
past HIV testing was linked, all persons with a negative test within a year were all classiﬁed as
recent, but none of those self-reporting a negative test within a year. This suggests that relying
on self-reporting of a previous negative result will increase the probability of testing and being
classiﬁed as recent for repeat testers, and lead to an underestimate of the true number of recent
infections. For ﬁrst-time testers, the proportion of the population diagnosed late is used to
estimate the time between infection and presenting for a test. For both Kiev City and Estonia,
I used estimates from previous years and estimated the proportion among all new diagnoses
rather than for ﬁrst-time testers speciﬁcally. Ideally this probability should have been estimated
for the population presenting for a test as part of the study. In Europe on average, where CD4
completion was >75%, 30% of persons were diagnosed with a CD4 cell count <200 cells/mm3,
with the average in the EU/EEA 26% similar to that estimated for Estonia, whereas among
Non-EU/EEA countries this proportion was much higher at 43%, again similar to Kiev City.
Secondly, population data particularly for MSM within Kiev City was estimated using published
literature, based on the work of AIDS Alliance and the European MSM internet survey (EMIS).
268There are uncertainties within these estimates, indicated by their wide ranges, and further work
is needed to establish the likely numbers at risk.
Thirdly, it is important to bear in mind that data from Kiev City may well not be generalizable
to the rest of Ukraine. For a better understanding of the epidemic in other regions our methods
need to be implemented across Ukraine. Acceptance rate was high (>99%) among attenders
and information on HIV risk behaviour was also available for >99% of those completing the
questionnaire.
Fourthly, although the LAg avidity was part of the evaluation process by CEPHIA, there
are still uncertainties regarding how the assay performs among the recombinant subtype
found in Estonia. Results among those known to be long-standing even after correcting
for misclassiﬁcation were considerably higher than previously identiﬁed suggesting recent
infections are being over-represented.
Finally, for Kiev City, the proportion of persons diagnosed late was not available by
subpopulations when extrapolating the true number of recent infections from the observed.
Among populations where the proportion diagnosed late is likely to be higher than that for the
overall population, the true number of recent infections is likely to be an overestimate and where
it is low this is likely to be an underestimate.
8.2 Further Work
Recommendations for further work include national implementation of the new data collection
method introduced in Kiev City. As data from Kiev City may not be representative of other
regions, wider implementation would help ensure HIV prevention efforts and testing strategies
are tailored to each region.
Efforts are currently underway to implement a more timely and centralised data collection
facility within Poland. In addition, further work is required to understand what the barriers
for testing are, and to increase testing frequencies, particularly in high risk populations, in line
with testing guidelines. One of the main issues arising from this work is the inadequate levels of
269testing. Through using the probability of testing and being classiﬁed as recent the true number
of recent infections within the population is extrapolated from the number testing, which points
to an undiagnosed population currently participating in risky behaviour and at risk of onward
transmission.
Furthermore, there is a need to quantify the link from testing to care, particularly among
persons recently infected who increase the risk of onward transmission. This will also aid the
compilation of the cascade in the country.
Finally, understanding how the LAg avidity assay reacts with recommbinent subtypes such
as the CRF06_cpx within Estonia is essential.
8.3 Implications for policy and practice
This work has several implications for policy and practice: the importance of diagnosing persons
recently-infected; targeting the undiagnosed population; and recognising and targeting those at
greatest risk of infection.
Recently infected individuals may be more likely to engage in high risk behaviours and
contributes substantially to onward transmission of HIV. There is a need to diagnoses and
target recently-infected persons. This is practically achieved by understanding of HIV and its
prevention, and ensuring frequent testing within at-risk groups. Furthermore, the extrapolation
process from the observed to the true number of recent infections using the testing frequencies
ofthepopulationrepresentsthehighnumbersofundiagnosedinfectionswithinsub-population.
This requires targeted testing, increasing knowledge of the importance of frequent testing, and
ensuring ease of access to testing facilities.
Although testing facilities are being accessed, the limited data currently collected in Ukraine
means that prevention and intervention efforts may not be relevant to the local epidemiology.
Inadequate surveillance and risk behaviour ascertainment results in a lack of prioritisation and
support among at-risk groups. Lack of knowledge regarding the sub-populations at greatest
risk makes it increasingly difﬁcult to target in terms of increasing awareness, prevention, and
270promoting testing.
Finally, efforts need to be made to increase referral into care and treatment coverage. In
Ukraine, treatment coverage and access to HIV-related care is particularly poor, during 2012,
only 67% of persons newly diagnosed in Ukraine accessed HIV related care following diagnosis,
with the estimated ART coverage of 28% [459].
8.4 Conclusions
This work has shown the importance of having a better understanding of the epidemic to ensure
interventions for prevention, and promotion of testing services are tailored to key populations.
Within Kiev City this not only meant understanding current transmission patterns using a TRI,
but for detailed surveillance information to have been collected. This knowledge base will better
enable targeted public health action, health promotion work, laying a foundation to enable local
and national guidelines to be developed, and to support work being conducted by government
and non-government organisations.
This study speaks to the need for targeted testing. The extrapolation process to estimate
the true number of recent infections indicates those populations are currently undiagnosed
participating in high-risk behaviour and at risk of onward transmission. Further work is needed
to understand what the barriers for testing are, and to increase testing frequencies, particularly
in high risk populations, in line with testing guidelines.
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328Appendix A
Incidence estimates
Incidence estimates from published studies identiﬁed using the method in section 2.2.
Publications grouped by study region, method of estimating incidence and population of focus
All incidence estimates were present by 100 pyrs at risk (or of follow-up).
High risk popualtions included: Commercial Sex Workers, Discordant Couples, High risk
adults, Injecting Drug Users, Men who have sex with men, persons of transgender, Prisoners and
Sero-discordant Married Couples. Testing populations included: Anonymous Testing, General
Testing Population, STD Clinic, Voluntary counselling and testing, Vaccine Cohorts, Injecting
drug use programs, New diagnoses.Other included: Accident and Emergency, Antenatal, Blood
Donors, Heterosexual contact, Community-based Cohorts, Male factory Workers, Household-
Based Surveillance, Military, Married Couples, Police Ofﬁcers, Population based survey.
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